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1. Summary 
Human papillomaviruses (HPVs) comprise a large group of small DNA viruses that infect 
mucosa and epithelia. Infections can be either asymptomaticand cleared by the immune 
system or they can persist and cause cancer. Many studies supported the causative role of 
HR-HPVs in cervical carcinoma, whereas the HPV-related causality of non-melanoma skin 
cancer (NMSC), where HPV is thought to act as a co-carcinogen, is not fully understood.  
Protein-protein interactions were studied in this work to get more insights into cutaneous PV 
tumor development and to obtain a comprehensive intraviral interactome of HPV31. 
Since expression of the two viral oncoproteins E6 and E7 are associated with the 
progression of HPV-related tumors, cutaneous E6 proteins of HPV5, 38 as well as CRPV 
were used as baits to perform mass-spectometry (MS)-based assays to identify new cellular 
interaction partners. Analysis of the MS data led to the confirmation of previously published 
interactors and to the identification of new proteins. Among them, the 17-Beta-
Hydroxysteroid Dehydrogenase isoforms 4 (17βHSD4) was validated as an interactor of both 
CRPV and 38E6.  
A flow cytometry-based FRET assay (FACS-FRET) was used to unravel the intraviral 
interactome of the HR type HPV31. Nine viral proteins were fluorophore-tagged and then 
tested for interactions between each other via FACS-FRET. The screening revealed new 
interactions besides confirming the previously reported ones. For the first time, we show an 
interaction between the E6 and E7 oncoproteins.  
These findings contribute to a better understanding of the molecular mechanisms by which 
cutaneous PV interfere with the host. The data might furthermore be the basis for future 
research elucidating mechanisms by which cutaneous PVs cause cancer and ultimately pave 
the path for new therapeutic options for the treatment of PV-induced malignancies. 
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Zusammenfassung 
 
Humane Papillomaviren (HPVs) umfassen eine große Gruppe von kleinen DNA-Viren, die  
die Schleimhaut und das Epithel infizieren. Infektionen können entweder asymptomatisch 
sein und durch das Immunsystem kontrolliert werden oder sie können persistieren und Krebs 
verursachen. Viele Studien unterstützen eine ursächliche Rolle von HR-HPVs in der 
Entstehung von Gebärmutterhalskrebs, während die HPV-bezogene Kausalität von Non-
Melanoma-skin cancer (NMSC), wo HPV als Co-Karzinogen wirkt, nicht vollständig geklärt 
ist. 
 
In dieser Arbeit wurden Protein-Protein-Wechselwirkungen untersucht, um Einblicke in die 
Tumor-Entwicklung durch kutane PV und in das intravirale Interaktom von HPV31 zu 
erhalten. 
 
Da die Expression der beiden viralen Onkoproteine E6 und E7 mit der Progression von HPV-
induzierten Tumoren korreliert, wurden die kutanen E6-Proteine von HPV5, 38 sowie CRPV 
als Baits verwendet, um Massenspektrometrie (MS) -basierte Assays durchzuführen, um 
neue zelluläre Interaktionspartner zu identifizieren. Die Analyse der MS-Daten führte zur 
Bestätigung von bisher veröffentlichten Bindungspartnern und zur Identifizierung neuer 
Proteine. Unter ihnen befindet das Protein 17-Beta-Hydroxysteroid Dehydrogenase 
Isoformen 4 (17βHSD4), welches als neuer Interaktor von CRPV und 38E6 validiert wurde. 
 
Ein Flüssigzytometrie-basierter FRET-Assay (FACS-FRET) wurde verwendet, um das 
intravirale Interaktom des HR-Typs HPV31 zu analysieren. Neun virale Proteine wurden mit 
Fluorophoren markiert und dann auf Wechselwirkungen miteinander mittels FACS-FRET 
getestet. Das Screening zeigte neben der Bestätigung von zuvor beschriebenen, auch bisher 
unbekannte Interaktionen. Zum ersten Mal konnte somit eine Interaktion zwischen den E6- 
und E7-Onkoproteinen gezeigt werden. 
 
Diese Erkenntnisse tragen zu einem besseren Verständnis der molekularen Mechanismen 
bei, durch welche kutane PV den Wirtsorganismus beeinflussen. Weiterhin stellen diese 
Ergebnisse das Fundament für zukünftige Forschungsvorhaben zur Aufklärung der 
molekularen Mechanismen dar, durch welche kutane PV Krebs verursachen, und ebnen 
letztlich den Weg für neue therapeutische Ansätze für die Behandlung von PV-induzierten 
Malignitäten. 
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2. Introduction 
2.1 Papillomaviruses 
Papillomaviruses (PVs) are small DNA viruses, belonging to the papillomaviridae family. 
They are able to infect mucosal and cutaneous epithelia and are characterized by a high 
tissue- and host-specificity. PVs classification is based on the comparison of the nucleotide 
sequence of the major capsid proteins L1 open reading frame (ORF). L1 is the most 
conserved gene in the viral genome and its sequence is used to differentiate new types 
(>10% different to the closest type), subtypes (2-10%) and variants (< 2%) [1]. More than 
200 PVs were identified so far, 174 of which are known to infect humans and are divided in 5 
genera: alpha, beta, gamma, mu and nu (Fig. 1). HPVs can be further divided in mucosal 
(Alpha) and cutaneous (Beta, Alpha4, Gamma, Mu, Nu) types based on their tissue tropism 
[2].  
 
 
Fig. 1 Classification of papillomaviruses (Figure adapted from de Villiers E. et al., 2004 [1]) 
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1.1.1 Clinical relevance 
Several HPV types inhabit skin and mucosa asymptomatically but some HPVs can lead to 
lesions ranging from self-limiting benign warts to abnormal malignant growth. Because of 
their documented association with tumors, some HPV types were classified as carcinogens 
by the International Agency for Research on Cancer (IARC) [3] (Fig. 2) 
 
Fig. 2 Classification of carcinogenicity of different HPV types made by IARC (Figure adapted 
from Bravo I.G. & Félez-Sánchez, M., 2015 [3]) 
 
Mucosal α-HPV types, because of their varying carcinogenic potential, can be subdivided in 
high risk (HR, associated with cervical cancer, other genital cancers and oropharyngeal 
cancers) and low risk (LR, related to genital warts and papillomas) [4]. Cervical cancer is the 
4th most common cancer in women worldwide with approximately 500,000 new cases every 
year (World cancer research fund: http://www.wcrf.org/). Cervical HPV infections are the 
most common sexually transmitted infections and HPV16 (50%), followed by HPV18, 45 and 
31 are the most common types detected in Europe [5]. It was shown that the majority of the 
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women are infected during their first sexual contact [6] and that women younger than 25 
years have the highest prevalence [7], [8]. Approximately 90% of cervical infections are 
cleared by the immune system within two years [9], however, a persistent infection can 
progress to cervical intraepithelial neoplasia (CIN), that is differentiated in mild (CIN1), 
moderate (CIN2) and severe (CIN3/carcinoma in situ) dysplasia. The pre-malignant lesions 
CIN1 and CIN2 can spontaneously regress over the years in 57% and 47% of the cases 
respectively [10], whereas an untreated CIN3 can develop cancer in 30-50% of the cases 
within 30 years [11]. A common feature of cervical cancers is the integration of the viral DNA 
into the host genome with the resulting disruption of the E2 gene, which is the viral regulator 
of transcription, replication, genome maintenance and partitioning, and the consequent 
constitutive expression of the E6 and E7 oncogenes that favor tumor growth [12]. 
Although mucosal HPVs were documented to be the causative agents of virtually all cervical 
carcinomas [13], it is still controversial whether cutaneous HPVs are causally involved for 
skin cancer development. 
The first reports showed that the β1-HPVs 5 and 8 are associated with skin cancers in 
patients with the autosomal recessive hereditary disease Epidermodysplasia verruciformis 
(EV) [14], [15]. Squamous cell carcinoma (SCC) can arise within 10-30 years after the first 
manifestation of benign lesions in 30-50% of EV-affected patients on sun-exposed sites [15] 
and 90% of these cancers are positive for HPV5 and 8 [16]. 
Nonmelanoma skin cancer (NMSC) is the most common cancer worldwide in the Caucasian 
population and accounts for almost 40% of all cancer cases [17]. NMSC comprises actinic 
ketatosis and Bowen’s disease but also squamous cell carcinoma (SCC) basal cell 
carcinoma and (BCC) that account for 16% and 80% of all skin cancers, respectively [18], 
[19]. For the development of NMSC, age, skin, UV light exposure and immunosuppression 
are major risk factors [20]. Concerning the immune status of the host, organ transplant 
recipients under immune suppression were documented to have a 50-100 times higher risk 
for NMSC [21]. Although HPV involvement in NMSC remains unclear in healthy individuals, 
β2-HPV infection is thought to be associated with NMSC since HPV DNA was found in 
approximately 50% of SCCs in immunocompetent individuals whereas it reached 80% in 
immunocompromised people [22], [23]. Unlike HR, cutaneous HPVs are most likely co-
carcinogens since they may contribute to cancer cooperating with other factors such as UV 
radiation and/or immunosuppression. The other main difference is that only a small number 
of NMSC cells contain viral DNA [24], [25] pointing towards a role of cutaneous HPVs in the 
beginning of tumorigenesis whereas in cervical cancer the viral oncoproteins are 
constitutively expressed [26]. 
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1.1.2 Genome organization 
The HPV genome is a circular double-stranded DNA comprising approximately 8 kb which 
contains a coding region of 8 or 9 ORFs (depending on the type) and an upstream regulatory 
region (URR) also known as long control region (LCR) which contains the origin of replication 
and regulatory elements (Fig. 3) [27]. The coding region encodes for early (E) and late (L) 
proteins. Early proteins play a role in replication, transcription, maintenance of the viral 
genome, cell cycle and apoptosis control while the late genes are transcribed and then 
translated in the structural proteins composing the icosahedral capsid.  
Two promoters and two different poly-adenylation sites control transcription of the 
polycistronic HPV mRNAs according to the differentiation status of the infected cell [28]. 
In the beginning of the infection, only the early promoter (p97 for HPV31 and 16; p105 for 
HPV18), located in the URR, is activated and can guide the expression of E1 and E2, for the 
establishment of the stable viral episomes, and E6 and E7, to control the cell cycle [27]. At 
the time of differentiation, the late promoter (p742 for HPV31; p670 for HPV16) is activated 
and this increases the transcription of E1 and E2 proteins [29], responsible for genome 
amplification [29]. At the same time it leads to the expression of E1^E4, E5, L2 and L1, 
responsible for genome packaging into viral particles and virion release [27]. Polyadenylation 
sites contribute to transcription regulation as well: the early polyadenylation site (pAE) drives 
the polyadenylation of the mRNAs produced in the first steps of the viral life cycle by the 
early promoter. Upon cellular differentiation, polyadenylation occurs via the late 
polyadenylation site (pAL) on the late promoter transcripts. Alternative splicing is another 
way how HPV regulates its gene expression [30]. 
 
 
Fig. 3 Linearized HPV31 genome showing the URR followed by the promoters and the 
polyadenylation sites that are directing transcription of the viral genes (figure taken from [27]). 
 
 
 7 
 
1.1.3 Viral proteins 
The only enzyme expressed by papillomaviruses is the E1 protein, an ATP-dependent 
helicase expressed at low levels in HPV-positive cells [31]. E1 recognizes AT-rich sequences 
in the origin (ori) of replication, next to the early promoter and its binding is strengthened by 
complex formation with E2. Upon binding, E1 assembles into double hexamers, its active 
form, and can recruit a complex for DNA replication on the viral ori where it unwinds the 
DNA, making it accessible for replication [32], [33]. 
The DNA binding protein E2 is the viral regulator of transcription, replication, genome 
maintenance and partitioning [34]. E2 acts mainly by recruiting cellular proteins to specific 
DNA sequences, called E2 binding sites (E2BS), which are predominantly present next to the 
E1BS at the ori. In this way E2 controls transcription in a dose-dependent manner and 
enhances E1 function in the initial phase of replication [35]. Another important function of E2 
is to ensure proper genome partitioning to each daughter cell during mitosis, by tethering the 
viral DNA to the segregating chromosomes [36]. 
The ORF of E4, the most expressed HPV protein, is located within the E2 ORF and is 
expressed as a splice variant, E1^E4 [37]. Historically, E4 was classified as an early protein, 
however many studies have demonstrated that it is involved in the late stages especially 
taking into account that the capsid proteins, L1 and L2, are expressed only in E4-positive 
cells and that the expression of E4 temporarily precedes the one of L2 and L1 [38]. 
Moreover, during its accumulation in the upper epithelial layers, E4 associates and disrupts 
the keratin network, pointing towards a possible role in virion release [39]. 
Many papillomaviruses, except the beta, gamma and mu genera, encode the E5 ORF, a 
small hydrophobic protein with transforming activity. E5 function was studied mainly in BPV, 
where it shows a strong tumorigenic activity, and in HPV16 where this activity is rather weak 
[40]. The role of E5 is not yet totally understood but it can stimulate cell growth by influencing 
mitogenic signals stemming from EGFR-mediated pathways: since E5 localizes on the 
membrane, it can bind EGF receptors, thus causing receptor dimerization and signaling 
activation [41], [42]. Moreover, by association with the vacuolar ATPase, E5 can delay the 
endosomal acidification which affects EGFR recycling with a consequent increased 
transmission of growth signals to the nucleus [43], [44]. By simultaneous endosomal 
alkalinisation, E5 contributes to immune escape by accumulating MHC class I molecules in 
the Golgi and thus reducing its expression on the membrane [40]. 
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The two structural proteins L1 and L2, generated by alternative splicing, are expressed 
during the late phases of the viral life cycle, engaging the late promoter and the pAL [45]. 
Virions are non-enveloped particles and the icosahedral capsids, approximately 55 nm in 
diameter, are composed by 360 molecules, organized in 72 pentamers, of the major capsid 
protein L1 and an unknown number of the minor capsid protein L2, which mainly resides in 
the central cavity of the L1 pentamer [46], [47]. An important feature of the L1 protein is that it 
is able to modulate its conformation depending on the viral cycle stage: in the beginning of 
the infection L1 guarantees viral attachment but after entry allows viral genome to enter the 
cell [48]. Although the L2 protein is hidden into the capsid during the first stages of infection, 
is thought to have a crucial role during viral attachment [49], [50]. Moreover, it has been 
shown that L2 contributes in later steps: following entry it could mediate transition to the 
Golgi network, and entrance of the viral genome into the cell nucleus [51]. 
 
1.1.4 Viral oncoproteins 
During the productive phase of viral life cycle the early proteins E6 and E7 play a key role in 
enhancing cell proliferation and delaying cellular terminal differentiation. By interfering with 
the host cell, the viral genome is amplified and an increased number of infectious viral 
particles can be produced [52]. When the viral genome integrates, as it is in the case of 
cervical cancer, E6 and E7 are constitutively expressed and, acting as oncoproteins, they 
favor cell proliferation and inhibition of apoptosis thereby sustaining cellular transformation 
(Bedell et al. 1987; Vousden et al. 1988). Earlier studies showed that HR-E6 and E7 are 
responsible for keratinocytes’s transformation [55], [56] and that E6, unlike E7, is not able to 
immortalize cells alone. However, when E6 is co-expressed, it increases the efficiency of 
immortalization. Compared to HR, LR-E6 and E7 have little or no immortalizing activity [57]. 
E6 and E7 can influence different cellular processes, ranging from cell cycle to cell death 
and, due to the fact that they were never been shown to possess enzymatic activity, they use 
mainly protein interactions to alter cellular protein functions [58], [59]. HR viral oncoproteins 
collaborate to favor cell growth and avoid apoptosis: they were both shown to contribute to 
genomic instability [60] which is needed for malignant progression and to interact with the 
BRCA1 (BReast CAncer 1) protein with the consequent release of hTERT (human 
Telomerase reverse transcriptase) repression [61]. On the other hand, HR-HPV E6 proteins 
were also shown to increase telomerase activity by interacting with the NFX1 (Nuclear 
Transcription Factor, X Box-Binding Protein 1) proteins [62].  
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Since cutaneous HPVs are mainly associated with benign warts, they were not so 
extensively studied like the α-HPVs. Previous reports, however, showed that HPV38 and 49 
have immortalizing activity [63], [64] and that the EV-associated types, HPV5 and 8, can 
activate telomerase [65]. 
Exclusive for HR E6 proteins’ structure is a dimerization domain at the N-terminus and a PDZ 
(PSD-95, Dlg, ZO-1 proteins) binding domain at the C-terminus. E6 proteins, in addition, 
contain two zinc-finger domains, formed by four Cys-X-X-Cys motifs [66], connected by a 
helical linker that together form a pocket able to bind LXXLL sequences, contained in cellular 
proteins that bind E6 of both mucosal and cutaneous HPVs [67] (Fig. 4). The most 
thoroughly studied property of HR-E6 is its interaction with the tumor suppressor protein p53 
[68], [69]. p53 regulates several cellular processes and is responsible for cell cycle arrest, 
apoptosis and senescence [70]. In normal cells p53 is inactive and constantly degraded by 
the proteasome, but its activation by DNA damage or cellular stress leads to cell cycle arrest 
or cellular apoptosis [71]. HR-E6 has been shown to form a ternary complex with p53 and 
with the ubiquitin ligase E6AP (E6 associated protein), which contains an LXXLL motif. E6, 
via E6AP, ensures cell cycle progression through p53 poly-ubiquitination and proteasomal 
degradation [72]. Also the cutaneous HPV38 E6 can interfere with p53 signaling by 
accumulating the p73 isoform which inhibits p53 activity [73]. Moreover, β-HPVs HPV5, 
HPV8, and HPV38 were shown to prevent stabilization of p53 in presence of genome 
instability [74].  
E6 proteins of cutaneous PVs interact with the LXXLL-peptide containing MAML 
(Mastermind-like) family of transcription activators [75], [76]. MAML proteins regulate Notch 
pathway activation and it has been shown that Notch signaling acts as a tumor suppressor in 
the skin [77]–[79]. HPV8 E6, by interacting with MAML1, can delay Notch-induced 
keratinocytes’s terminal differentiation and therefore favor HPV life cycle progression [80]. 
Cutaneous and HPV16 E6 can regulate p53 also through its association with the 
acetyltransferase p300 (Muench et al. 2010b; Zimmermann et al. 1999). By binding p300, E6 
blocks p53 acetylation and consequently inhibits the transcription of p53 regulated genes 
[83]. HPV5 and 8 bind p300 much more efficiently if compared to HPV16 or HPV38 and this 
binding leads to p300 in an E6AP-independent manner [81]. 
PDZ domain-containing proteins have tumor suppression functions and can interact with the 
C-terminus of HR-E6. HDlg1, hDlg4 [84], MAGI-1, -2, -3 [85], [86] and MUPP1 [87] are PDZ 
proteins known to be targeted by E6. However, E6-mediated inactivation or degradation of 
PDZ proteins does not seem to be directly related to the carcinogenic potential of HPV [88], 
[89]. 
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E6 can inhibit apoptosis in different ways: LR, HR and the cutaneous HPV5 and 8 E6 interact 
with Bak (Bcl-2 homologous antagonist/killer), a pro-apoptotic protein, and induce its E6AP- 
dependent degradation in response to UV DNA damage [90], [91]; FADD (Fas-associated 
death domain), a protein involved in the extrinsic apoptosis pathway, can also be degraded 
by E6 [92]. 
Moreover, through alternative splicing a short isoform of HR-E6 named E6* is produced. This 
protein, which comprises the N-terminus of E6, does not interact with LXXLL, but instead 
interacts with full length E6 and E6AP [93] and inhibits p53 degradation thereby controlling 
E6 activity. 
 
 
Fig. 4 HPV16 E6 structure (Figure adapted from [94]) 
 
E7 proteins consist of approximately 100 amino acids and their structure is characterized by 
a zinc-finger motif at the C-terminus, which is also a dimerization domain [66]. The amino 
terminus of E7 share sequence similarity with the Simian virus 40 large T antigen (SV40 T-
Ag) and the Adenovirus E1A protein (Ad-E1A) in two regions called conserved regions (CR) 
1 and 2 [95], [96]. The CR1 and 2 domains, as for SV40 T-Ag and Ad-E1A, are responsible 
for the transforming activity of HR-E7 [97] (Fig. 5). 
 
HR-E7s interact with the pocket protein family (pRb, p107, p130) through the LXCXE motif in 
the CR2 domain and this interaction is stronger in HR-HPVs when compared to LR- and EV-
associated HPVs [98]–[100].  
pRb is an oncosuppressor that normally limits the activity of the E2F transcription factor, thus 
inhibiting cell cycle progression from G1 to S phase until the cell is prepared to divide. In the 
absence of pRb, E2F activates the transcription of genes involved in cell growth [101]. In the 
context of a HPV infection, the E7 protein abrogates pRb-E2F interaction by degrading or 
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just binding pRb, leading to deregulated cell cycle and thus contributing to cancer 
development [102].  
E7 proteins from different types bind UBR4 (p600), an E3 ubiquitin ligase [103], and for 
HPV16 it was shown to be involved in transformation and anchorage-independent growth 
[104]. For HPV16 E7 it was also documented that pRb degradation is obtained via E7 
interaction with ZER1. The ternary complex pRb-16E7-ZER1 can then associate with the 
cullin2 complex that targets pRb for degradation [103], [105]. 
Moreover, HR-E7 can induce chromatin remodeling through interactions with histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) as well as histone 
methyltransferases (HMTs) and demethylases [106], [107].  
Like E6, E7 contributes indirectly to hTERT transcription, since hTERT promoter contains an 
E2F binding site that can be activated once pRb is blocked [108].  
Telomerase activation and pRb inactivation are essential for immortalization [109]. 
 
 
Fig. 5 HPV16 E7 structure (Figure modified from [94]) 
 
1.1.5 Cottontail Rabbit PapillomaVirus (CRPV) 
The relationship between papilloma virus and cancer was first demonstrated by infection of 
domestic rabbits with CRPV [110]. CRPV, also known as Shope rabbit papillomavirus, is a 
kappa PV and was first found in warts of cottontail rabbits [111]. Former studies showed that 
CRPV could infect different rabbit strains, where it promotes skin tumor formation within 3 to 
6 weeks post infection [110]. However, only in domestic rabbits these papillomas progress in 
80% of the cases to invasive carcinoma in 6-12 months without any other co-factor, whereas 
in cottontail rabbits, its natural host, they generally regress spontaneously [112], [113]. 
Clearly, infection of domestic rabbits with CRPV is a suitable method to study several 
aspects of PV infections in vivo and, in particular, to understand the complex mechanisms 
behind PV-induced skin tumors. 
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1.1.6 CRPV genome and viral proteins 
The CRPV genome is similar to HPV in organization and protein sequence conservation (Fig. 
6). It consists of 7,868 nucleotides encoding 10 genes [114] that follow the same time- and 
space-dependent expression pattern as it is for HPVs. Viral transcription is regulated by 
three early promoters (PE-1, PE-2, PE-3) and one late promoter (PL). Two polyadenylation 
sites (poly-AE, poly-AL) and alternative splicing are also involved in regulating transcription. 
As for other PVs, early genes are transcribed as polycistronic mRNAs in the initial phase of 
infection but transcription starts from three different early promoters; the transcripts are poly-
adenylated at the poly-AE site and are subjected to alternative splicing. In the last stage of 
differentiation, when only L1 and L2 are produced, transcription begins at the PL and the 
resulting mRNAs are poly-adenylated at the poly-AL.  
 
Fig. 6 Linearized CRPV genome showing the URR, the promoters and the polyadenylation sites that 
are directing transcription of the viral genes (figure taken and modified from [115]). 
 
Protein sequences and functions are also conserved among PVs. There are, however, few 
exceptions. In HR-HPVs, the E6* isoform derives from alternative splicing while the two 
CRPVE6 proteins (Long and Short E6) are expressed by two different promoters [116], [117]. 
Long E6 (LE6) transcription initiates at the first ATG and Short E6 (SE6) is translated from a 
second transcript that starts at the second ATG contained within the LE6 sequence [116]. 
Unlike HR-HPVs, CRPVE6 proteins are not able to bind and degrade p53, however by 
binding p300 they indirectly interfere with p53-mediated apoptosis [63]. CRPVE7 shares 
some functional similarities with HR-HPVE7: among other things, both bind pRb resulting in 
the release of E2F that stimulates cell cycle progression [118]. 
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1.2 HPV life cycle 
1.2.1 Attachment and viral entry 
It has been suggested that the initial infection takes place in proliferating cells of the basal 
layer after a micro lesion of the epithelium has occurred [29]. Several studies investigated the 
entry step of HPV life cycle leading to the conclusion that the first contact is between the 
major capsid protein L1 and a receptor present on the cell surface or on the extracellular 
matrix (ECM). The majority of the studies demonstrated that HPVs use heparin sulfate 
proteoglycans (HSPGs) [119], [120] as their main attachment receptors. HSPGs are complex 
glycoproteins composed of a core protein with covalently attached heparan sulfate chains. 
They are either expressed on the cell surface on the cell surface (Syndecan-1 and glypicans) 
or secreted into the ECM (agrin, perlecan, type XVIII collagen) [121]. During wound healing, 
basal keratinocytes highly express a specific HSPG, Syndecan-1, that was also 
demonstrated to be mainly expressed in the epithelial tissue, specifically in proliferating 
keratinocytes making it a perfect candidate as a potential attachment receptor (Sapp & 
Bienkowska-Haba 2009; Shafti-Keramat et al. 2003).  
However, other studies propose that the primary binding might take place at the basement 
membrane, excluding an involvement of a cell membrane receptor but rather suggesting that 
a secreted HSPG might be required. Laminin 5, highly expressed during wound healing by 
migrating keratinocytes and released into the ECM, is a putative protein for this role as it 
might act as a transient receptor that allows HPV capsid proteins to bind the attachment 
receptors on neighboring cells [123], [124]. 
The nature of the primary attachment receptor is still controversial but it is certain that the 
binding of L1 to the receptor leads to the exposure of the hidden N-terminus of the minor 
capsid protein L2, a process mediated by the cell chaperone cyclophilin B. This 
conformational change leads to the cleavage of the L2 amino-terminal domain by a furin 
convertase [47] which might result in a loss of affinity for the primary receptor and the 
subsequent exposure of a secondary receptor binding site in L1 [49], [50] (Fig. 7). 
Although the nature of the secondary receptor, responsible for HPV internalization is still 
controversial, there are a few candidates that seem to form a protein complex to help HPV in 
entering the cell: α6 integrins (α6β1, specifically expressed in the cells of the basal layer, and 
α6β4, mainly expressed during wound healing on epithelial cells) and epidermal growth 
factor receptors (EGFRs, highly expressed in the epithelial basal layer) were shown to be 
 14 
 
able to bind HPV. Moreover, after the binding, α6 integrins and EGFRs may collaborate in 
assembling an entry platform in association tetraspanins [125].  
Previous studies showed that viral particles co-localize with the tetraspanins CD151 and 
CD63. Tetraspanins can form complexes, called tetraspanin-enriched microdomains (TEMs), 
associating with other membrane proteins, such as α6 integrins and EGFRs. The hypothesis 
is that TEMs may be responsible of transferring HPV binding from the primary to the 
secondary receptor complex [125], [126].  
After cell surface binding, to initiate a productive infection, HPV particles are internalized into 
the cell. It is evident that HPV entry occurs by endocytosis [127].  
 
Fig. 7 HPV internalization model. The process shows primary and secondary receptor binding.        
(1) The virion binds to the primary attachment receptor, HSPG1. (2) The binding is transferred to 
secondary HSPG binding sites present on the cell surface (HSPG2) and this results in conformational 
changes leading to the exposure of the L2 amino terminus and furin cleavage. (3) Another 
conformational change triggers endocytosis. Extracellular matrix (ECM); Laminin 5 (LN5); 
HeparanSulfate ProteoGlycan (HSPG); cyclophilin B (CyPB). (Figure taken from [49]). 
 
Non-enveloped viruses’s preferred endocytosis pathways are the clathrin- and the caveolae-
mediated pathways [128]. Although earlier studies confirmed the same for HPV [129], [130], 
a lot of recent data are supporting the idea of a clathrin- and caveolae-independent 
mechanism [131], [132]. This new alternative pathway has not been fully characterized but it 
requires the tetraspanin CD151, the tyrosine kinase and actin activities [125], and it might 
use TEMs as an entry platform [132]. 
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1.2.2 Uncoating and intracellular trafficking  
Internalized intact viral particles exceed the size to pass through the nuclear pore, so they 
must undergo capsid disassembly before entering into the nucleus [133]. It was shown that 
capsids are directed to the endosomal compartment upon arrival in the cytoplasm [132], 
[134]. HPV virions are trafficked in perinuclear CD63 containing vescicles, that are acidified 
by a vacuolar ATPase [135], a process that helps the uncoating of the virions and leads to 
the release of the L2/Genome complex [131], [136]. As soon as viral uncoating occurs, L1 
and L2 are separated by cellular chaperones, such as cyclophilin, in different compartments. 
The minor capsid protein, along with the viral DNA is retrogradely transported to the Golgi 
network [137], [138] by the retromer complex that enables recycling of factors to the cell 
surface. From the Golgi compartment, the L2/viral DNA complex is transported to the 
nucleus along microtubules: the L2 protein interacts with the microtubule motor protein 
dynein and this allows the movement to the nucleus [139], [140]. It is well established that L2 
accompanies the viral genome and the complex accumulates in specific nuclear structures 
responsible for viral transcription and replication, known as promyelocytic leukemia (PML) 
nuclear bodies or nuclear domain 10 (ND10) [141], [142] (Fig. 8). 
 
Fig. 8 Viral uncoating and endocytosis (Figure modified from [125]) 
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1.2.3 Viral genome maintenance, amplification and virions 
production  
The HPV life cycle is tightly dependent on cellular differentiation. After a micro lesion the viral 
particles enter the basal layer, where wound healing occurs and infection presumably takes 
place in stem-cells in the basal layer, granting a long-term maintenance of the viral DNA in 
the tissue [143]. As with most viruses, PV replication is totally dependent on the cell and viral 
genome is replicated with the cellular DNA. HPV gene expression follows a spatial and 
temporal pattern (Fig. 9). Upon infection, viral genomes are replicated and, after being 
established as episomes, are kept at low copy number in the basal layer [29]. In this first 
replication step the viral proteins E1 and E2 are thought to play a major role: E2 binds to the 
viral DNA and recruits the helicase E1 to the viral origin where it can assemble the cellular 
replication machinery; to ensure the viral genome maintenance, E2 can anchor the newly 
synthesized viral genomes to the segregating cellular chromosomes [31]. The virus has to 
overcome the loss of proliferation due to the natural differentiation process every epithelial 
cell undergoes. On one hand HPV needs proliferating cells to use the cellular replication 
machinery, on the other hand, it cannot totally inhibit differentiation since other viral proteins 
need differentiation-related transcription factors [143]. This delicate balance is mainly 
maintained in the upper layer by the viral proteins E6, E7 (and presumably E5) and E2. The 
viral oncogenes, E7 and E6, act mainly on cell cycle progression and downregulation of 
apoptosis as described before. 
E2 has a central role in regulating the expression of all the viral genes in a dose-dependent 
manner: if high levels of E2 are present it behaves like a repressor of the early promoter (all 
the early genes are downregulated) but when E2 is not abundant transcription through the 
early promoter is activated and as a result E2 regulates both its own expression and, 
consequently, the viral copy number [27]. During neoplastic progression to cervical cancer, 
this subtle regulation is abolished because HPV integrates its DNA into the host genome 
causing deletion of the E2 gene and therefore leading to an increased expression of the viral 
oncogenes E6 and E7 [144]. Once the genome has been amplified and the infected cells 
have differentiated, infectious viral particles have to be build and released with dead skin 
cells. Upon differentiation, the late promoter is activated and the late proteins L1 and L2 can 
be produced. L2, the first protein synthesized, is localized in the PML bodies where it can 
recruit the capsomeres formed by L1 in the cytosol and, although it has been shown that viral 
particles can be formed without L2, when L2 is present both packaging and infectivity were 
demonstrated to be more efficient [31]. Once the virions are ready, it was hypothesized that 
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E4 might help the viral particles in egressing from the cell surface by disrupting the keratin 
network [39].  
 
 
Fig. 9 HPV temporal and spatial protein expression pattern (Figure adapted from [29]) 
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3. Aim of the work 
The molecular mechanisms that HPV uses to promote tumorigenesis in HPV-related cancers 
outside of the cervix uteri are not yet understood. While cervical HPV oncoprotein 
interactions were investigated in several studies, much less is known about the interactions 
of cutaneous HPV oncoproteins and only few studies refer to the intraviral interactome of the 
HPV. Protein-protein interaction studies are strong tools to gain more insights into the 
pathogenicity of viruses and, therefore, the objectives of this study were to identify new viral-
host interaction partners of the cutaneous E6 oncoproteins, in particular of CRPV and 
HPV38, and to create a network of HPV31 intra-viral protein interactions.  
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4. Materials and methods 
4.1 Materials 
4.1.1 Media for bacteria 
LB Medium (Luria Bertani Bouillon): 25 g of high salt LB Broth Base (Fluka) dissolved in 1 l 
of H2O. 
LB Agar: 15 g of Select Agar (Gibco®) dissolved in 1 l of LB Medium. 
SOC Medium: 2% (w/v) Bactotryptone, 0.5% (w/v) BactoYeast Extract, 10 mM NaCl, 2.5 mM 
KCl, 10mM MgCl2, 10 mM MgSO4 and 20 mM Glucose. 
Freezing Medium: 50 % LB Medium, 50 % Glycerin. 
 
4.1.2 Bacteria 
E.coli DH5α (Clontech) Genotype F- 80dlacZ M15 (lacZYA-argF) U169 recA1 endA1 hsdR17 
(rk-, mk+) phoA supE44-thi-1 gyrA96 relA1 
 
4.1.3 Media and solutions for eukaryotic cells 
DMEM + FBS: Dulbecco’s Modified Eagle Medium (Gibco® by Life Technologies) 
supplemented with 10% of fetal bovine serum (FBS, PAA) and with 50 mg/l of Gentamicin 
(Sigma-Aldrich).  
DMEM + CS: Dulbecco's Modified Eagle Medium (Gibco® by Life Technologies) with 50 mg/l 
Gentamicin (Sigma-Aldrich) and 10% Calf Serum (CS) (Gibco by Life Technologies) 
F-Medium: Ham's F-12 GlutaMAX and DMEM/Ham's F-12 (1:1 v/v) supplemented with 1.8 
mM Adenin, 417 µg/ml Hydrocortison, 50 µg/ml Insulin, 50 µg/ml Transferrin, 0.02 µM 
Triiodthyronin T3, 10 µM Cholera toxin, 1% v/v Penicillin/Streptomycin, 10% HyClone (HC, 
HyClone Laboratories, Inc.) 
N/Terts Medium: DMEM + DMEM/Ham’s F12 (3:1 v/v) (Gibco® by Life Technologies) with 
10% fetal bovine serum, 1% L-glutamine, 1% Penicillin/Streptomycin and supplemented with 
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RM+ (0.4 μg/ml Hydrocortisone, 5 μg/ml Insulin, 0.01 μg/ml EGF, 10 µM Cholera toxin, 1.8 
mM Adenine, 5 μg/ml Transferrin and 0.0013 μg/ml Lyothyronine (L4) 
Freezing Medium:  
- C33A, HeLa, SiHa, CaSki, HEK293T, A431, Phoenix: DMEM supplemented with 20% 
FBS and 10% DMSO  
- NIH3T3-J2 with DMEM+CS supplemented with 10% CS and 10% DMSO  
- NIKs with N/Terts medium supplemented with 10 % HC and 10 % DMSO 
 
PBS: Dulbecco’s Phosphate-Buffered Saline without CaCl2 und MgCl2 (Gibco® by Life 
Technologies) 
Opti-MEM®: Reduced-Serum and antibiotic-free medium used for DNA and siRNA 
transfection (Gibco® by Life Technologies) 
G418: Stock solution 100 mg/ml in ddH2O (Biochrom) 
Puromycin: Stock solution 1 mg/ml in ddH2O (Calbiochem) 
Penicillin-Streptomycin (10,000 U/ml): solution containing 10,000 units/ml of penicillin and 
10,000 µg/ml of streptomycin (Gibco® by Life Technologies) 
Trypsin-EDTA: solution containing 2.5 g/l of trypsin and 0.38 g/l of EDTA with Phenol red 
(Gibco® by Life Technologies) 
Versene Solution: PBS (Gibco® by Life Technologies) with 0.5 mM EDTA 
Mitomycin C: Stock solution 0.4 mg/ml (Medac) in PBS (Gibco® by Life Technologies) 
Polybrene (Hexadimethrine bromide) solution: Stock solution 5 mg/ml (1000x) (Sigma-
Aldrich) 
Glucose: Solution with ≥ 99.5% of D-(+)-Glucose (Sigma-Aldrich) 
Fugene HD: transfection reagent (Promega) 
HiPerfect: siRNA transfection reagent (Qiagen) 
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4.1.4 Eukaryotic cell lines 
 
Cell lines Description 
HeLa  HPV18-positive cervix carcinoma cell line [145] 
NHK  Normal human keratinocytes [146] 
NIH3T3-J2  Murine Fibroblasts cell line [147] 
C33a Human HPV-negative cervical carcinoma cells mutated in p53 and pRb 
proteins [148]  
SiHa  HPV16-positive cervix carcinoma cell line [149] 
HEK 293T Human embryonal kidney cell line with adenovirus E1A ad SV40 Large-
T-Antigen [150] 
NIKS Spontaneously immortalized human keratinocytes cell line [151] 
Phoenix Retroviral packaging cell line based on 293T [152] 
CaSki  HPV16-positive cervix carcinoma cell line [153] 
A431 Epidermoid carcinoma cell line overexpressing EGFR and mutated in 
p53 [154] 
AVS Primary keratinocytes, harboring the whole CRPV genome, 
immortalized with CRPV particles [155] 
N/Terts Human foreskin keratinocytes immortalized with the catalytic subunit of 
human telomerase [156] 
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4.1.5 Commercial kits  
Kit Catalogue number Brand 
QIAquick Gel Extraction Kit 28706 Qiagen 
QIAprep Spin Miniprep Kit 27106 Qiagen 
QIAprep Spin Midiprep Kit 12945 Qiagen 
Rneasy Mini Kit 74106 Qiagen 
QIAshredder 79656 Qiagen 
QuantiTect Reverse Transcription Kit 205311 Qiagen 
LongRange PCR Kit 206401 Qiagen 
LightCycler 480 SYBR Green I Master 04707516001 Roche 
µMACS HA Isolation Kit 130-091-122 Miltenyi Biotec 
Rapid I Ligation Kit K1422 Thermo 
scientific 
Protein detection Pierce 660nm 22660 Thermo 
Scientific 
SuperSignal West Dura Extended Duration 
Pierce 
34075 Thermo 
Scientific 
SuperSignal West Femto Maximum 
Sensitivity Substrate Pierce 
34095 
 
Thermo 
Scientific 
NE-PER Nuclear and Cytoplasmic Extraction 
Reagents 
78833 Thermo 
Scientific 
Gaussia Juice Kit 102541 P.J.K. 
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4.1.6 Enzymes 
Restriction endonucleases: Thermo Scientific, NEB 
DNA polymerases:  
- GoTaqR DNA Polymerase (Promega) 
- Pyrobest DNA polymerase (Takara) 
 
Fast AP (Thermo Scientific, EF0654) 
4.1.7 Reference ladders  
Protein ladders: 
- Spectra Multicolor Broad Range Protein Ladder (Thermo Scientific) 
- Pageruler Prestained Protein Ladder (Thermo Scientific) 
DNA ladder: 
- 1 kB Plus DNA Ladder (Invitrogen) 
 
4.1.8 Buffers and solutions 
DNA loading buffer: 20% Ficoll 400, 0.1 M Na2EDTA pH 8.0, 1% SDS, 0.25% bromophenol 
blue or 0.25% xylene cyanol. 
Protein loading buffer (4X): ROTI®-LOAD 1 reducing (Roth). 
MCLB (Mammalian Cell Lysis Buffer): 50mM Tris, 150mM NaCl, 0.5% (v/v) NP-40 
(IGEPAL CA-630, Sigma Aldrich), cOmplete Protease Inhibitor Cocktail (Roche) 
RIPA buffer: 10 mM NaF, 10 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% (v/v) 
Triton X-100, 1.5% (v/v) SDS, 0.5% (w/v) Deoxycholate, cOmplete Protease Inhibitor 
Cocktail (Roche) 
Coomassie staining solution: 2.5 g Coomassie-Brilliant-Blue R-250(Merck), 454 ml H2O, 
92 ml acetic acid 
Coomassie destaining solution: 454 ml Methanol, 471 ml H2O, 75 ml acetic acid  
TAE buffer (50X): 2 M Tris, 1 M Acetic acid, 100 mM Na2EDTA, pH 8.5 
Ethidiumbromid: solution ready-to-use 500 µg/ml (Roth) 
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TBS (10X): 500 mM Tris, 1.5 M NaCl, pH 7.5 
TBS-T: 1XTBS with 0.1% TWEEN® 20 
PBS: 137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, pH 7.2 
PBS-T: 1xPBS buffer + 0.1% (v/v) Tween 20 
Ponceau S solution: 0.1% (w/v) Ponceau S in 5% (v/v) acetic acid 
4.1.9 Antibodies 
4.1.9.1 Primary antibodies 
 
Antigen Species Manufacturer Dilution WB/IF 
α-tubulin  mouse monoclonal Calbiochem (DM1A, #CP06) 1:1000 
17β-HSD4 mouse monoclonal Santa Cruz (A-6, sc-365167) 1:1000/1:400 
Actin mouse monoclonal Sigma-Aldrich (AC-40, A3853) 1:1500 
E6AP rabbit polyclonal Santa Cruz (H-182, sc-25509) 1:1500 
EGFR mouse monoclonal Dako (M7239, Clone E30) -/1:500 
FLAG rabbit monoclonal Cell Signaling (#2368) 1:1000 
HA  mouse monoclonal Covance (16B12) 1:1500/1:1000 
HA  rabbit monoclonal Cell signaling (C29F4, #3724) 1:1000/1:1600 
HDAC1 mouse monoclonal Santa Cruz (10E2, sc-81598) 1:500 
HDAC2 mouse monoclonal Santa Cruz (F-6, sc-55542) 1:1000 
HSP90  mouse monoclonal Santa Cruz (sc-69703) 1:2000 
KRIP-1  rabbit polyclonal Transduction Laboratories 
(#610680) 
1:1000 
LSD1/KDM1A rabbit monoclonal Cell Signaling (C69G12, #2184) 1:1000/1:400  
MAML1 rabbit polyclonal Cell Signaling (#4608) 1:1000 
p300 rabbit polyclonal Santa Cruz (C-20, sc-585) 1:1000 
p53  mouse monoclonal Santa Cruz (DO-1, sc-126) 1:1000 
pRb mouse monoclonal Cell signaling (4H1, #9309) 1:2000/1:200 
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4.1.9.2 Secondary antibodies 
 
Antigen Species Manufacturer Dilution 
anti-rabbit IgG  swine polyclonal Dako (P0399) 1:1000 
anti-mouse IgG  rabbit polyclonal Dako (P0260) 1:2500 
anti- goat IgG  rabbit polyclonal Dako (P0449) 1:1000 
anti-mouse (green)  goat anti-mouse, 
IRDye 800 
Odyssey Infrared Imaging (926-
32210D) 
1:15000 
anti-mouse (red)  goat anti-mouse, 
IRDye 680 
Odyssey Infrared Imaging (926-
32211D) 
1:15000 
anti-rabbit (green)  goat anti-rabbit 
IRDye 800 
Odyssey Infrared Imaging (926-
32211D) 
1:15000 
anti-rabbit (red)  goat anti-rabbit 
IRDye 680 
Odyssey Infrared Imaging (926-
32221D) 
1:15000 
anti- goat (red)  donkey anti goat 
IRDye 680 
Odyssey Infrared Imaging (926-
68071) 
1:15000 
 
4.1.10 DNA constructs 
4.1.10.1 Expression vectors 
 
pMSCVpuro-L3HA: at the C-terminus of the multiple cloning site of the pMSCVpuro vector a 
12 amino acids linker followed by 3 HA-Tag epitopes (with stop codon) was cloned via 
XhoI/EcoRI; after digestion with BglII/XhoI a sequence can be inserted which will then be 
expressed as a 3xHA-tagged protein (internal database # 2384, AmpR) (Fig. 10) . 
 
Fig. 10 pMSCVpuro-L3HA. Scheme showing how the viral proteins were 3xHA-tag cloned. aa: amino 
acids; 3xHA: triple HA tag.  
 
pMSCV-CRPVLE6M98S-L3HA: CRPVLE6M98S (amplified from # 2138, the mutation 
Methionine to Serine at position 98 ensures the exclusive expression of CRPVLE6) was 
cloned into pMSCV-L3HA (#2384) via BglII and XhoI. The new generated vector was 
registered in the internal database as # 2431, AmpR.  
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pMSCV-CRPVSE6-L3HA: CRPVSE6 was cloned into pMSCV-L3HA (# 2384) via BglII and 
XhoI. The new generated vector was registered in the internal database as # 2432, AmpR.  
pMSCV-HPV5E6-L3HA: HPV5E6 (# 595) was cloned into pMSCV-L3HA (# 2384) via BglII 
and XhoI. The new generated vector was registered in the internal database as # 2433, 
AmpR.  
pMSCV-HPV38E6-L3HA: HPV38E6 (amplified from # 2048) was cloned into pMSCV-L3HA 
(# 2384) via BglII and XhoI. The new generated vector was registered in the internal 
database as # 2433, AmpR.  
pCMV-N-Flag_linker_HA: expression vector kindly given by Karl Munger, based on pCMV-
Bam-Neo with the addition of a N-terminal Flag-linker-HA tag. The multiple cloning site 
contains an EcoRV and a BamHI site (Internal database # 2509, AmpR). 
pCMV-N-Flag_linker_HA-CRPVLE6M98S: CRPVLE6M98S (amplified from # 2138, the 
mutation Methionine to Serine at position 98 ensures the exclusive expression of CRPVLE6), 
was cloned into pCMV-N-Flag_linker_HA (# 2509) via EcoRV. The new generated vector 
was registered in the internal database as # 2511, AmpR.  
pCMV-N-Flag_linker_HA-CRPVSE6: CRPVSE6 was cloned into pCMV-N-Flag_linker_HA 
(# 2509) via EcoRV. The new generated vector was registered in the internal database as # 
2512, AmpR.  
pCMV-N-Flag_linker_HA-HPV5E6: HPV5E6 (amplified from # 595) was cloned into pCMV-
N-Flag_linker_HA (# 2509) via EcoRV. The new generated vector was registered in the 
internal database as # 2513, AmpR.  
pCMV-N-Flag_linker_HA-HPV38E6: HPV38E6 (amplified from # 2048) was cloned into 
pCMV-N-Flag_linker_HA (# 2509) via BamHI. The new generated vector was registered in 
the internal database as # 2514, AmpR.  
Notch Intracellular Domain (NICD): Notch Intracellular Domain received from Scott Vande 
Pol (Internal database # 2536, AmpR). 
pBabe-puro: Retroviral vector kindly given from Scott Vande Pol [75] (Internal database # 
2755, AmpR). 
pBabe-puro BPVE6: Retroviral vector containing BPV1 E6 kindly given from Scott Vande 
Pol [75] (Internal database # 2756, AmpR).  
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pBabe-puro CRPVLE6 M98S: CRPVLE6 M98S was PCR amplified, using # 2511 as 
template, adding EcoRI restriction sites and then cloned into the pBabe-puro vector (# 2536). 
The new generated vector was registered in the internal database as # 2757, AmpR.  
pBabe-puro CRPVLE6 M98S Flag_linker_HA: The Flag_linker_HA-CRPVLE6 M98S was 
excised from pCMV-N-Flag_linker_HA-CRPVLE6M98S (# 2511) and then cloned into the 
pBabe-puro vector (# 2536). The new generated vector was registered in the internal 
database as # 2758, AmpR. 
peYFP-C1: Clontech vector encoding for eYFP, kindly donated by Prof. Schindler. Using 
NheI/AgeI and XhoI/EcoRI it is possible to insert sequences that will be C- and N-terminally 
tagged, respectively (Fig. 11, internal database # 2590, KanR). 
pmTagBFP-C1: Clontech vector encoding for mTagBFP, kindly donated by Prof. Schindler. 
Using NheI/AgeI and XhoI/EcoRI it is possible to insert sequences that will be C- and N-
terminally tagged, respectively (Fig. 11, internal database # 2598, KanR). 
 
Fig. 11 pmTagBFP-C1 and peYFP-C1 vectors (Clontech, given by Prof. Schindler) figure adapted by 
[157]. HPV31 sequences were cloned into the vectors via NheI/AgeI for the C-terminal tag and via 
XhoI/EcoRI or Kpn2I/SmaI for the N-terminal tag.  
 
peYFP-mTagBFP: expression vector encoding for eYFP-mTagBFP in a single protein 
constitutively giving a positive FRET signal, kindly donated by Prof. Schindler, used as 
positive control for FACS-FRET experiments (Internal database # 2750, KanR). 
peYFP-HPV31 E1 N-Ter: The new generated vector was registered in the internal database 
as # 2589, KanR.  
pmTagBFP-HPV31 E1 N-Ter: HPV31 E1 was PCR amplified and cloned into pmTagBFP via 
Kpn2I/SmaI. The new generated vector was registered in the internal database as # 2725, 
KanR.  
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peYFP-HPV31 E2co N-Ter: HPV31 E2co (codon-optimized version synthesized by 
Invitrogen) was PCR amplified and cloned into peYFP via Kpn2I/SmaI. The new generated 
vector was registered in the internal database as # 2726, KanR.  
pmTagBFP-HPV31 E2co N-Ter: HPV31 E2co (codon-optimized version synthesized by 
Invitrogen) was PCR amplified and cloned into pmTagBFP via Kpn2I/SmaI. The new 
generated vector was registered in the internal database as # 2727, KanR.  
peYFP-HPV31 E8^E2Cco N-Ter: HPV31 E8^E2co (codon-optimized version synthesized by 
Invitrogen) was PCR amplified and cloned into peYFP via Kpn2I/SmaI. The new generated 
vector was registered in the internal database as # 2728, KanR.  
pmTagBFP-HPV31 E8^E2Cco N-Ter: HPV31 E8^E2co (codon-optimized version 
synthesized by Invitrogen) was PCR amplified and cloned into pmTagBFP via Kpn2I/SmaI. 
The new generated vector was registered in the internal database as # 2729, KanR.  
peYFP-HPV31 E1^E4 N-Ter: HPV31 E1^E4 was PCR amplified and cloned into peYFP via 
Kpn2I/SmaI. The new generated vector was registered in the internal database as # 2730, 
KanR.  
pmTagBFP-HPV31 E1^E4 N-Ter: HPV31 E1^E4 was PCR amplified and cloned into 
pmTagBFP via Kpn2I/SmaI. The new generated vector was registered in the internal 
database as # 2731, KanR.  
peYFP-HPV31 E5 N-Ter: HPV31 E5 was PCR amplified and cloned into peYFP via 
Kpn2I/SmaI. The new generated vector was registered in the internal database as # 2734, 
KanR.  
pmTagBFP-HPV31 E5 N-Ter: HPV31 E5 was PCR amplified and cloned into pmTagBFP via 
Kpn2I/SmaI. The new generated vector was registered in the internal database as # 2735, 
KanR.  
peYFP-HPV31 E6sm N-ter: HPV31 E6 was PCR amplified and a silent mutation (TG) 
within the splicing donor site at position 105 was inserted into the E6 ORF via overlapping 
PCR. E6sm was then cloned into peYFP via Kpn2I/SmaI. The new generated vector was 
registered in the internal database as # 2738, KanR.  
pmTagBFP-HPV31 E6sm N-Ter: HPV31 E6 was PCR amplified and a silent mutation 
(TG) within the splicing donor site at position 105 was inserted into the E6 ORF via 
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overlapping PCR. E6sm was then cloned into pmTagBFP via Kpn2I/SmaI. The new 
generated vector was registered in the internal database as # 2739, KanR.  
peYFP-HPV31 E7 N-Ter: HPV31 E7 was PCR amplified and cloned into peYFP via 
Kpn2I/SmaI. The new generated vector was registered in the internal database as # 2740, 
KanR.  
pmTagBFP-HPV31 E7 N-Ter: HPV31 E7 was PCR amplified and cloned into pmTagBFP via 
Kpn2I/SmaI. The new generated vector was registered in the internal database as # 2741, 
KanR.  
peYFP-HPV31 L1co C-Ter: HPV31 L1co (codon-optimized version synthesized by 
Invitrogen) was PCR amplified and cloned into peYFP via NheI/AgeI. The new generated 
vector was registered in the internal database as # 2746, KanR.  
pmTagBFP-HPV31 L1co C-Ter: HPV31 L1co (codon-optimized version synthesized by 
Invitrogen) was PCR amplified and cloned into pmTagBFP via NheI/AgeI. The new 
generated vector was registered in the internal database as # 2747, KanR.  
peYFP-HPV31 L2co C-Ter: HPV31 L2co (codon-optimized version synthesized by 
Invitrogen) was PCR amplified and cloned into peYFP via NheI/AgeI. The new generated 
vector was registered in the internal database as # 2748, KanR.  
pmTagBFP-HPV31 L2co C-Ter: HPV31 L2co (codon-optimized version synthesized by 
Invitrogen) was PCR amplified and cloned into pmTagBFP via NheI/AgeI. The new 
generated vector was registered in the internal database as # 2749, KanR.  
 
4.1.10.2 Reporter vectors 
 
Hes1-luc: Hes1-Luciferase (Notch responsive) reporter gene from Annika Wallenberg 
(internal database # 2535, AmpR). 
pGL 31URR luc: reporter plasmid containing HPV31 nt 7067 to 107 in pGL3 basic [158] 
(internal database # 752, AmpR). 
pCMV Gluc (Gaussia): commercial artificial reporter containing the sequence for the 
secreted Gaussia Luciferase (GLuc) under the control of the Cytomegalovirus (CMV) 
promoter (New England Biolabs, internal database # 1770, AmpR ). 
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4.1.11 Oligonucleotides 
4.1.11.1 Cloning primers 
 
Cloning in pMSCV: 
Primer name Sequence (5’ 3’) Position (nt) 
CRPVLE6 BglII F aacgaaAGATCTatggagaactgcctgccacg 154-173 
CRPVSE6 BglII F gcaaggAGATCTatgcgttgtacagtttgcgg 445-464 
CRPVLE6_SE6 XhoI R gcggccCTCGAGtctaaattctgtgaagttaa 972-953 
HPV5E6 BglII F ggtaatAGATCTatggctgagggagccgaaca 200-219 
HPV5E6 XhoI R ccgacgCTCGAGccaatcatgataaaaatgct 670-651 
HPV38E6 BglII F ggccggAGATCTatggaactaccaaaacctca 200-219 
HPV38E6 XhoI R aaggccCTCGAGttctattgctttgcaatgcc 622-603 
 
Cloning in pCMV: 
Primer name Sequence (5’ 3’) Position (nt) 
CRPVLE6 EcoRV F 
 
ctttatGATATCgagaactgcctgccacgctc 157-180 
CRPVSE6 EcoRV F cgccagGATATCcgttgtacagtttgcggaag 448-467 
CRPVLE6_SE6 EcoRV R cggcgcGATATCtcatctaaattctgtgaagt 975-956 
HPV5E6 BamHI F 
 
ctaaatGGATTCgctgagggagccgaacacca 203-222 
HPV5E6 BamHI R 
 
cgggcgGGATTCttaccaatcatgataaaaat 673-654 
HPV38E6 BamHI F 
 
cgccagGGATCCgaactaccaaaacctcaaac 203-222 
HPV38E6 BamHI R 
 
cgggcgGGATCCtcattctattgctttgcaat 625-606 
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Cloning in peYFP and pmTagBFP: 
Primer name Sequence (5’ 3’) Position (nt) 
HPV31E1 Kpn2I F 
 
gattatTCCGGAgctgatccagcaggtacaga 1865-1881 
HPV31E1 SmaI R 
 
cgccggCCCGGGtcataatgttctaatatttt 2751-2732 
HPV31E2 co Kpn2I F 
 
aattatTCCGGAgagacactgagccagcggct 
2696-2715 (codon-
optimized) 
HPV31E2 co SmaI R 
 
atactaCCCGGGtcagatggtcatgtagccgg 
3811-3792 (codon-
optimized) 
HPV31 E8 Kpn2I F 
 
atataTCCGGAgccggatctggcggagg 
1262-1281 (codon-
optimized) 
HPV31 E2C SmaI R 
 
accgatCCCGGGctagatggtcatgtagc 
3811-3790 (codon-
optimized) 
HPV31E1^E4Kpn2I F 
 
gattatTCCGGAgctgatccagcagtgacgaaata
tcctt 
865-884 
HPV31E1^E4SmaI R 
 
cgctgtCCCGGGttataggtgtagttgcagga 3578-3559 
HPV31E5Kpn2I F 
 
cgcggcTCCGGAattgaactaaatatttctac 3819-3838 
HPV31E5SmaI R 
 
agcgtaCCCGGGttactgttgacttaaaaaag 4070-4051 
HPV31E6Kpn2I F 
 
agcgatTCCGGAttcaaaaatcctgcagaaag 111-130 
HPV31E6SmaI R 
 
gattatCCCGGGttacacttgggtttcagtac 557-538 
HPV31E6sm 95 F 
 
actgcaaaggGcagttaaca 206-225 
HPV31E6sm 115 R 
 
tgttaactgCcctttgcagt 225-206 
HPV31E7Kpn2I F 
 
agctatTCCGGAcgtggagaaacacctacgtt 563-582 
HPV31E7SmaI R 
 
atcgcaCCCGGGttacagtctagtagaacagt 856-837 
HPV31L1co NheI F 
 
agctatGCTAGCatgagcctgtggaggcccag 5552-5571 (codon-
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optimized) 
HPV31L1co AgeI R 
 
ataaACCGGTgcacctgctcccttcttggtcttcttcct
ct 
7063-7044 (codon-
optimized) 
HPV31L2 co NheI F 
 
aatcatGCTAGCatgcggagcaagcggagcac 
4171-4190 (codon-
optimized) 
HPV31L2 co AgeI R 
 
atattaACCGGTgcacctgctccggcagccac 
5568-5549 (codon-
optimized) 
 
4.1.11.2 Sequencing primers 
Primer name Sequence (5’ 3’) Position (nt) 
pMSCV 1333 F CCCTTGAACCTCCTCGTTCGACC 1333-1356 
pMSCV_1473 R CAGCGGGGCTGCTAAAGCGCATGC 1473-1449 
HPV5E6 379 F TTAGATTGCTGTGGCAGAGG 579-601 
HPV5E6 450 R ACACTGCCTACAGATTCCCTTC 650-628 
HPV38E6 257 F TTGAACAGGTGGAGCAACAG 457-477 
HPV38E6 395 R CCTTTCCAATTGCCTCTAACC 595-574 
pCMV-Flag-F  GGACTACAAGGATGACGATG 
Standard 
sequencing primer 
pCMV-Flag-R GATCCGTCGAGGAATTCAC 
Standard 
sequencing primer 
pBabe puro 5 F CTTTATCCAGCCCTCAC 
Standard 
sequencing primer 
pBabe-puro 3 R ACCCTAACTGACACACATTCC 
Standard 
sequencing primer 
BFP-YFP seq 511 F CCCATTGACGCAAATGGGCG Standard 
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sequencing primer 
BFP-YFP seq 1400 R ATGATCAGTTATCTAGATCCG 
Standard 
sequencing primer 
HPV31L2 co 565 F CATCAGCACCCACAACTACG 6117-6137 
HPV31L2 co 805 R TGTGGCTGGTGTTGCTGAAG 6357-6337 
HPV31E1 823 F AACAATTGAAAAATTATTAG 2688-2708 
HPV31E1 1213 R TTTGTCACATCTACTTTTAA 3078-3058 
HPV31L1co 728 F CGGCGACACCCTGTTCTTCT 4899-4919 
HPV31L1co 935 R TAGGGCTTGTTGAAGATCTG 5106-5086 
 
 
4.1.11.3 siRNAs 
 
- AllStar Negative control siRNA 
 
Negative control siRNA (1027281, Qiagen) 
- si18E6 [159] CACTTCACTGCCAAGACATA (Qiagen) 
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4.2 Cell Culture 
4.2.1 Cell cultures and cell lines storage 
Cells were maintained at 37°C, 5% CO2 and 99% of relative humidity on plastic plates 
(Nunc, all except NIKS with Primaria).  
C33A, HeLa, SiHa, CaSki, HEK293T, Phoenix cell lines were maintained in cell culture with 
DMEM + FBS, N/Terts with N/Terts Medium, 3T3 J2 with DMEM + CS medium, NIKS cells 
were cultured in F-medium together with growth-arrested feeder cells, 3T3 J2. The feeder 
cells were treated with 80 ng/ml mitomycin C (Medac) for 1-2 h in order to arrest their growth, 
then were washed 3 times with 5 ml PBS to be added to NIKS cells. 
When cells were confluent, the medium was removed, the plate was washed with 5 ml PBS 
and incubated at 37°C with 1 ml of Trypsin (Gibco® by Life Technologies). After few minutes 
trypsin was inactivated by adding as much medium as needed to split the cells and the cells 
were then transferred to new culture dishes. 
To store the cells, medium was removed from confluent plates, cells were washed with 5 ml 
PBS, trypsinized and spun down at 250 x g for 5 min at 20°C. Cell pellets were re-suspended 
in freezing medium using 1 ml for one original 10 cm plate. Each ml was then transferred in a 
cryotube and stored at -80°C in a freezing box (Nalgene) for at least 24 h.  
Cells were thawed using a water bath at 37°C. Cell suspension was transferred to a 10 cm 
dish together with 9 ml of medium. The day after the medium was exchanged with 10 ml of 
fresh new medium. 
 
4.2.2 DNA transfection 
The day before transfection, cells were counted in a Neubauer chamber and seeded 
depending on the cell type and the plate format. Exogenous DNA was transfected using the 
nonliposomal transfection reagent Fugene HD (Promega), according to the manufacturer´s 
protocol. Briefly, 24 h after seeding, DNA and Fugene were mixed at a ratio of 5:1 (C33a), 
5:2 (HeLa, HEK293T) or 4:1 (N/Terts) in the serum-free medium, OptiMEM (Life 
technologies), vortexed, and after a 15 min of incubation at RT the complexes were added 
drop-wise to the cells.  
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4.2.3 Establishment of stable cell lines 
To establish NIKS cells stably expressing different E6s the packaging cell line Phoenix was 
used. Transient transfections were performed with Fugene using a Fugene/DNA ratio of 5:2. 
The process was divided in three different steps: 
 
1. Retroviruses generation 
 
3 x 106 Phoenix cells were seeded in 10 cm plates and were transfected with 4 µg of 
DNA (pMSCVpuro-L3HA, pMSCV-CRPVLE6M98S-L3HA, pMSCV-CRPVSE6-L3HA, 
pMSCV-HPV5E6-L3HA, pMSCV-HPV38E6-L3HA) the day after. 24h later the medium 
was exchanged to 7 ml of DMEM with 10% FCS and gentamicin and the plates were 
incubated at 32°C. At the same time 1.5 x 106 NIKS cells were seeded in 60 mm plates in 
F-medium without feeder cells. 
 
2. Transduction 
 
Supernatant from Phoenix cells was sterile-filtered, Polybrene was added to a final 
concentration of 10 μg/ml. NIKS cells were then incubated with the supernatant for 4 h 
and afterwards 4 ml of F-medium were added for 24 h.  
 
3. Selection 
 
NIKS cells were then split onto of 3T3 J2 feeder cells in 10 cm plates. 24 h later antibiotic 
selection was started (150 µg/ml Neomycin and 0.4 µg/ml Puromycin) and was continued 
for at least 10 days. 
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4.3  Molecular Cloning and DNA/RNA methods 
 
4.3.1 Agarose gel electrophoresis 
DNA and RNA fragments were separated with agarose gel electrophoresis. Agarose gels, in 
this study, were made with 0.8 – 1.2% of agarose dissolved in electrophoresis buffer (TAE 
buffer) with the addition of ethidium bromide (Roth). Once solidified, the agarose gel was 
placed in the electrophoresis unit to run at 80-110 V for 40-60 min. 
 
4.3.2 DNA purification from agarose gels 
DNA fragments, after separation in an agarose gel, were cut out with a scalpel under a 320 
nm UV light and the bands were purified with QIAquick Gel Extraction Kit (Qiagen). 
 
4.3.3 Nucleic acid concentration determination 
Nucleic acid concentrations were measured after purification of plasmids (QIAprep Spin 
Miniprep Kit, Qiagen) or DNA fragments (QIAquick Gel Extraction Kit, Qiagen) with the 
Nanodrop® ND-1000 (Thermo scientific) according to the manufacturer´s instructions. For 
measuring nucleic acids, the ratio of absorbance at 260 nm and 280 nm is used as a 
measure of nucleic acids purity. A 260/280 ratio of ~1.8 was considered as “pure” for DNA; a 
ratio of ~2.0 was accepted as “pure” for RNA. For this purpose 2 µl of water were used as 
blank and, after that, then samples were measured. 
 
4.3.4 DNA digestion with restriction enzymes 
Restriction endonucleases were used for digestion of plasmids or PCR amplicons following 
the manufacturer´s protocol. In the case of digested vectors, an additional step of 
dephosphorylation with FastAP (Fermentas) was performed, in order to avoid re-ligation 
during the process of plasmid- insert ligation. The digested fragments were then purified, 
after their separation during an agarose gel electrophoresis. 
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4.3.5 Plasmid-insert Ligation 
For transformation of competent bacteria, digested plasmids and fragments were ligated 
using the Rapid DNA Ligation Kit (Thermo scientific). For each transformation reaction, 30 ng 
of the vector were used and DNA and inserts were ligated following the molar ratio 1:3. The 
reaction mixture was incubated for 10 min at 22 °C and then used to transform competent 
bacteria. 
 
4.3.6 Generation of competent bacteria 
DH5α were cultured overnight in 100 ml of LB medium without antibiotics. On the next day 20 
ml of the overnight culture were grown in 400 ml of LB medium for 1.5-2 hours until the OD600 
reached 0.45-0.55. All the following steps were carried out at 4°C. 
The bottle containing the 420 ml of culture was incubated on ice for 30 minutes and then the 
culture was divided in 50 ml tubes and centrifuged at 4000 rpm for 10 min at 4°C. The 
supernatant was then removed and the remaining pellets were re-suspended in 100 ml of 
ice-cold TFB1 buffer. An incubation of 15 minutes on ice followed and then the tubes were 
centrifuged at 4000 rpm for 10 min at 4°C. Supernatants were discarded, pellets were re-
suspended in 20 ml of ice-cold TFB2 and incubated on ice for 15 min. In the end, the 
suspension was aliquoted in 1.5 ml microcentrifuge tubes, shock-frozen in liquid nitrogen and 
immediately stored at -80°C. 
The efficiency of transformation was assessed by transforming 10 ng of DNA in 100µl 
bacteria and counting the number of colonies the day after on the plate. The best  achievable 
efficiency was 108 colonies / µg of DNA. 
TFB1 pH 5.8 with NaOH           TFB2 pH 6.5 
MES 10mM 
RbCl 100mM 
CaCl2 x 2H2O 10mM 
MnCl2 x 4H2O (Only after pH 5.8) 
MOPS 10mM 
RbCl 10mM 
CaCl2 x 2H2O 75mM 
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4.3.7 Bacteria transformation 
To transform bacteria, 15 µl of the ligation reaction were added to 100 µl of competent 
bacteria, incubated on ice for 30 min and then heat-shocked at 42°C for 90 seconds. 
Immediately after they were put back on ice and 350 µl of SOC medium were added before 
growing the bacteria, while shaking, at 37°C for 45 minutes. Bacteria were then plated on 
antibiotic containing LB-plates and were incubated overnight at 37°C. 
 
4.3.8 Selection of clones, DNA extraction and sequencing 
The day after transformation, the antibiotic resistant plates were checked for the presence or 
absence (plates with the cleaved and dephosphorilated empty vector re-ligated) of colonies. 
For each new generated plasmid, few colonies were picked and grown overnight. The 
following day DNA was extracted from the overnight cultures using the Miniprep Kit (Qiagen), 
DNA was digested with suitable restriction endonucleases and only the positive clones were 
prepared to be sequenced by the GATC Biotech (Konstanz) company. 
 
4.3.9 PCR 
Primer design was in accordance with the general criteria [160]: 
- unique oligonucleotide sequence in the template 
- primer length inbetween 18-25 nt 
- optimal annealing temperature around 60°C 
- GC content at least 50% 
For the PCR reactions the following polymerases were used: the proof reading Pyrobest 
DNA polymerase (Takara) was used for cloning and the GoTaq Polimerase (Promega) was 
used for testing mycoplasma contamination in cell culture and to screen clones. 
For the PCR reactions with the Pyrobest DNA polymerase (Takara), according to the 
manufacturer’s protocol, the reaction mixture contained 10X of supplied Pyrobest buffer, 4 μl 
of 10 µM dNTPs mix, 1 µl of 100μM primer forward and reverse, < 500 ng of DNA template 
and 0.25 μl of polymerase in a final volume of 50 μl. 
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Step Temperature Time Number of Cycles 
Initial Denaturation 98°C 3 minutes 
1 cycle 
 
Denaturation 98°C 
30 sec 
 
 
Annealing 
 
42–65°C 0.5–1 minute 25–35 cycles 
Extension 72°C 
1min/kb 
 
 
Final Extension 72°C 10 minutes 
1 cycle 
 
Final Hold 4°C Indefinite 1 cycle 
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4.4 Protein methods 
4.4.1 Cellular lysis 
Proteins were isolated from cell culture dishes by removing the medium, washing with cold 
PBS and either trypsinizing or scraping the cells from the plate. The samples were shortly 
spun down in a table top centrifuge at 13.000 rpm for 5 minutes at 4°C and, after discarding 
the supernatants, pellets were re-suspended in MCLB buffer supplemented with protease 
inhibitor (cOmplete Protease Inhibitor Cocktail Tablets, Roche). Lysis took place on ice for 
15-30 minutes and afterwards the samples were centrifuged at 13.000 rpm for 5 minutes at 4 
°C to separate the cell debris. The protein loading buffer (4X ROTI®-LOAD 1, Roth) was 
added to the collected supernatants and samples were denatured for 5 min at 95°C. The 
ready-to-use lysates were stored at -20°C. 
 
MCLB (Mammalian Cell Lysis Buffer) 
50mM Tris  
150mM NaCl 
0.5% (v/v) NP-40 (IGEPAL
®
 CA-630, Sigma Aldrich) 
cOmplete Protease Inhibitor Cocktail (Roche) 
4.4.2 Western blot 
For western blot analysis, samples were run on 6-12 % SDS–polyacrylamide gels [162], the 
proteins were then transferred for 90 minutes at 90 Volts in CAPS buffer to a nitrocellulose 
membrane (0.22 µM Potran, Schleicher & Schuell). The membrane was then blocked with 
5% nonfat dry milk dissolved in 1X TBS-T at RT for 1 hour to reduce unspecific binding of the 
primary antibody. Unless otherwise specified, primary antibodies (4.1.9.1) were diluted in 
TBS-T and the membrane was incubated on a shaker at 4°C, after being washed three times 
with TBS-T. The following day the membrane was washed three times with TBS-T and the 
secondary antibody (4.1.9.2) was incubated for 1 h at RT on a shaker. After rinsing the 
membrane from the excess of not bound antibody the bands were detected using either the 
SuperSignal West Dura Extended Duration Substrate (Thermo Scientific), in the case of the 
HRP-conjugated antibodies, or were directly acquired with the Odyssey Fc (LI-COR) and 
analyzed with the Image Studio Software (LI-COR). In rare cases, the membrane was re-
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probed after removing the bound antibodies with a stripping buffer overnight at 4°C and 
blocked again, allowing a second incubation with different primary and secondary antibodies. 
 
Resolving 
buffer 
 
Stacking 
buffer 
 
SDS-PAGE 
running buffer 
(5X) 
 
CAPS buffer 
 
Stripping 
buffer 
 
1.5 M Tris  
pH 8.8 
 
 
1.5 M Tris 
pH 6.8 
 
125 mM Tris 
0.96 M Glycine  
0.5% (w/v) SDS 
 
10 mM CAPS,  
10% (v/v) 
Methanol 
pH 10.3 
 
62.5 mM Tris pH 
6.8 
2% SDS  
50 mM DTT 
 
4.4.3 Dual-reporter luciferase assay 
Luciferase assays are useful tools for reporter quantitation in cells. When luciferase 
catalyses the oxidation of D-luciferin, light is emitted and this can be measured with a 
luminometer in relative luciferase activity (RLUs). In a dual reporter luciferase assay two 
reporters encoding different luciferase enzymes are expressed at the same time. Generally, 
the second reporter is used as an internal control and helps to eliminate experimental 
fluctuations that may be due to differences in cell viability and transfection efficiency. In our 
assay activities of Firefly (Fluc, Photinus pyralis) and Gaussia (Gluc, Gaussia princeps) were 
measured and the Gaussia-Juice Luciferase Assay (P.J.K) was used. 
The day before transfection 5x104 C33A cells/well were seeded in the 24-well plate. First, the 
activity of the Gaussia luciferase released into the medium was measured. For this purpose 
5 µl of the medium were pipetted in a tube to measure the turnover of the substrate 
Coelenterazine in the luminometer (LUMAT LB9507, EG&G Berthold). Afterwards the 
medium was removed and the cells were washed twice with 500 µl of cold PBS and lysed 
with 150μl of cold luciferase lysis buffer. After 10 minutes of lysis on ice, 100 µl of lysates 
were pipetted in tubes already containing 100 µl of luciferase assay buffer to determine the 
luciferase activity of the Firefly luciferase in the luminometer. Each condition was measured 
in duplicate (2 wells), and, after normalizing the firefly values to the Gaussia values 
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(Fluc/Gluc), the average of the two resulting values was taken to minimize the experimental 
variability. 
 
Luciferase lysis buffer Luciferase assay buffer 
 
100 mM KPO4 pH 7.8 
1% Triton-X-100 
1 mM DTT 
 
100 mM KPO4 pH 7.8 
15 mM MgSO4 
1 mM ATP 
1:50 Luciferin solution 
- 100 mM KPO4 pH 7.8 
- 15 mM MgSO4 
- 1 mM ATP 
- 50 mM Luciferin 
 
 
4.4.4 Co-ImmunoPrecipitation (CoIP) 
All the CoIPs were performed using the µMACS HA Isolation Kit (Miltenyi Biotec). One 10 cm 
dish of confluent cells was enough for a small scale CoIP, while for a big scale CoIP either 
ten 10 cm plates or four 15 cm plate were used. All steps were carried out at 4°C. What 
follows will describe the small scale CoIP, but in brackets are the volumes for the big scale.  
Medium was removed from the dish, cells were washed with ice-cold PBS and 1 ml (4ml) of 
pre-cooled MCLB buffer supplemented with the cOmplete Protease Inhibitor Cocktail Tablets 
(Roche) was added. Cells were scraped with a rubber policeman from the dish, transferred to 
a microcentrifuge (falcon) tube, mixed well and incubated on ice for 30 min. 
After this incubation period, samples were spun down at 10.000 x g for 10 min to sediment 
cell debris (in the case of the large scale, the centrifugation step was repeated more than 
once to have the supernatant as clean as possible from cell debris). Supernatants were 
transferred to a pre-chilled tube: 1/10 of the sample was kept as INPUT control sample and 
the rest was used for the pull down assay. 30 µl (120 µl) of anti-HA magnetic beads were 
added to the lysates and incubated in the cold room on an orbital shaker for 1 h. In the 
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meanwhile elution buffer (Roti-load, Roth) was heated to 95°C, the µ-columns placed in the 
magnetic field of the µMacs separator and 200µl lysis buffer were applied to the columns and 
let to flow through. After incubation with magnetic beads was finished, the suspensions were 
applied onto the columns and the lysates were left to run through (“FLOW THROUGH” 
sample). After washing the columns 5 times with the lysis buffer, the immunoprecipitates (IP) 
were collected applying 20 µl of pre-heated elution buffer and incubating for 5 minutes at 
room temperature. Another 50 µl (24 µl) of elution buffer were added and then samples were 
centrifuged at 1000 rpm for 1 min. 1/10 of the IP samples was used for western blot analysis 
and the rest for the mass spectrometry analysis.  
 
4.4.5 Proteome analysis 
4.4.5.1 Tryptic digestion of proteins 
For proteome analysis, samples were given to the Proteome Center Tübingen (PCT) to 
proceed with the proteomics analysis. Samples were loaded on a NuPAGE Bis-Tris 4-12% 
gradient gel (Invitrogen). After short gel run and brief Coomassie staining each gel piece was 
cut into small pieces. Destaining was performed by washing three times with 10 mM ABC 
and acetonitrile (ACN) (1:1, v/v) and was followed by protein reduction with 10 mM DTT in 20 
mM ABC for 45 minutes at 56°C, and alkylation with 55 mM iodoacetamide in 20 mM ABC 
for 30 minutes at room temperature in the dark. The gel pieces were then washed twice for 
20 minutes in destaining solution followed by dehydration with ACN. The liquid was removed 
and gel pieces were swollen at room temperature by adding 13 ng/µl sequencing grade 
trypsin (Promega) in 20 mM ABC. Digestion of proteins was performed at 37°C overnight. 
The resulting peptides were extracted in three subsequent incubation steps with 30% 
ACN/3% TFA; with 80% ACN/0.5% acetic acid; and with 100% ACN. Supernatants were 
combined, ACN was evaporated in a vacuum centrifuge and peptides were desalted using 
C18 StageTips. 
4.4.5.2  Nano LC-MS/MS analysis 
All digested peptide mixtures were separated on the EasyLC nano-HPLC (Proxeon 
Biosystems) coupled to an LTQ-Orbitrap-XL (Thermo Fisher Scientific). Binding and 
chromatographic separation of the peptides was performed on a 15 cm fused silica emitter of 
75 µm inner diameter (Proxeon Biosystems), in-house packed with reversed-phase ReproSil-
Pur C18-AQ 3 µm resin (Dr. Maisch GmbH). The peptide mixtures were injected onto the 
column in HPLC solvent A (0.5% acetic acid) at a flow rate of 500 nl/min and subsequently 
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eluted with a 107 minute segmented gradient of 2-80% of HPLC solvent B (80% acetonitrile 
in 0.5% acetic acid) at a flow rate of 200 nl/min. Each sample was run once. The mass 
spectrometer was operated in the data-dependent mode to automatically switch between MS 
and MS/MS acquisition. Survey full scan MS spectra were acquired in the mass range from 
m/z 300 to 2000 in the orbitrap mass analyzer at a resolution of 60,000. Accumulation target 
value of 106 charges was set and the lock mass option was used for internal calibration 
(Olsen et al., 2005). The ten most intense ions were sequentially isolated and fragmented in 
the linear ion trap using collision-induced dissociation (CID) at the ion accumulation target 
value of 5000 and default CID settings. The ions already selected for MS/MS were 
dynamically excluded for 90 s. The resulting peptide fragment ions were recorded in the 
linear ion trap. In total, 4 LC-MS measurements were performed in the first experiment and 5 
in the second experiment. 
4.4.5.3 MS Data Processing and Analysis 
Raw data were analyzed using MaxQuant (version 1.2.2.9) that, thanks to recently 
developed sophisticated normalization and matching algorithms [163], provided parts per 
million (ppm) level mass accuracy, confident identification of proteins (False Discovery Rate 
less than 1% on peptides and proteins level, with a minimum of 2 peptides per protein) and 
accurate intensity-based label-free quantification. The searched database was Uniprot 
(88,692 protein entries) and a common contaminant database of 247 proteins entries, 
allowing partial trypsin cleavage of 2 missed cleavages, was used. Additionally, one small 
database containing sequence of protein plasmids was created and used for search. 
Oxidation of methionines and N-terminal acetylation were specified as variable modifications, 
whereas carbamidomethylation on cysteines was defined as a fixed modification. The 
fragment mass tolerance was 6 ppm (monoisotopic mass), and the mass window for the 
precursor was set to 0.5 Da. The Maxquant output files were parsed for further analysis 
using the statistical tool suite Perseus (version.1.3.0.4). First, hits to the reverse database, 
contaminants and proteins only identified with modified peptides were eliminated. For every 
bait, a separate grouping was defined for valid values in the specific bait pull-downs. The 
interacting protein were identified and quantified only when present in the 2 biological 
replicates. The Label Free Quantification (LFQ) ratios were quantified using the intensity-
based absolute quantification (iBAQ) algorithm [164] in order to identify interactors of LE6, 
SE6 and 38E6. The iBAQ ratios where normalized to fit a Gaussian normal distribution and 
at least two values were necessary to calculate the median, therefore, since HPV5 E6 was 
tested only once, the possible interactors of HPV5 E6 were not quantified. The one sided 
significance B statistical test (p<0.05) as described by MaxQuant [165] was applied in order 
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to identify significant proteins interactions compared to the empty vector control. To identify 
differential interactions between LE6 and SE6, the iBAQ ratios from each analysis were 
divided by each other’s. Subsequently, the two sided Significance B statistical test (p<0.05) 
was applied in order to identify interactions disparities that significantly changed between 
LE6 and SE6. 
 
4.4.6 SILAC  
4.4.6.1 Introduction 
Stable isotope labeling by amino acids in cell culture (SILAC) is a metabolic labeling 
approach that represents a powerful tool for quantitative proteomics. SILAC relies on 
metabolic incorporation of stable isotope-labeled amino acids provided in cell culture media 
into all newly synthesized proteins [166]. 
Custom-synthesized cell culture media without essential amino acids, such as arginine and 
lysine, are supplemented with isotope labeled arginine and lysine. Because there is no 
chemical difference between the labeled and the natural amino acid, cells behave exactly like 
cells grown in medium with unlabeled amino acids. Mammalian cells are not able to 
synthesize essential amino acids and, therefore, when labeled essential amino acids are 
supplied in the medium instead of the natural ones, cells use them for protein synthesis. All 
the natural amino acids will be replaced by the isotope labeled analogs as soon as the cells 
are gone through a certain number of cell divisions. Since serum contains free (unlabeled) 
amino acids, SILAC culture media were supplemented with commercially available dialyzed 
fetal bovine serum, where no detectable traces of amino acids are found [167], [168]. 
An important advantage of SILAC is that lysates from cells grown in different culture media 
can be mixed before analysis but only as long as their protein amounts are the same. During 
a mass spec experiment proteins are fragmented and peptides are detected based on their 
mass/charge ratio. Using isotopes, atoms with the same charge but different mass, will allow 
to differentiate the same protein coming from cells grown in different media by analyzing 
mass spectra. To quantify a change in protein amount in a certain condition, SILAC relies on 
ratios between isotope labeled proteins isolated from the same cell line grown in heavy, 
medium-heavy or light label media and to see a difference between the two samples, the 
starting samples have to have an equal protein amount [169] (Fig. 12). Protein amounts were 
equalized by measuring the total protein concentration in each sample with the Pierce™ 
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660nm Protein Assay Reagent (ThermoFisher Scientific) and adjusting each sample volume 
in order to have the same total protein amount in each sample. 
Fig. 12 Isotope mass differences and quantification. m: mass; z: charge. 
4.4.6.2 Samples preparation 
In our study (Fig. 13) C33a cells were grown in SILAC heavy label (Lys8Arg10), medium-
heavy label (Lys4Arg6) or light label (Lys0Arg0) media in 60 mm dishes and after 14 days 
labeled amino acid incorporation rate, measured by the Proteome Center of Tübingen, was 
found higher than 95% in all cases. Moreover, cells grown in heavy and medium-heavy 
media behaved exactly the same as the ones grown in light medium, showing that there was 
no difference due to the isotope labeling amino acids substitution.  
 
Fig. 13 SILAC work flow 
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For the Nano-LC-MS/MS analysis 5 x 106 cells were seeded into 4 x 15 cm plates. 
Expression vectors containing pCMV-Flag-Linker-HA alone, pCMV-Flag-Linker-
HA+CRPVLE6 M98S or pCMV-Flag-Linker-HA+CRPVSE6 were transfected in cells grown in 
different media as shown in Table 1 and the experiment was performed in duplicate inverting 
the media. 
Table 1 
 pCMV+LE6 pCMV+SE6 pCMV 
1st SILAC Heavy label Heavy-Medium label Light label 
2nd SILAC Heavy-Medium label Light label Heavy label 
 
Cells were harvested 48 h post transfection with a cell scraper in 4 ml of pre-chilled MCLB 
buffer supplemented with the cOmplete Protease Inhibitor Cocktail Tablets (Roche) and 
collected in falcon tubes on ice, where the lysis continued for 30 min. After lysis, tubes were 
centrifuged, supernatants were kept on ice and protein concentration was measured. Input 
samples with equivalent protein concentrations were incubated with 120 µl of magnetic anti-
HA beads (Milteniy) and CoIP was performed as described. All the immunoprecipitates, 
except 1/10 kept to test the CoIP efficiency in a western blot, were then mixed 1:1:1 and 
given to the core facility, Proteome Center Tübingen (PCT), to proceed with the proteomics 
analysis. 
4.4.6.3 Nano-LC-MS/MS 
Immunoprecipitates from each cell line were mixed 1:1:1 (“light” to “heavy” to “medium”). 
Protein mixture was loaded on the gel and each of 6 gel slices was digested with Trypsin 
according to the protocol published by Macek et al.[170]. All peptides were measured on 
Easy-LC nano-HPLC (Proxeon Biosystems) coupled to an LTQ Orbitrap Elite mass 
spectrometer (Thermo Fisher Scientific). Liquid chromatography was done with a 15 cm 
fused silica emitter with an inner diameter of 75 μm and a tip diameter of 8 μm in-house 
made nano-HPLC column, packed with reversed-phase ReproSil-Pur C18-AQ 3 μm resin 
(Dr. Maisch GmbH). Peptides were flushed with HPLC solvent A (0.5 % acetic acid) at a flow 
rate of 500 nL/min with the maximum pressure of 280 Bar. Elution was done using 
segmented 90 min gradient (LTQ Orbitrap Elite) of 5 - 90 % HPLC solvent B (80 % ACN, 
0.5 % acetic acid) at a flow rate of 200 nL/min. The eluted peptides were ionized in an 
electrospray ionization (ESI) source (Proxeon Biosystems) set to positive ion mode. Full scan 
MS spectra were acquired in the orbitrap analyzer in a mass range from m/z 300 - 2000 at a 
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resolution of 120,000 (LTQ Orbitrap Elite), followed by fragmentation in LTQ mass analyzer 
of the top 20 (LTQ Orbitrap Elite) most intense precursor ions with collision induced 
dissociation (CID) at a target value of 5000 charges. Dynamic exclusion was used to exclude 
fragmented masses for 90 sec.  
4.4.6.4 Data processing and analysis  
The mass spectrometer data were processed using MaxQuant suite V 1.2.2.9 [165], [171]. 
Spectra were searched using Andromeda search engine [172] against the proteome 
database of Homo sapiens (UniProt complete proteome database, taxonomy ID 9606), 
consisting of 88,692 protein entries and 247 commonly observed lab contaminants. Mass 
tolerance for first search was set to 20 ppm, and to 6 ppm for the main search. Multiplicity 
was set to three. Lys0, Arg0; Lys4, Arg6 and Lys8, Arg10 for “light”, “medium” and “heavy” 
samples, respectively. Full tryptic specificity was required and a maximum of two missed 
cleavages were allowed. Carbamidomethylation of cysteine was set as fixed modification 
while oxidation (M) and acetylation (on N-term) were chosen as variable modifications. Initial 
mass tolerance for the precursor ion was set to 6 parts per million (ppm) and 0.5 Da at the 
fragment ion level. For quantification of proteins, minimum two peptides with at least seven 
amino acids had to be detected. The maximum allowed posterior error probability (PEP) was 
set to 1 and the false discovery rate (FDR) to max 1 % for peptides and proteins. Re-
quantification was enabled while second peptides disabled. 
4.4.6.5 Bioinformatic analysis 
Perseus V 1.3.0.4, a module from the MaxQuant suite [165], was used for calculation of the 
Pearson correlation for both proteome. This was done by extraction of the H/L ratios from 
ProteinGroups.txt file, generated in MaxQuant. Contaminants, reverse hits or identified by 
site were removed, values Log2 transformed and the Pearson correlation calculated for the 
H/L ratios of both replicates. 
The calculation of significantly changing proteins and phosphorylation sites was also done in 
Perseus V 1.3.0.4 (two-tailed “Significance B” test; p ≤ 0.05). H/L ratios were transformed to 
Log2, whereas intensities of peptides or phosphorylation sites were Log10 transformed. 
We applied truncation based on Benjamini-Hochberg [173] corrected p-values with threshold 
value of 0.05 to test whether specific annotation terms are significantly enriched or depleted 
among the chosen set of proteins of interest.  
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4.4.7 Immunofluorescence (IF) 
For Immunofluorescence assays, 200.000 cells were grown on coverslips contained in 6 well 
dishes. The day after medium was removed and they were rinsed with PBS. Cells were fixed 
with 100 µl Acetone + Methanol (1:1) for 2 min at RT. Coverslips were then washed 3 times 
with PBS and blocked for 1 hour at RT with 50 µl of PBS + 3% BSA. Primary antibody was 
diluted in PBS + 3% BSA and incubated overnight at 4°C in a humid chamber. The following 
day, the antibody solution was removed and the coverslips were washed 3 times with PBS-T. 
Incubation with the secondary antibody was done at RT for 1 hour in a dark and humid 
chamber. After washing the coverslips 3 times with PBS-T, a 20 sec DAPI staining was 
performed and 3 further washing steps followed. In the end, coverslips were mounted onto 
glass slides using one drop of FluoPrep (Biomerieux, REF 75521) and let to dry for at least 1 
h. Microscopy analyses were performed using the fluorescence microscope Axiovert M200 
(Zeiss).  
 
4.4.8 FACS-FRET 
Fluorescence resonance energy transfer (FRET), first described by Theodor Förster in 1946, 
is a phenomenon that describes the energy transition from a fluorophore (donor) in an 
excited state to a neighboring fluorophore (acceptor) by dipole-dipole interaction [174]. The 
efficiency of this energy transfer depends primarily on the distance between fluorophores that 
have to be less than 10 nm [175] thus making FRET a suitable method to determine direct 
interactions between two molecules in close proximity. The availability of several spectral 
variants of the Green Fluorescent Protein (GFP) [176] made FRET a suitable tool to 
investigate protein-protein interactions. By tagging the protein of interest with one of the GFP 
variants, FRET can be used to investigate interactions of native proteins in living cells. The 
spectral characteristics of the chosen fluorophores are also very important: the donor’s 
emission spectrum have to overlap with the excitation spectrum of the acceptor, so that the 
energy released by the donor can excite the acceptor (Fig. 14). Combining FRET with FACS 
permits the evaluation of thousands of cells in a short time and minimizes the blurred signals 
resulting from the spectral overlap, making FACS-FRET a powerful technique to detect 
protein-protein interactions [157].  
For FACS-FRET experiments, 150.000 C33a cells were seeded in 12 well plates, transfected 
with 1 µg of DNA the day after and harvested 48 h post-transfection. Cells were washed 
twice with PBS, after removing the medium from the wells, and, afterwards, they were re-
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suspended in PBS + 1% FBS and kept on ice before analysis. The MACSQuant Analyzer 
(Miltenyi Biotec) was used to perform FACS-FRET measurements. First, viable cells were 
identified using the forward scatter (FSC) and the sideward scatter (SSC) gating strategy. A 
405 nm laser was used to excite the donor (BFP) and the V1 channel was used to detect its 
emission through a 450/50 filter. The acceptor was excited with a 488 nm laser and its 
emission was quantified with the B1 channel via a 525/50 filter. FRET signals were 
measured with the V2 channel (525/50). To identify only FRET-positive cells the gating took 
into account the false positive signals deriving from the excitation of the acceptor (with the 
405 nm laser) and combine it with the negative control (cells co-expressing donor and 
acceptor) (Fig. 14A) and the positive control (cells expressing a fusion construct of donor-
acceptor) (Fig. 14B). The remaining cells are evaluated for FRET by adjusting the gate to 
define cells which are co-transfected with BFP and YFP only and should thus be FRET-
negative and with a BFP-YFP fusion construct that represent the FRET-positive cell 
population. 
 
Fig. 14 FRET. When there´s an overlap between the donor emission and the acceptor excitation 
wavelength, if the two fluorophores are not close enough there will be any FRET (A), if the two 
proteins are in close proximity, there will be FRET (B). 
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4.4.9 Proximity ligation assay (PLA) 
PLA is a method to investigate direct protein-protein interactions and the Duolink kit (Sigma 
Aldrich) was used for this purpose (Fig. 15) . Cells were processed as for an 
immunofluorescence until the incubation with the primary antibody. The step of the 
incubation with the secondary antibodies was substituted with the incubation with the PLA 
secondary antibody probes and all the following steps were performed following the 
manufacture’s protocol. Briefly, the probes were ligated and, in case of close proximity of the 
two proteins investigated and consequently of the bound antibodies, the formation of a circle 
followed. A rolling circle amplification with fluorescently labeled nucleotides led to the 
formation of fluorescent spots, an indication of protein-protein interaction. Microscopy 
analyses were performed using the fluorescence microscope Axiovert M200 (Zeiss).  
 
Fig. 15 PLA principle (Figure adapted from the Duolink kit manual, Sigma Aldrich) 
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5. Results 
5.1 Identification of new cutaneous E6 interaction 
partners 
Persistent infection of keratinocytes with high-risk types (HR) of human papillomavirus (HPV) 
is causally related to the development of cervical cancer. The deregulation of cellular 
processes by the viral oncoproteins E6 and E7 is essential for malignant transformation of 
the cells.  
While much is known about the features of the HR-HPV oncoproteins and their contribution 
to the development of cancer, the role of E6 and E7 of cutaneous papillomaviruses related to 
nonmelanoma skin cancer (NMSC) remains not fully understood. Therefore, this part of the 
work aimed at evaluating the protein-binding characteristics of the E6 protein of different 
cutaneous types through liquid chromatography/mass spectrometry (LC/MS)-based 
proteomics.  
 
5.1.1 Transient expression of E6 HA-tagged proteins 
To investigate viral-host interactions of cutaneous E6 proteins, a system for exogenous 
protein expression had to be established. Therefore E6 proteins of HPV 5, 38 and CRPV 
were, HA (hemagglutinin) tagged and expressed in HPV negative cell lines. Since stable 
expression of the HA-tagged proteins did not result in the production of a sufficient protein 
amount for proteomic analysis in NIKS cells (Supplementary results, Fig. S1 and S2), the 
expression system was changed to a transient expression system. First, E6 genes were 
cloned into the pCMV vector containing an N-terminal Flag_Linker_HA tag (pCMV-N-
Flag_Linker_HA, a kind gift from Dr. K. Munger). Subsequently, the HPV-negative cell line 
C33a was transfected with these constructs and protein expression was analyzed on a 
western blot (Fig. 16). 
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Fig. 16 Western blot showing HA-tagged E6 protein expression in transiently transfected C33a 
cells. Lysates were analyzed with an anti-HA antibody and either KRIP1 or α-tubulin were used as 
housekeeping proteins. On the left, molecular weights are indicated in kDa. UT: untransfected; CMV: 
pCMV-N-Flag_Linker_HA empty vector; LE6: pCMV-N-Flag_Linker_HA-CRPVLE6; SE6: pCMV-N-
Flag_Linker_HA-CRPVSE6; 5E6: pCMV-N-Flag_Linker_HA-HPV5E6; 38E6: pCMV-N-
Flag_Linker_HA-HPV38E6. 
 
All the tagged E6 proteins transiently expressed in C33a cells were detected and a clear 
band at the expected molecular size was observed for CRPVLE6 and SE6 and for HPV5 and 
38E6. Untransfected (UT) cells and the empty vector control showed no band.  
An immunofluorescence was also performed to evaluate expression and localization of the 
tagged E6 proteins. In Fig. 17 an example of C33a cells transfected with the empty vector 
(CMV), CRPVLE6 (LE6) and HPV38E6 (38E6) is shown. 
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Fig. 17 Immunofluorescence showing expression of LE6 and 38E6. C33a cells were stained with 
an anti-HA antibody (green). Cell nuclei were stained with DAPI (blue). Merge shows the overlay of 
HA and DAPI stainings.  
 
Immunofluorescence analysis revealed that both LE6 and 38E6 were expressed in C33a 
cells and that their localization was nuclear and cytoplasmic. 
 
5.1.2 E6 HA-tagged proteins bind to their known interaction 
partners 
In order to determine whether the HA-tagged E6 proteins are functional, a co-
immunoprecipitation (CoIP) was performed to analyze the proteins’ interacting protein-
binding capabilities on known interaction partners (Fig. 18). 
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Fig. 18 CoIP of Flag_linker_HA tagged E6 proteins. HA-tagged proteins were tested for the binding 
to p300 (300 kDa, upper panel, IP) and MAML1 (130 kDa, middle panel, IP), that were used as 
positive controls for the pull down. Specific HA signals were detected for all the proteins  (lower panel, 
LE6 ~40 kDa , SE6 ~35 kDa, 5E6 ~20 kDa, 38E6 ~19 kDa) in both inputs (IN) and immunoprecipitates 
(IP) with the exception of LE6 and SE6 that were only visible in the IP. CMV: pCMV-N-
Flag_Linker_HA empty vector; LE6: pCMV-N-Flag_Linker_HA-CRPVLE6; SE6: pCMV-N-
Flag_Linker_HA-CRPVSE6; 5E6: pCMV-N-Flag_Linker_HA-HPV5E6; 38E6: pCMV-N-
Flag_Linker_HA-HPV38E6. Molecular sizes are shown in kDa on the left. 
 
The western blot analysis of the CoIP experiment shows no band for the HA-tagged E6 
proteins in the input (IN) samples and only appears in the immunoprecipitate (IP) samples. 
Bands for p300 were detected in the CRPV LE6, SE6 and 5E6 expressing cell lysates while5 
and 38E6 pulled down MAML1.  
The interaction of CRPVE6 and MAML1 remains elusive, because there might be a species-
specificity incompatibility as a rabbit protein was expressed in human cells, meaning that 
CRPVE6 might not be able to bind human MAML1 (hMAML1) but could potentially be able to 
associate with rabbit MAML1 (rMAML1).  
Because an anti-rabbit MAML1 antibody is not available and the anti- human MAML1-
antibody does not recognize rabbit MAML1 (Fig. 19-A), due to protein sequence differences 
in the epitope targeted by the anti-human MAML1 antibody, described in the antibody 
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datasheet as a peptide surrounding His 810 residue (Fig. 19-B), a CoIP using rabbit cells, to 
test whether CRPVE6 was able to pull down rMAML1, could not be performed. 
 
 
Fig 19 MAML1 antibody does not recognize rabbit MAML1. A: western blot showing that MAML1 
was detected in C33a but not in AVS (Primary rabbit keratinocytes, harboring the whole CRPV 
genome) cells. α-tubulin was used as a loading control. On the left, molecular sizes are indicated in 
kDa. B: Blast alignment of MAML1 protein sequences of the human and rabbit isoform showing 
difference in the region where the antibody used is supposed to bind. Human MAML1 (hMAML1); 
rabbit MAML1 (rMAML1).  
 
Although E6 protein expression levels revealed by the CoIP were variable, some E6 proteins 
were able to pull down their reported interacting partners. This confirmed that the tagged E6-
proteins were functional at protein-protein interaction level. 
 
5.1.3 CRPVLE6 downregulates Notch activation in C33a cells 
E6 proteins of some types of β-HPVs and BPV1 were previously reported to be able to 
interfere with the Notch signaling pathway [75], [76]. CRPV resembles some of the 
cutaneous PV features and this led to the hypothesis that LE6 might also be able to affect 
Notch pathway activation. To investigate this, luciferase assays using a Notch-responsive 
luciferase plasmid were performed. For this reason LE6 was cloned into the retroviral vector 
pBabe-puro with and without the Flag-Linker-HA tag. C33a cells were co-transfected with a 
Notch-responsive luciferase plasmid expressing Hes1-luc, a known Notch transcriptional 
target, and Gaussia luciferase plasmid pCMV-Gluc, as well as with either BPV1E6, the 
CRPVLE6 expression plasmids or the empty vector. Notch-dependent transcription was 
activated upon co-expression of the Notch Intracellular Domain (NICD). As a result, BPV1E6 
expression resulted in the repression of Notch activity. Moreover, LE6, with and without tag, 
seemed to able to downregulate Hes1-luc activity when Notch signaling was activated (Fig. 
20).This suggests that the protein is both expressed and functional with and without the tag 
in C33a cells.  
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Fig. 20 Luciferase assay showing Notch repression by LE6. C33a cells were transiently 
transfected with Hes1 luciferase reporter plasmid, together with pBabe-puro-CRPVLE6 (LE6), 
CRPVLE6_Flag_Linker_HA (LE6 FLHA) or BPVE6, with or without the Notch IntraCellular Domain 
(NICD). Gaussia was used as an internal transfection control. The bars represent luciferase activities 
relative to the empty vector ± NICD transfected cells (pBabe). White bars represent luciferase activity 
in empty vector transfected cells, grey bars, black bars and striped bars show BPVE6, CRPVE6 and 
CRPVE6_Flag-linker-HA activity. On the left is shown Hes1 basal activity whereas on the right is the 
activity after co-transfection with NICD, and therefore Notch pathway activation. Data are presented as 
the average ± standard deviations of five different experiments. 
 
Although a clear interaction between LE6 and MAML1 could not be demonstrated (Section 
5.1.2), the luciferase assay demonstrates that LE6 interferes with Notch pathway, as other 
proteins do by interacting with MAML1 (i.e. BPV1 E6), with a mechanism that still has to be 
elucidated. 
 
5.1.4 Proteome analysis of E6 tagged proteins using label free 
quantification 
Once expression and functionality of the tagged E6 proteins was assessed, a protein 
interaction analysis was performed. Flag-HA-tagged proteins were transiently expressed in 
C33a cells and a CoIP was carried out after 48 hours using the whole cell lysate. A western 
blot was performed to verify the presence of the HA-tagged proteins and the efficiency of the 
Co-IP (Fig. 21). MAML1 was used as a control for the pull down efficiency of HPV5 and 
38E6. The CoIP and the proteomic analysis were repeated twice in two independent 
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experiments, using different DNA preparations and different cell passages, to prove the 
reproducibility of the experiment.  
 
 
 
Fig. 21 CoIP of Flag_linker_HA tagged E6 proteins. HA-tagged E6 proteins were tested for the 
binding to MAML1 (upper panel) that was used as positive control for the pull down, in two 
independent experiments. Specific HA signals were detected for all the proteins  (lower panels, LE6 
~40 kDa , SE6 ~35 kDa, 5E6 ~20 kDa, 38E6 ~19 kDa) in both inputs (IN) and immunoprecipitates (IP) 
at the expected sizes. CMV: pCMV-N-Flag_Linker_HA empty vector; LE6: pCMV-N-Flag_Linker_HA-
CRPVLE6; SE6: pCMV-N-Flag_Linker_HA-CRPVSE6; 5E6: pCMV-N-Flag_Linker_HA-HPV5E6; 
38E6: pCMV-N-Flag_Linker_HA-HPV38E6. Molecular sizes are shown in kDa on the left. 
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As shown by the western blot analysis, the specific bands detected with an anti-HA antibody 
demonstrated that proteins were expressed. Moreover, MAML1 was pulled down by HPV5 
and 38E6 (Fig. 20, upper panels) indicating that the CoIP worked.  
The next step was to perform a proteome analysis using the immunoprecipitates. With this 
aim, a label free quantitative mass spectrometry experiment was performed by the core 
facility Proteome Center of Tübingen (PCT). Using and analyzing the data obtained by the 
PCT, the cellular interaction partners of LE6, SE6 and 38E6 were identified. 
Since more than 2000 proteins were identified in each experiment an analysis procedure was 
performed to sort and quantify them (Materials and methods, section 4.4.5.3). Briefly, raw 
data were analyzed with MaxQuant (version 1.2.2.9), and then further analyzed using the 
statistical tool suite Perseus (version.1.3.0.4). The label free quantification (LFQ) ratios were 
quantified using the intensity-based absolute quantification (iBAQ) algorithm in order to 
identify interactors of LE6, SE6 and 38E6. 
A list of interaction partners for LE6, SE6 and 38E6 was generated (Supplementary results, 
Fig. S3, S4, S5 and S6). In Fig. 22-A, -B, -C, the distribution of the Log2 ratios of proteins’ 
iBAQs from LE6, SE6 and 38E6 is represented using scatter plots, whereas in Fig. 23 are 
shown the differential interaction partners of LE6 and SE6. 
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Fig. 22 Scatter plots of the Log2 ratios of proteins’ iBAQs from LE6, SE6 and 38E6. The 
distribution is a Gaussian normal distribution with a median of 0 and a standard deviation of 1.The plot 
represent two independent experiments. Highlighted in red are the significantly interacting proteins 
with LE6, SE6 and 38E6, and the names of few important proteins described in literature.  
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Fig. 23 Scatter plot of differential interaction partners of LE6 and SE6. The iBAQs distribution is a 
Gaussian normal distribution with a median of 0 and a standard deviation of 1. Highlighted in red are 
the significantly interacting proteins of SE6 (on the left) and LE6 (on the right) the names of few 
important proteins described in literature, where progressively dark red proteins are the most 
represented proteins interacting specifically with LE6 or SE6.  
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In total, 2792 proteins were identified and quantified from the 3 datasets, where 195 proteins, 
186 proteins and 188 proteins were significantly identified as interactors of LE6, SE6 and 
38E6 respectively (Fig. 24). 
 
 
Fig. 24 Venn diagram showing the specific and common interacting proteins of 38E6, LE6, and 
SE6. The blue circle represents the interacting proteins identified for LE6, the pink circle represents 
the interacting proteins identified for SE6 and the yellow circle represents the interacting proteins 
identified for 38E6. The intersections among the colored areas show the common interacting proteins. 
 
Furthermore it was found that 60, 27 and 10 proteins were exclusive common interactors of 
38E6+SE6, 38E6+LE6 and LE6+SE6, respectively whereas 32 proteins were identified to 
interact with all the three baits (Table 5).  
The common interacting proteins between LE6 and SE6, 38E6 and LE6, 38E6 and SE6, are 
summarized in Tables 2, 3 and 4 respectively. Additionally, in Table 5 the proteins common 
in the three datasets are also shown. 
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Table 2. Common proteins between LE6 and SE6. List of common interacting proteins, where 
Protein IDs represent the Uniprot identification numbers, Gene symbols are the abbreviated names of 
the genes, EntrezGene IDs are the Entrez gene identification numbers. 
 
Uniprot ID Gene Symbol EntrezGene ID Gene description
O75486 SUPT3H 8464 suppressor of Ty 3 homolog (S. cerevisiae)
Q9H9B4 SFXN1 94081 sideroflexin 1
Q15363 TMED2 10959 transmembrane emp24 domain trafficking protein 2
Q16878 CDO1 1036 cysteine dioxygenase type 1
E5KLJ5 OPA1 4976 optic atrophy 1 (autosomal dominant)
P30536 TSPO 706 translocator protein (18kDa)
Q96KC2 ARL5B 221079 ADP-ribosylation factor-like 5B
Q86W74 ANKRD46 157567 ankyrin repeat domain 46
Q9H2U2 PPA2 27068 pyrophosphatase (inorganic) 2
Q9NTG7 SIRT3 23410 sirtuin 3  
 
Table 3. Common proteins between 38E6 and LE6. List of common interacting proteins, where 
Protein IDs represent the Uniprot identification numbers, Gene symbols are the abbreviated names of 
the genes, EntrezGene IDs are the Entrez gene identification numbers. 
 
Uniprot ID Gene Symbol EntrezGene ID Gene description
Q6NZY4 ZCCHC8 55596 zinc finger, CCHC domain containing 8
Q9Y5U9 IER3IP1 51124 immediate early response 3 interacting protein 1
Q9Y320 TMX2 51075 thioredoxin-related transmembrane protein 2
J3QR07 YTHDC1 91746 YTH domain containing 1
O60573 EIF4E2 9470 eukaryotic translation initiation factor 4E family member 2
Q92615 LARP4B 23185 La ribonucleoprotein domain family, member 4B
P63220 RPS21 6227 ribosomal protein S21
B4E2P2
Q8N0U8 VKORC1L1 154807 vitamin K epoxide reductase complex, subunit 1-like 1
P14927 UQCRB 7381 ubiquinol-cytochrome c reductase binding protein
Q9NZE8 MRPL35 51318 mitochondrial ribosomal protein L35
Q9Y3C6 PPIL1 51645 peptidylprolyl isomerase (cyclophilin)-like 1
P57105 SYNJ2BP 55333 synaptojanin 2 binding protein
P49821 NDUFV1 4723 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa
Q8IUE6 HIST2H2AB 317772 histone cluster 2, H2ab
A6NHR9 SMCHD1 23347 structural maintenance of chromosomes flexible hinge domain containing 1
Q15388 TOMM20 9804 translocase of outer mitochondrial membrane 20 homolog (yeast)
O60831 PRAF2 11230 PRA1 domain family, member 2
P26196 DDX6 1656 DEAD (Asp-Glu-Ala-Asp) box helicase 6
P62487 POLR2G 5436 polymerase (RNA) II (DNA directed) polypeptide G
B3KY94 CDIPT 10423 CDP-diacylglycerol--inositol 3-phosphatidyltransferase
Q15436 SEC23A 10484 Sec23 homolog A (S. cerevisiae)
A7MAP1
F5H3A1
P78527 PRKDC 5591 protein kinase, DNA-activated, catalytic polypeptide
Q9UNL2 SSR3 6747 signal sequence receptor, gamma (translocon-associated protein gamma)
P05023 ATP1A1 476 ATPase, Na+/K+ transporting, alpha 1 polypeptide  
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Table 4. Common hits between 38E6 and SE6. List of common interacting proteins, where Protein 
IDs represent the Uniprot identification numbers, Gene symbols are the abbreviated names of the 
genes, EntrezGene IDs are the Entrez gene identification numbers. 
 
Uniprot ID Gene Symbol EntrezGene ID Gene description
P61604 HSPE1 3336 heat shock 10kDa protein 1
Q9UHA4 LAMTOR3 8649 late endosomal/lysosomal adaptor, MAPK and MTOR activator 3
Q9Y333 LSM2 57819 LSM2 homolog, U6 small nuclear RNA associated (S. cerevisiae)
Q9UDW1 UQCR10 29796 ubiquinol-cytochrome c reductase, complex III subunit X
P17677 GAP43 2596 growth associated protein 43
P62312 LSM6 11157 LSM6 homolog, U6 small nuclear RNA associated (S. cerevisiae)
P99999 CYCS 54205 cytochrome c, somatic
Q6I9Y2 THOC7 80145 THO complex 7 homolog (Drosophila)
O95777 LSM8 51691 LSM8 homolog, U6 small nuclear RNA associated (S. cerevisiae)
P38117 ETFB 2109 electron-transfer-flavoprotein, beta polypeptide
O95415 BRI3 25798 brain protein I3
P04181 OAT 4942 ornithine aminotransferase
A2A274
P34897 SHMT2 6472 serine hydroxymethyltransferase 2 (mitochondrial)
G3V5Z7
P00505 GOT2 2806 glutamic-oxaloacetic transaminase 2, mitochondrial
P40926 MDH2 4191 malate dehydrogenase 2, NAD (mitochondrial)
Q92688 ANP32B 10541 acidic (leucine-rich) nuclear phosphoprotein 32 family, member B
Q96HE7 ERO1L 30001 ERO1-like (S. cerevisiae)
O75390 CS 1431 citrate synthase
E7ESZ7
Q8NBQ5 HSD17B11 51170 hydroxysteroid (17-beta) dehydrogenase 11
O95249 GOSR1 9527 golgi SNAP receptor complex member 1
P36551 CPOX 1371 coproporphyrinogen oxidase
Q9Y4Y9 LSM5 23658 LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae)
P50213 IDH3A 3419 isocitrate dehydrogenase 3 (NAD+) alpha
P12004 PCNA 5111 proliferating cell nuclear antigen
J3KPS3
Q9BUN8 DERL1 79139 derlin 1
O75439 PMPCB 9512 peptidase (mitochondrial processing) beta
P00367 GLUD1 2746 glutamate dehydrogenase 1
P49419 ALDH7A1 501 aldehyde dehydrogenase 7 family, member A1
Q9BUL8 PDCD10 11235 programmed cell death 10
O15145 ARPC3 10094 actin related protein 2/3 complex, subunit 3, 21kDa
P55735 SEC13 6396 SEC13 homolog (S. cerevisiae)
P30519 HMOX2 3163 heme oxygenase (decycling) 2
J3KQ97
Q9NYF8 BCLAF1 9774 BCL2-associated transcription factor 1
O75348 ATP6V1G1 9550 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1
Q96MC6 HIAT1 64645 hippocampus abundant transcript 1
P24752 ACAT1 38 acetyl-CoA acetyltransferase 1
Q9UQ80 PA2G4 5036 proliferation-associated 2G4, 38kDa
P23434 GCSH 2653 glycine cleavage system protein H (aminomethyl carrier)
Q9NUP9 LIN7C 55327 lin-7 homolog C (C. elegans)
Q96S55 WRNIP1 56897 Werner helicase interacting protein 1
P00390 GSR 2936 glutathione reductase
P23368 ME2 4200 malic enzyme 2, NAD(+)-dependent, mitochondrial
P30044 PRDX5 25824 peroxiredoxin 5
P47897 QARS 5859 glutaminyl-tRNA synthetase
Q16643 DBN1 1627 drebrin 1
Q32Q12
P35241 RDX 5962 radixin
P38919 EIF4A3 9775 eukaryotic translation initiation factor 4A3
P55072 VCP 7415 valosin containing protein
P06576 ATP5B 506 ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide
F8VQ10
Q00610 CLTC 1213 clathrin, heavy chain (Hc)
P54136 RARS 5917 arginyl-tRNA synthetase
Q12931 TRAP1 10131 TNF receptor-associated protein 1
P10809 HSPD1 3329 heat shock 60kDa protein 1 (chaperonin)  
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Table 5. Common hits between 38E6, SE6 and LE6. List of common interacting proteins, where 
Protein IDs represent the Uniprot identification numbers, Gene symbols are the abbreviated names of 
the genes, EntrezGene IDs are the Entrez gene identification numbers. 
 
Uniprot ID Gene Symbol EntrezGene ID Gene description
Q7Z417 NUFIP2 57532 nuclear fragile X mental retardation protein interacting protein 2
O75381 PEX14 5195 peroxisomal biogenesis factor 14
P61326 MAGOH 4116 mago-nashi homolog, proliferation-associated (Drosophila)
P51970 NDUFA8 4702 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19kDa
Q15428 SF3A2 8175 splicing factor 3a, subunit 2, 66kDa
Q96C36 PYCR2 29920 pyrroline-5-carboxylate reductase family, member 2
Q9BZK7 TBL1XR1 79718 transducin (beta)-like 1 X-linked receptor 1
O75323 GBAS 2631 glioblastoma amplified sequence
Q8WZ42 TTN 7273 titin
O75352 MPDU1 9526 mannose-P-dolichol utilization defect 1
Q9Y5S9 RBM8A 9939 RNA binding motif protein 8A
P04637 TP53 7157 tumor protein p53
P54819 AK2 204 adenylate kinase 2
Q9BSR8 YIPF4 84272 Yip1 domain family, member 4
Q96J01 THOC3 84321 THO complex 3
P00492 HPRT1 3251 hypoxanthine phosphoribosyltransferase 1
P62310 LSM3 27258 LSM3 homolog, U6 small nuclear RNA associated (S. cerevisiae)
Q9Y3E0 GOLT1B 51026 golgi transport 1B
P22695 UQCRC2 7385 ubiquinol-cytochrome c reductase core protein II
P78347 GTF2I 2969 general transcription factor IIi
P28331 NDUFS1 4719 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa (NADH-coenzyme Q reductase)
P38606 ATP6V1A 523 ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A
Q15459 SF3A1 10291 splicing factor 3a, subunit 1, 120kDa
P61803 DAD1 1603 defender against cell death 1
Q9Y2W1 THRAP3 9967 thyroid hormone receptor associated protein 3
O75306 NDUFS2 4720 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa (NADH-coenzyme Q reductase)
Q12874 SF3A3 10946 splicing factor 3a, subunit 3, 60kDa
P13861 PRKAR2A 5576 protein kinase, cAMP-dependent, regulatory, type II, alpha
P09661 SNRPA1 6627 small nuclear ribonucleoprotein polypeptide A'
P08579 SNRPB2 6629 small nuclear ribonucleoprotein polypeptide B
P41252 IARS 3376 isoleucyl-tRNA synthetase
Q9ULV4 CORO1C 23603 coronin, actin binding protein, 1C  
 
5.1.5 Identification of known interaction partners 
After processing and sorting the putative interacting proteins, it was not possible to identify 
the interactions already described in literature, as p300 and MAML1. 
Concerning p300, known to interact with LE6 and SE6, it was identified in both pull downs 
but not significantly. This result could be related to the fact that p300 is part of a protein 
family and therefore not enough unique peptides were identified. For this reason p300 was 
automatically eliminated by the software as it did not fit to the parameters set. Although the 
western blot shown in Fig. 17 demonstrates the interaction of p300 with LE6 or SE6, possibly 
due to the large homology between CBP (CREB-binding protein) and p300 (68%), the 
software was unable to distinguish which of the two proteins was the direct interactor and 
only detected that p300/CBP was involved. 
MAML1, although shown to be a strong 38E6 binder by White et al. 2012, was never pulled 
down in the two aforementioned experiments. This might be explainable once more by the 
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fact that it belongs to a huge protein family which does not allow the generation of enough 
unique peptides. 
Moreover, as the strict parameter significance B was applied to the whole analysis, this might 
have affected the entire quantification.  
Except for the binding of 38E6 to p53, that was highly reproducible since it was present in 
both the experiments and was also shown by western blot (Fig. 25, this figure was previously 
shown as Fig. 18), p300 and MAML1 were only identified by western blot. 
 
 
Fig. 25 Western blot showing 38E6 and p53 interaction. HA-tagged proteins were tested for the 
binding to p300 (upper panel, IP) and MAML1 (middle upper panel, IP), that were used as positive 
controls for the pull down. p53 was also shown to be pulled down by 38E6 (lower panel). Specific HA 
signals were detected for all the proteins  (middle lower panel, LE6 ~40 kDa , SE6 ~35 kDa, 5E6 ~20 
kDa, 38E6 ~19 kDa) in both in the inputs (IN) and immunoprecipitates (IP) with the exception of LE6 
and SE6 that were only visible in the IP. CMV: pCMV-N-Flag_Linker_HA empty vector; LE6: pCMV-N-
Flag_Linker_HA-CRPVLE6; SE6: pCMV-N-Flag_Linker_HA-CRPVSE6; 5E6: pCMV-N-
Flag_Linker_HA-HPV5E6; 38E6: pCMV-N-Flag_Linker_HA-HPV38E6. Molecular sizes are shown in 
kDa on the left. Figure previously shown as Figure 18. 
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5.1.6 Functional analysis 
A functional enrichment analysis was carried out using the tool suite FunRich [178]. The 
proteins identified were analyzed and, for each bait, it was identified in which biological 
pathway (Fig. 26), cell line (Fig. 27) and transcription factors (Fig. 28) they were involved in. 
Hypergeometric uncorrected p-values were used for statistics. 
5.1.6.1 Biological pathways 
 
Fig. 26 Functional enrichment analysis of biological pathways using FunRich. Genes enriched in 
the highest probable pathways (p< 0.001) are showed. 
 
 68 
 
Fold enrichment was calculated by comparing the identified proteins against all the proteins 
as background. In biological pathways, all the baits show an involvement in mRNA 
processing, respiratory electron transport, ATP synthesis and citric acid cycle, although at 
different levels. Moreover, LE6 and 38E6 share pathways involved in transcription while non 
homologous end-joining and the insulin receptor recycling pathways are exclusive of LE6 
and SE6, respectively. 
5.1.6.2 Sites of expression 
 
Fig. 27 Functional enrichment analysis of site of expression using FunRich. Genes enriched in 
the highest probable sites (p< 0.001) are showed. 
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Concerning the site of expression, the cell lines where the genes were found to be 
expressed, are showed in Fig. 27. For all the baits, consistent with their role as oncoproteins, 
the cell lines identified were all linked to cancer. Ovarian carcinoma (CaOV3, OVCAR3, 
ES2), colorectal carcinoma (HCT 116, CRC), ascites cancer cell lines were common to all, 
while the proteins enriched in SE6 pull downs showed a strong expression in melanoma cell 
line as well and LE6 also in embryonic stem cells and embryonal carcinoma cells. 
5.1.6.3 Transcription factors 
 
Fig. 28 Functional enrichment analysis of transcription factors using FunRich. Genes linked to 
the highest probable transcription factors are showed. 
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The putative transcription factors shared by LE6, SE6 and 38E6 are three: the GA Binding 
Protein Transcription Factor Alpha Subunit (GABPA), the member of ETS oncogene family 
(ELK1) and the Nuclear Receptor Subfamily 4, Group A, Member 2 (NR4A2).  
Observing the graph in Fig. 28 it is possible to notice that, while the transcription factors 
involved with 38E6 and SE6 are highly significant, the ones of LE6, although highly 
represented, are not.  
In addition, it is possible to see that LE6 and 38E6 have further common transcription factors, 
as the E2F Transcription Factor 1 (E2F1), the CAMP Responsive Element Binding Protein 1 
(CREB1) and the SAM Pointed Domain Containing ETS Transcription Factor (SPDEF). On 
the other end, SE6 shares additional transcription factors only with 38E6: the Kruppel-Like 
Factor 7 (KLF7), the STimulated by Retinoic Acid 13 protein (STRA13) and the Signal 
Transducer and Activator of Transcription 1 (STAT1). Transcription factors exclusively 
associated to LE6 are the Zinc Finger and BTB Domain Containing 14 (ZFP161) and the 
ETS Homologous Factor (EHF) and of 38E6 is SP1. 
 
5.1.7 Proteome analysis of CRPVE6 proteins using SILAC 
For stronger validation, an additional approach was used. SILAC (Stable Isotope Labeling 
with Amino acids in cell Culture) is a metabolic labeling strategy which uses stable isotope 
labeled amino acids in the growth medium. First, SILAC is a quantitative method that allows 
the comparison of up to three different conditions in the same experiment. Moreover, the 
labeling allows the identification of hits in the empty vector-transfected cells that can be 
excluded and considered as background.  
SILAC was used to perform a proteome analysis and this experiment focused on the rabbit 
proteins CRPVLE6 and SE6.  
C33a cells were cultivated in SILAC DMEM medium until they reached a full incorporation of 
isotope labeled amino acids. Afterwards, C33a cells were transiently transfected with Flag-
HA-tagged CRPVLE6 and SE6 and after 48 hours the whole cell lysate was used to perform 
a CoIP. A western blot was carried out to demonstrate the presence of the HA-tagged 
proteins and the efficiency of the Co-IP (Fig. 29). The protein amounts were kept constant in 
all input (IN) samples, as shown by the level of the housekeeping gene α-tubulin (~60kDa 
band). The efficiency of the CoIP was confirmed by the presence of the unique specific band 
detected by an anti-HA antibody.  
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Fig. 29 CoIP of Flag_linker_HA tagged CRPV E6 proteins. CRPV LE6 and SE6, as well as the 
empty vector (CMV), were transiently expressed in C33a cells. The western blot shows the specific 
band for LE6 (~40 kDa) and SE6 (~35 kDa) using an anti-HA antibody (lower panel). An HA signal 
was detected for all the proteins (lower panel) in both inputs (IN) and immunoprecipitates (IP) at the 
expected sizes. On the left, equal amounts of IN, representing an aliquot of the cell extract from 
transfected cells before the CoIP, and on the right are shown the IP, 1/10 of the samples resulting 
from the CoIP. Samples were analyzed for the presence of a reference protein using an anti-α-tubulin 
antibody. Molecular weights are shown in kDa on the left.  
 
Immunoprecipitates (IP) were analyzed by the PCT. In the first experiment, C33a cells 
transfected with the empty vector (CMV) were grown in the light medium (L), those 
transfected with LE6 in the heavy medium (H) and the SE6-transfected cells were labeled 
with the medium-heavy medium (M). In the first run, 2049 proteins were identified and they 
were plotted according to their intensities and ratios as shown in Fig. 30.  
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Fig. 30 Data analysis scatter plot of possible interaction partners. Peptide transformed intensities 
(Log10) were plotted against SILAC ratios (Log2) of protein groups normalized to their respective 
protein. Significant outliers are located on the left and right sides of the main distribution. The plots 
show protein abundance changes between CMV and LE6 (H/L) in A, CMV and SE6 (M/L) in B and 
LE6 and SE6 (H/M) in C.  
 
In Fig. 30-A, where the proteins identified in LE6 are compared to the ones found in the 
empty vector pull down, it was possible to distinguish the typical bell-shaped distribution. In 
this graph, outliers, corresponding to highly significant SILAC ratios, surrounded the main 
population of unspecific binders. Since putative interaction partners are proteins with high 
ratios and high intensities, the dots in the upper right corner were representative of the 
proteins that mainly interact with LE6 whereas proteins on the left were enriched in the empty 
vector pull down. 
The plot in Fig. 30-B show the distribution of the proteins found in the SE6 pull down 
compared to the empty vector. No proteins were detected in the upper right corner, enough 
distant from the distribution of nonspecific binding proteins, meaning that no possible binding 
candidates were identified. SE6 was also not significantly distant from the distribution, 
leading to the conclusion that its expression was not high enough. 
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LE6 and SE6 CoIP were compared as shown in Fig. 30-C. Since SE6 pull down did not 
correctly work, it was expected that no significant outliers could be found in this plot, where 
only LE6 was shown to be significantly distant from the main distribution. 
The list of 2148 putative interaction proteins was analyzed. Only the proteins with a p-value ≤ 
0.05 were taken into consideration and were sorted in descending order according to their 
intensities.  
Although the western blot of SE6 did not show a high expression level (Fig. 29 and 30-B), an 
analysis was performed however to identify proteins involved in relevant pathways. As 
expected, no interesting proteins were detected. On the other hand, LE6 analysis yielded a 
selection of 60 proteins (Supplementary results, Fig. S7) and an interesting relation was 
found among some of them. Five proteins were selected (Table 5) as they all are part of the 
NuRD complex and therefore thought to be relevant for an oncoprotein. 
Table 5 Relevant proteins detected in the first LE6 SILAC experiment. In the table are shown the 
intensities, the ratios, the p-values, the protein IDs (Uniprot) and the protein names of proteins 
detected in the first LE6 experiment that are linked to the NuRD complex. Proteins are sorted by 
descending intensity.  
 
Intensity H+L Ratio H/L p value H/L Protein IDs Protein Names
8,729885 1,696261 0,001 Q09028 Chromatin assembly factor 1 subunit C
7,731814 1,598079 0,010 Q13547 Histone deacetylase 1; Histone deacetylase 2
7,698066 1,591201 0,010 F6S0T5 BRAF35-HDAC complex protein BHC110; Lysine-specific histone demethylase 1A
7,040725 2,022368 0,018 Q14839-2 ATP-dependent helicase CHD4
6,881898 2,631523 0,002 Q13330 Metastasis-associated protein MTA1; Metastasis-associated protein MTA3  
 
The next step was to validate if LE6 binds to at least one of the detected proteins to assess a 
possible involvement of LE6 in the recruitment of the NuRD complex. Since KDM1A (Uniprot 
ID F6S0T5) was identified also in the label free approach, although not significant, this was 
the first protein investigated. First, the membrane of the western blot performed to determine 
the validity of the CoIP before processing the samples was re-probed with an anti-KDM1A 
antibody (Fig. 31, this figure was previously shown as Fig. 29). 
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Fig. 31 CoIP of Flag_linker_HA tagged CRPV E6 proteins. Figure previously shown as Fig. 29. 
CRPV LE6 and SE6, as well as the empty vector (CMV), were transiently expressed in C33a cells. 
The western blot shows the specific band for LE6 (~40 kDa) and SE6 (~35 kDa) using an anti-HA 
antibody (lower panel). An HA signal was detected for all the proteins (lower panel) in both inputs (IN) 
and immunoprecipitates (IP) at the expected sizes. On the left, equal amounts of IN, representing an 
aliquot of the cell extract from transfected cells before the CoIP, and on the right are shown the IP, 
1/10 of the samples resulting from the CoIP. Samples were analyzed for the presence of a reference 
protein using an anti-α-tubulin antibody (middle panel) and for the pull down of KDM1A (upper panel). 
Molecular weights are shown in kDa on the left.  
 
As shown by the western blot, a band, although weak, was detected in the 
immunoprecipitate of LE6 and this validated the SILAC result concerning KDM1A. 
To verify the reproducibility of LE6 interaction with KDM1A, additional CoIP experiments 
were performed but the interaction could not be confirmed (Supplementary results, Fig. S8).  
This way, it was possible to show that there is no evident interaction between LE6 and 
KDM1A, although a band for KDM1A was visible in the immunoprecipitate of the SILAC 
samples (Fig. 31). LE6 binding to HDAC1 and HDAC2 was also evaluated, by repeating the 
CoIP, but no bands were detected (Supplementary results, Fig. S9). 
The SILAC experiment was repeated twice, inverting the media in which cells were grown, to 
verify technical and biological reproducibility as shown in Table 6.  
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Table 6. Culture conditions for the two SILAC experiments. The table shows how cells were 
labeled in each experiment where Heavy (H), Medium (M) and Light (L) represent the three different 
media. 
 
 CMV CRPVLE6 CRPVSE6 
1st SILAC L H M 
2nd SILAC H M L 
 
To highlight the relevant common proteins between the first and the second SILAC 
experiment, they were correlated and plotted as shown in Fig. 32. 
 
Fig. 32 Scatter plot showing correlation with inverted SILAC labels. Forward SILAC ratios (Log2) 
of protein groups normalized to their respective protein were plotted against their reverse ratios. 
Specific binders of LE6 and SE6 are found in the right lower quadrant of each plot whereas 
surrounding the center of the axes are the unspecific binders. A. LE6 SILAC ratios inverted. B. SE6 
SILAC ratios inverted.  
 
The correlation analysis (Fig. 32-A) for LE6 showed that its pull down was highly 
reproducible, whereas this was not the case for the one of SE6 (Fig. 32-B). This is probably 
due to the low level of its expression (Fig. 29).  
As shown in Fig. 32-A, LE6 had a high ratio, statistically distant from the distribution, which is 
expected from the exogenous expression of a bait protein. Moreover, statistically significant 
specific binders of LE6 were identified in the lower right quadrant because ratios were 
calculated in Log2 and specific binding proteins showed positive ratios in the first experiment 
and negative ratios in the second one. 
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On the other hand, it was not possible to identify specific binders of SE6 as shown in Fig. 32-
B where SE6 and significant proteins in the lower right quadrant were not enough distant 
from the distribution of nonspecific binding proteins in the center of the axes. Only in the 
lower left quadrant a small number of proteins were identified but they were most likely 
contaminants. Moreover, the intensity for the SE6 protein was the same in the CMV- and 
SE6-transfected cells leading to a non-significant value. Therefore, it was assumed that 
either the transfection or the pull down did not properly work for SE6 in both experiments.  
From each experiment a list of possible proteins was determined and reproducibility was 
verified taking into account all the common hits between the two experiments (304) 
(Supplementary results, Fig. S10), leading to 19% overlap of all the possible candidates (Fig. 
33). 
 
Fig. 33 Common hits between the two experiments. The list of possible candidates of the first 
SILAC (green) and the second SILAC (yellow) were overlapped and the common candidates were 
304, shown in the intersection. 
 
Proteins were sorted according to their ratios and p-values. Only proteins with a p-value 
< 0.05 and a significant ratio were analyzed and compared between the two experiments and 
a list of 17 possible interacting proteins is showed in Table 7. 
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Table 7. List of the best LE6 interacting proteins. Proteins sorted by high ratio and p-value < 0.05 
in both SILAC experiments. Ratio H/L refers to the first experiment and Ratio H/M to the second. 
Protein IDs represent the Uniprot identification numbers. 
 
Ratio H/L (SILAC 1) Ratio H/M  (SILAC 2) p-value SILAC 1 p-value SILAC 2 Protein IDs Protein Names
4,274709 -6,63279 4,92E-18 1,10E-101 LE6
2,33674 -1,39665 1,87E-06 1,62E-03 Q04637-9 Eukaryotic translation initiation factor 4 gamma 1
2,024213 -0,6487561 2,24E-05 3,27E-02 Q9NVI7-2 ATPase family AAA domain-containing protein 3A
1,835358 -0,7399261 1,77E-04 2,95E-02 Q13263 KRAB-associated protein 1
1,468583 -0,8122322 2,64E-03 8,12E-03 O95816 BAG family molecular chaperone regulator 2
1,708894 -2,919424 5,48E-03 4,13E-07 P51659 17-beta-hydroxysteroid dehydrogenase 4
1,682933 -1,840836 6,30E-03 4,16E-05 P78344 Death-associated protein 5
1,584289 -1,645616 1,05E-02 2,31E-04 Q8WWM7-3 Ataxin-2 domain protein
1,574634 -2,18554 1,10E-02 1,86E-05 P04075-2 Fructose-bisphosphate aldolase A
1,22002 -1,811422 1,13E-02 5,44E-05 P04792 28 kDa heat shock protein
2,151794 -2,312796 1,13E-02 6,56E-05 Q9BSV6 Leukocyte receptor cluster member 5
1,471604 -1,013917 1,26E-02 1,95E-02 O00411 DNA-directed RNA polymerase, mitochondrial
1,182184 -0,7010133 1,52E-02 2,15E-02 P62280 40S ribosomal protein S11
1,451752 -0,8359862 1,99E-02 6,50E-03 Q8N163 Deleted in breast cancer gene 1 protein
1,101112 -1,056311 2,37E-02 6,50E-04 Q92616 GCN1-like protein 1
1,054223 -0,896818 3,02E-02 3,69E-02 Q9NX02 NACHT, LRR and PYD domains-containing protein 2
1,296663 -0,9981546 3,96E-02 2,13E-02 Q7KZF4 100 kDa coactivator  
 
As shown in Table 7, all the proteins had high (positive or negative) ratios and the p-values 
were much lower than the 0.05 threshold, meaning that these proteins were significantly 
distant from the distribution of nonspecific binders and also that the probability that they are 
real binding proteins is very high. Moreover, as a control, LE6 was the protein with highest 
and lowest p-values, a feature expected from a bait protein. 
Although both SILAC experiments with SE6 as bait protein did not show any reproducibility 
and no good expression of SE6 itself (Fig. 15, Fig. 17), a comparison was carried out. 
However, the analysis did not yield any meaningful result since it was not possible to identify 
proteins with high enough ratios and statistically significant distant from the group of proteins 
that represent unspecific binders. 
 
5.1.8 Comparing SILAC with label free quantification 
Finally, SILAC results were compared to the results obtained from the label free proteome 
analysis to determine whether relevant proteins were common to the two approaches. Only 
LE6 was taken into account since 38E6 was not analyzed and SE6 was not well expressed 
in the SILAC approach. 
Comparing the results obtained from the label free and the SILAC quantifications, it is 
possible to identify 62 proteins (Supplementary results, Fig. S11), that were common to the 
two approaches. 
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5.1.8.1 Validation of 17-Beta-Hydroxysteroid Dehydrogenase 4 (17βHSD4) as a new 
promising E6 interaction partner 
 
Since SILAC is quantitative and more standardized than the label free quantification, the 
results obtained with SILAC were considered more reliable than those obtained with the label 
free quantification. The results obtained with the two approaches were compared and 62 
proteins were identified in both (Supplementary results, Fig. S11).  
The final aim was to find at least one of the best LE6 interacting proteins identified by SILAC 
also in the label free analysis. For this purpose, protein families were analyzed in detail and 
the analysis was not restricted to single isoforms, since, as previously explained, large 
protein families rarely yield many unique peptides, which affects the analysis. Many isoforms 
of the 17-Beta-Hydroxysteroid Dehydrogenase protein family were present in both 
approaches and therefore, based on already published studies, it was decided to investigate 
further the protein 17-Beta-Hydroxysteroid Dehydrogenase isoform 4 (17βHSD4, Uniprot ID 
P51659). It is a bifunctional protein involved in the peroxisomal beta-oxidation pathway for 
fatty acids but it was shown that it stimulates the growth of human keratinocytes by inducing 
cyclin D2 [179] and inhibits oxidative stress-induced apoptosis in keratinocytes by promoting 
Bcl-2 expression [180]. 
Additional experiments were performed to determine whether the interaction between LE6 
and 17βHSD4 can be validated. 
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First, a western blot was carried out to verify that 17βHSD4 interacts with LE6 (Fig. 34, 
shown also in the supplementary data as Fig. S8). 
 
Fig. 34 Western blot to validate 17βHSD4 interaction with LE6. Figure shown also in the 
supplementary data as Fig. S8. HA-tagged LE6 and 38E6 were tested for the binding to p300 (upper 
panel, IP) and MAML1 (middle upper panel, IP), that were used as positive controls for the pull down. 
KDM1A was not pulled down by neither LE6 nor 38E6 (central panel), as shown before. Specific HA 
signals were detected for 38E6  (lower panel, 38E6 ~19 kDa) in both inputs (IN) and 
immunoprecipitates (IP) with the exception of LE6 (~40 kDa) that was not detectable. It was not 
possible to observe an interaction with 17βHSD4 (middle lower panel). CMV: pCMV-N-
Flag_Linker_HA empty vector; LE6: pCMV-N-Flag_Linker_HA-CRPVLE6; 38E6: pCMV-N-
Flag_Linker_HA-HPV38E6. Molecular sizes are shown in kDa on the left. 
 
As shown by the western blot, the interaction between LE6 and 17βHSD4 could not be 
validated, probably due to the fact that LE6 was not expressed, as observed in the western 
blot. However, further investigations were performed.  
An immunofluorescence assay, where C33a cells were transfected with the empty vector 
(CMV) or CRPVLE6 (LE6), was used to check whether the two proteins co-localize, which is 
a hint of their interaction (Fig. 35).  
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Fig. 35 Immunofluorescence showing localization of KDM1A and 17βHSD4. C33a cells 
were stained with an anti-HA antibody (green) and an anti-KDM1A or 17βHSD4 antibody 
(red). Cell nuclei were stained with DAPI (blue). Merge shows the overlays of the different 
stainings.  
 
Immunofluorescence analysis showed a visible co-localization of LE6 and 17βHSD4. 
Additionally, the co-localization of LE6 and KDM1A was investigated to confirm the results 
previously obtained by the western blot shown in Fig. 31. Similar to the prior results, no co-
localization was observed (Fig. 35). CMV-transfected cells were used as a control of KDM1A 
or 17βHSD4 localization in the absence of LE6.  
To investigate whether this co-localization corresponded to a direct interaction, a proximity 
ligation (PLA) assay was performed with the same antibodies (17βHSD4 and KDM1A) used 
for the co-localization analysis. C33a cells were transfected with CMV and LE6, and 38E6 
was used as an additional control (Fig. 36 and 37).  
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Fig. 36 LE6 interaction with KDM1A and 17βHSD4 via PLA. C33a cells were incubated with an 
anti-HA antibody and an anti-p300, pRb, KDM1A, 17βHSD4 antibody. Cell nuclei were stained with 
DAPI (blue). Red PLA dots represent single protein-protein interactions. Merge shows the overlay of 
the PLA and DAPI staining. The right column of images shows magnifications of the merged images. 
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Fig. 37 38E6 interaction with KDM1A and 17βHSD4 via PLA. C33a cells were incubated with an 
anti-HA antibody and an anti-p53, pRb, KDM1A, 17βHSD4 antibody. Cell nuclei were stained with 
DAPI (blue). Red PLA dots represent single protein-protein interactions. Merge shows the overlay of 
the PLA and DAPI staining. The right column of images shows magnifications of the merged images. 
 
In the immunofluorescence analysis (Fig. 35) p300 and pRb were used as positive and 
negative controls, respectively, for PLA signals, because it is known that LE6 interacts with 
p300 while it does not interact with pRb. As expected, there was a strong interaction between 
LE6 and p300, whereas no PLA spots were detected when the interaction between LE6 and 
pRb was investigated. 
Concerning KDM1A, the results confirmed that there is no direct interaction with LE6, 
whereas 17βHSD4 showed, that it not only localized in the same cellular region as LE6 
(immunofluorescence Fig. 35), but also to interact with LE6 (PLA Fig. 36), although to a 
lesser extent than p300. 
A similar result was obtained in the case of 38E6 (Fig. 37). p53, a known interaction partner 
of 38E6, showed a strong interaction while no interaction with pRb was detected. KDM1A, as 
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well, did not show a clear interaction with 38E6, while the interaction between 38E6 and 
17βHSD4 was confirmed. 
In conclusion, the interaction between LE6, 38E6 and 17βHSD4 was confirmed by 3 different 
methods and in three independent experiments, pointing towards a role of 17βHSD4 in 
collaborating with cutaneous E6.  
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5.2 HPV31 intraviral interactome 
The HR-HPV31, one of the causative agents linked to cervical cancer, was widely studied 
concerning viral-cellular protein interactions. This work aimed to perform a complete 
screening of the viral proteins to investigate how they interact with each other. A FACS-
FRET approach [157] was used to elucidate the intraviral network.  
 
5.2.1 Expression of Fluorescently labeled-proteins in the HPV-
negative cell line C33a 
To explore HPV31 viral-viral protein interactions, all the viral genes (E1, E2, E8^E2C, E1^E4, 
E5, E6, E7, L1 and L2, Fig. 38) were cloned into vectors containing either the yellow 
fluorescent protein (YFP) (peYFP-C1, Clontech) or the blue fluorescent protein (BFP) 
(pmTagBFP-C1, Clontech) tag. 
  
 
 
Fig. 38 Schematic overview of HPV31 genome. HPV31 linearized genome is represented on top. 
Below splice donor (SD) and splice acceptor (SA) sites are identified by nucleotide positions and 
dashed lines. Figure adapted from [181]. 
 
First, it was evaluated whether the tag had to be expressed N- or C-terminally to avoid 
unwanted changes in protein expression, localization and functionality. Previous experience 
in the lab showed that, in particular HPV 31 E1, E2 and E8^E2C were expressed and 
functional when the tag was located at the N-terminus. The remaining genes were cloned in 
both ways and then tested. A summary of the tag position is shown in Table 8.  
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Table 8. Fluorescent tag position for each viral protein. 
 
 
Except for the capsid proteins, all the other proteins were used with the N-terminal tag. 
Moreover, E2, L1 and L2 were codon-optimized (E2co, L1co, L2co) and for E6 a splicing 
mutant was created altering the splicing donor site at position 105 in the E6 ORF. The 
mutation led to a substitution from T to G, a silent mutation not affecting the protein 
sequence. This was used to avoid the synthesis of the two versions E6 and E6*, and, instead 
ensured the expression of full length E6. 
C33a cells were transiently transfected with constructs containing the YFP-tagged viral gene 
sequences assuming that the BFP tag affected them in the same way, and a western blot 
was carried out to evaluate their expression. 
Hsp90100
55
45
35
100
130
YFP      E1   E1^E4  E2co   E5       E6      E7    L2co     L1co E8^E2C
YFP
YFP
A B
YFP 27 kDa
E1 98 kDa
E1^E4 37 kDa
E2co 77 kDa
E5 36,5 kDa
E6sm 44,7 kDa
E7 38 kDa
L2co 77 kDa
L1co 83,4 kDa
E8^E2C 47 kDa
 
 
Fig. 39 Western blot showing YFP tagged-HPV31 proteins in transiently transfected C33a cells. 
(A) In the lower panel, lysates were probed with an anti-Hsp90 antibody and in the middle and upper 
panels an anti-GFP antibody was used to detect the YFP-tagged proteins. On the left, molecular 
weights are indicated in kDa. (B) Expected protein molecular weights expressed in kDa. co: codon-
optimized. 
 
As shown by the western blot, all the proteins were expressed. No band for Hsp90 was 
present in the E2co lysate, since a cellular fractionation was performed to enhance E2 
protein amount and only the nuclear fraction not expressing Hsp90 was analyzed. All the 
other proteins were shown to be expressed in different amounts (Fig. 39-A), but a specific 
band around the expected molecular weight was detected for each one (Fig. 39-B). 
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The next step was to test protein localization in order to verify that the tag did not affect 
protein localization. For this purpose immunofluorescence was performed in transiently 
transfected C33a cells (Fig. 40). 
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Fig. 40 Immunofluorescence showing HPV31 YFP-tagged proteins localization. C33a cells were 
transiently transfected with YFP- tagged proteins. On the left, the YFP (green) signal, in the middle cell 
nuclei stained with DAPI (blue) and on the right the overlay between YFP and the nuclei signal 
(Merge). 
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Table 9. Expected and observed HPV31 protein localization. 
Proteins Expected localization Observed localization
E1 Nuclear (Sakakibara et al. 2011) Nuclear
E2 Nuclear (Sakakibara et al. 2011) Nuclear
E8^E2C Nuclear (Stubenrauch et al. 2007) Nuclear
E1^E4 Keratin-association (Doorbar 2013) Cytoplasmic
E6 Nuclear and cytoplasmic (Zanier et al. 2012) Nuclear
E7 Nuclear and cytoplasmic (Todorovic et al. 2011) Nuclear and cytoplasmic
E5 ER, Golgi, nuclear envelope (DiMaio & Petti 2013) Cytoplasmic
L1 Nuclear (Zhou et al. 1991) Nuclear
L2 Nuclear (Becker et al. 2004) Nuclear
 
As shown in Fig. 40 and summarized in Table 9, in transiently transfected C33a cells HPV31 
proteins did not show any altered localization due to the tag. All the previously reported 
cellular localizations listed in the third column of Table 9 were confirmed. 
 
5.2.2 Fluorescently tagged proteins are functional 
To characterize the proteins’ functionality, different assays were carried out. It was not 
possible to test each protein since only for some of them enough information about their role 
and their interactions are available. Hence functionality could only be tested for E1, E2, 
E8^E2C, E6 and E7. 
5.2.2.1 E6 and E7 
As discussed above, it is well known that HR-E6 degrades p53 by interacting with the E6AP 
protein. Furthermore, HR-E7 is known to bind to pRb. Both p53 and pRb are mutated in the 
C33a cell line, which is why the keratinocyte cell line N/Terts, which contains wild type p53 
and pRb, was used to perform a CoIP experiment with YFP-tagged E6 and E7 as baits (Fig. 
41).  
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Fig. 41 CoIP showing HPV31 E6 and E7 interactions. YFP-tagged E6 and E7 were tested for the 
binding to pRb (upper panel, IP) and E6AP (middle panel, IP). An YFP signal was detected for all the 
samples (lower panel) in both inputs (IN) and immunoprecipitates (IP). Molecular sizes are shown in 
kDa on the left. YFP: peYFP-C1; E7: peYFP-C1+HPV31E7; E6: peYFP-C1+HPV31E6. 
 
As demonstrated by the western blot, E7 (44 kDa) and E6 (38 kDa) proteins were well 
expressed, although a single YFP band was present in each sample. The western blot 
showed that E6 binds E6AP, whereas E7 binds pRb demonstrating that the tag did not 
interfere with their abilities to interact with other proteins. 
5.2.2.2 E1, E2 and E8^E2C 
HPV replication is finely regulated by the interplay of the three proteins E1, E2 and E8^E2C. 
While E1 and E2 contribute to replication and transcriptional activation, E8^E2C was shown 
to be a negative regulator, mainly by competing with E2 for the DNA binding site in the 
upstream regulatory region (URR). These functions were analyzed through a reporter assay, 
in which the viral tagged proteins were co-transfected with a luciferase construct under the 
control of the HPV31 URR (Fig. 42). 
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Fig. 42 Luciferase assay showing E1, E2 and E8^E2C modulation of HPV31 URR activity. C33a 
cells were transfected with 10 ng of the pGL 31URR-luc (HPV31 URR) vector and respectively 100, 10 
and 10 ng of the expression vectors encoding for YFPE1, E2 and E8^E2C. Luciferase activity was 
measured after 48h. The bars represent the average and standard deviation of three independent 
experiments and luciferase activities are relative to the E1+E2-transfected cells. Gaussia was used as 
an internal transfection control. Two tailed unpaired Student’s t-test:* p < 0.05; ** p < 0.01; ns: not 
significant. 
 
As expected, the empty vector (peYFP-) and the single proteins did not activate transcription 
of the luciferase reporter gene. Conversely, the co-transfection of E1 and E2 led to a strong 
activation of replication and transcription, whereas when E8^E2C was transfected together 
with E1 and E2 a statistically significant repression of transcription activity (approximately 
80%) was observed. These results indicate that the tag did not affect the proteins’ function.  
 
5.2.3 FACS-FRET screening for HPV31 intraviral interactions 
After showing that the labeled proteins were expressed, correctly localized and functional, a 
flow cytometry-based FRET (FACS-FRET) assay was performed to discover all the 
interactions among HPV31 proteins. To check whether C33a cells were a suitable cell line for 
FACS-FRET analysis, cells were first transfected with the YFP and BFP empty control 
vectors either separately or both combined. Additionally, a YFP-BFP control vector was 
transfected containing a fusion ORF that results in a constitutive FRET signal, since the two 
fused proteins remain in close proximity, which is the basis for the FACS-FRET 
methodology. In Fig. 43, the results of this FACS-FRET adjustment experiment are shown.  
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Fig. 43 Adjustment of FACS-FRET settings for C33a. A MACSQuant flow cytometer was used to 
measure FRET signals in C33a. Cells were transfected with the controls: YFP (A), BFP (B), YFP+BFP 
(C) and YFP-BFP (fusion construct giving a FRET positive signal, D). (1) FSC/SCC: along the Y-axis 
there is the FSC (Forward SCatter), a measure of the frontal light scattered from the cells (cell size); 
along the X-axis there is the SCC (Side SCatter) that measures the amount of laser beam that 
bounces off of particulates inside of the cell (cell complexity/granularity). (2) P1: identifies all the living 
cells and 4 different subpopulations: Lower Left corner (LL2, double negative); Lower Right corner 
(LR2, BFP positive cells); Upper Left corner (UL2, YFP positive cells); Upper Right corner (UR2, 
double-positive cells). (3) P3 (P1/UR2): an enlargement of the P1/UR2 where double-positive cells are 
gated and false positive FRET signals resulting from YFP excitation by the 405 nm laser are excluded. 
(4) P4: FRET-positive cells. 
 
The four transfections (YFP, BFP, YFP+BFP, YFP-BFP) were used to adjust the gates in 
order to select only the FRET-positive cells, among all the double positive cells. 
To identify only FRET-positive cells, the gating took into account the false positive signals 
deriving from the excitation of the YFP (with the 405 nm laser) and combine it with the 
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negative control (cells co-expressing YFP+BFP) and the positive control (cells expressing a , 
YFP-BFP fusion construct). 
The remaining cells are evaluated for FRET signals by adjusting the gate to include cells, 
which are co-transfected with BFP and YFP and were FRET-negative or cells expressing the 
YFP-BFP fusion protein representing a FRET-positive cell population (switch into the gate in 
Fig. 43-4D). 
Once assessed that C33a are suitable for FACS-FRET measurements, each fluorophore-
tagged viral protein was tested for an interaction with itself and with each other. Two 
combinations were used, where both the YFP and the BFP versions of the proteins took part. 
Gates were adjusted according to the positive control (YFP-BFP fusion construct) were 
FRET-positive cells were more than 95% and to the negative control (YFP and BFP vectors 
co-transfection), in which cells that gave a FRET signal were less than 1%. A minimum of 
500 cells in the double positive cells gate and a FRET signal of at least 10% as a cut off were 
also taken into consideration. 
A large screening was performed using all the possible combinations to investigate 
previously described interactions (related not only to HPV31 but also to 16 and 18) and to 
discover new intraviral interactions (Fig. 44).  
A
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Fig. 44 FACS-FRET screening in C33a cells. Cells were transfected with YFP- and BFP- tagged 
proteins for hetero- (A) and homodimerization (B). The Y-axis represents the percentage of FRET-
positive cells whereas the X-axis shows the combinations used. Horizontal red lines represent the 
10% and 35% FRET signal cuts off. FRET Signals between 10% and 35% identify putative 
interactions, whereas percentages above 50% indicate strong interactions. The negative control is the 
co-transfection of YFP and BFP (YFP+BFP) and the positive control is the YFP-BFP fusion construct. 
Statistical significance was calculated with a two-tailed unpaired Student’s t test. ns: not significant; * 
p<0.05; ** p<0.01; *** p<0.001. 
 
As shown by the figure 44, many interactions demonstrated to be strong and statistically 
significant. To have a better readout of the huge dataset, more detailed analyses where 
performed. 
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A table including all the interactions already reported in literature was constructed (Table 10). 
Table 10. Summary of HR-HPV published intraviral interactions 
 
E1 [182]  
        
E2 [183] [184] 
       
E8^E2C 
 
[185] [185] 
      
E1^E4 
 
[186] 
 
[187] 
     
E5 
    
[188] 
    
E6 
 
[189] 
   
[190] 
   
E7 
 
[191] 
    
[192] 
  
L1 
 
[193] 
     
[48] 
 
L2 
 
[194] 
     
[195] 
 
 
E1 E2 E8^E2C E1^E4 E5 E6 E7 L1 L2 
 
To highlight the previously known and the newly discovered protein-protein interactions, the 
data were presented in a table, taking into account only the statistically significant 
interactions and visually differentiating those previously described (orange boxes) and the 
new interactions (green boxes) (Table 11). 
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Table 11. Summarized results of FRET signals in C33a cells. Green boxes represent new 
interactions whereas orange boxes show interactions already described in at least one of the HR-HPV 
types. White boxes white are for FRET mean values below 10% and/or not significant. n: number of 
independent experiments; Mean: mean value of FRET; SD: standard deviations; Statistical 
significance (Sign.) was calculated with a two-tailed unpaired Student’s t test. ns: not significant; * 
p<0.05; ** p<0.01; *** p<0.001. 
 
n 3
Mean 10,26
E1 SD 8,38
Sign. ns
n 4 4
Mean 65,23 39,91
E2 SD 4,10 11,89
Sign. *** ***
n 5 5 5
Mean 13,39 80,20 71,29
E8^E2C SD 5,16 4,95 5,21
Sign. *** *** ***
n 3 3 4 3
Mean 12,02 23,08 28,13 62,01
E1^E4 SD 6,50 8,71 11,37 6,09
Sign. * * ** ***
n 3 3 3 3 4
Mean 3,46 4,67 1,06 19,33 36,18
E5 SD 3,05 3,26 0,34 6,33 5,04
Sign. ns ns ns ** ***
n 4 6 3 4 3 4
Mean 26,27 24,76 72,04 30,27 2,39 16,34
E6 SD 7,87 12,55 6,77 9,10 1,41 4,90
Sign. *** *** *** *** ns ***
n 9 3 3 3 3 5 4
Mean 13,91 36,92 21,32 24,48 3,47 59,68 6,92
E7 SD 8,15 7,51 8,27 1,74 0,81 14,60 2,77
Sign. *** ** * *** ** *** **
n 4 3 3 3 3 3 3 5
Mean 14,37 22,99 30,72 11,25 2,05 30,43 23,57 48,08
L1 SD 5,91 7,23 4,08 2,50 0,30 10,83 4,03 16,45
Sign. ** ** *** ** ** ** *** ***
n 3 5 3 4 0 4 4 3 2
Mean 19,28 12,57 63,60 22,07 12,25 28,94 68,83 30,95
L2 SD 5,04 9,25 17,04 6,48 2,32 8,36 18,96 35,83
Sign. ** * ** ** *** *** ** ns
E1 E2 E8^E2C E1^E4 E5 E6 E7 L1 L2  
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As shown in Table 11, most of the interactions analyzed were statistically significant (36 out 
of 45). All the previously reported interactions concerning E2, E8^E8C, E4, E5, E6, L1 and 
L2, and some of E1 and E7 were confirmed.  
As shown by other groups, E2 interacts with all investigated proteins, except E5 and Table 
11 shows that strong FRET signals (ranging from 12.57 and 80.20%) confirmed the already 
published interactions with L2, L1, E1^E4, E6, E7, E1 and E2-E2 dimerization. 
For E1, FRET signals were detected for all the proteins investigated, except E5. As 
expected, FRET signals with E2 had the highest values, confirming a very strong interaction. 
E1 hexamerization was not confirmed, because the FRET value was below 10% and also 
non-significant. 
For E8^E2C, the strongest signal, following the interaction with E2, was the 
homodimerization. Unpublished interactions also include E1^E4, E7, L1 and the interactions 
with L2 and E6.  
As shown in Table 11, E1^E4 forms dimers and interacts with E2. E1^E4 is the only viral 
protein interacting with E5 and unreported interactions with E6, E7 and L1 were also 
observed. 
For E5 all the FRET values were below 5% and/or not significant. The co-transfection of E5 
and L2 never reached the 500 cells threshold in the double positive cells’ gate, so that the 
values were automatically excluded from the analysis. Although the cell population analyzed 
was alive, it seemed that the two proteins could not be expressed at the same time. 
For E6, it is known that it forms homodimers and that it interacts with E2, observations that 
were confirmed in this work. Additionally, new interactions were found (Table 11): E6 
interacts with E1, E1^E4, L1 and L2. However, the highest FRET values were documented 
between E6 and E8^E2C and between E6 and E7. 
By analyzing E7, new interactions with E1, E8^E2C, E1^E4, E6, L1 and L2 were detected. 
E7 dimerization was below the 10% threshold and could not be confirmed, differently from 
the already published E7-E2 interaction that is reported in Table 2. 
The FACS-FRET assay confirmed that the capsid proteins, L1 and L2, interact with each 
other and with E2. L1 was previously shown to form dimers, differently from L2, both proven 
in the FACS-FRET experiments. Apart from the already reported interactions, the viral capsid 
proteins showed new interactions with E1, E8^E2C, E1^E4, E6 and E7. 
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A network map including the previously published and the interactions found via FACS-FRET 
was constructed with the open source program NAViGaTOR 
(http://ophid.utoronto.ca/navigator/) and is shown in Fig. 45. 
FRET interaction
Published interaction
FRET+published interaction
 
Fig. 45 The HPV31 intraviral interaction network. Red lines represent HPV31 new interactions 
found by FRET, black lines represent interactions reported in literature and not confirmed with the 
FACS-FRET assay, whereas dashed green lines show interactions both reported and confirmed by 
FRET. The network was generated with the program NAViGaTOR. 
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5.2.4 Validation of the interaction between HPV31 E6 and E7  
In order to confirm the interaction between E6 and E7, a CoIP was performed. Therefore, 
C33a cells were transfected with YFP, BFP, YFPE6, BFPE7, YFPE7 and BFPE6 containing 
vectors. Then, the CoIP was performed using anti-GFP beads (able to recognize some GFP 
variants including YFP but not BFP) so that the YFP-tagged proteins were used as baits (Fig. 
46).  
 
Fig. 46 CoIP showing HPV31 E6 and E7 interactions. YFP- and BFP-tagged E6 and E7 were used 
to perform a CoIP, where the baits were the YFP-tagged E6 and E7. YFP and BFP only containing 
vectors were used as negative controls. On the left (A and B) the inputs (IN) show the expression of 
each protein. Immunoprecipitates (IP) show the interaction between E6 and E7, in both combinations. 
Membranes were probed with an anti-BFP (A) and an anti-GFP (recognizing also YFP) (B) antibody. 
Proteins in bold are the ones detected by the antibody. YFP: peYFP-C1; BFP: pmTagBFP-C1; 
YFPE6: peYFP-C1+HPV31E6; YFPE7: peYFP-C1+HPV31E7; BFPE6: pmTagBFP-C1+HPV31E6; 
BFPE7: pmTagBFP-C1+HPV31E7. Molecular sizes are shown in kDa on the left. 
 
As shown by the western blot analysis in Fig. 46, where the upper panel (Fig. 46-A) was 
incubated with an anti-BFP antibody and the lower panel (Fig. 46-B) with an anti-GFP 
antibody, the inputs showed that the single proteins were expressed. The 
immunoprecipitates showed that E6 pulled down E7 and vice versa validating the initial 
FACS-FRET screening results. 
 
 100 
 
6. Discussion 
Protein-protein interaction assays were used as tools to investigate HPV-associated 
carcinogenesis mechanisms. LE6 protein, as one of the oncoproteins of the Cottontail Rabbit 
Papillomavirus (CRPV) was analyzed to discover new host interaction partners using a 
proteomics approach. One of the HR-HPV types, HPV31, was studied to determine its 
intraviral interactome using a FACS-FRET assay.   
6.1 Cutaneous E6 interaction partners 
Although much is known about the high risk (HR) oncoproteins, only a limited number of 
studies demonstrated the involvement of the cutaneous E6 and E7 proteins in cellular 
transformation [64], [67], [99], [196].  Because of its similarities with the cutaneous HPVs, the 
Cottontail Rabbit Papillomavirus (CRPV) represents a suitable model to investigate 
papillomavirus-associated skin lesions [197]. By infecting the skin of New Zealand white 
rabbits it is possible to follow tumor formation and progression in vivo . For these reasons we 
aimed at identifying interactors of the CRPV oncoproteins LE6 and SE6, for acquiring more 
detailed knowledge about molecular mechanisms leading to tumorigenesis. This knowledge 
can subsequently be applied to study tumor formation and progression in vivo as well as 
translated to HPV-induced skin tumors. Although the infection of New Zealand white rabbits 
represents the best model to study HPV-related skin tumors, due to the lack of complete 
annotation of the rabbit genome and of a protein library, CRPV oncogenes were expressed 
and studied in the HPV-negative human keratinocytes cell line C33a. 
Up to now, only few studies reported cutaneous E6 protein interactions with cellular targets. 
Some cutaneous HPVs (5, 8, 38 and others), by interacting with the Mastermind-like (MAML) 
family of transcription activators [75], [76], repress Notch pathway activation that was shown 
to act as a tumor suppressor in the skin when activated [77]–[79]. HPV38 E6 protein was 
also shown to interact with p53, but in contrast to HR-E6 no degradation is needed to alter its 
function [64], [73]. The only information available about CRPVLE6 is its interaction with the 
acetyltransferase p300 [63], a feature shared with HPV 5, 8 and 38 [81]. In the present study, 
HPV 5, 38 E6 and CRPVLE6 and SE6 were used as baits to search for previously 
unreported interactions. Experiments preceding the proteomic approaches confirmed the 
published interactions with MAML1 and p53 for HPV38 E6 and the one of LE6 and SE6 with 
p300 via simple CoIP.  
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Mucosal and cutaneous HPV E6 proteins share the characteristic of binding LXXLL peptide-
containing proteins [67]. Well-studied examples of this property are E6AP for the α-HPVs and 
MAML1 for the β-HPVs. Since CRPV E6 resembles some characteristics of the β-HPV E6 
proteins, it is reasonable to hypothesize an interaction between CRPVE6 and MAML1. This 
is strengthened by the fact that both LE6 and SE6 contain 8 and 6 repetitions of the Cys-X-X-
Cys motif [198], respectively, a feature common to other HPV E6 proteins that, however, 
mostly contain just 4 motifs. However, most likely due to mismatched species-specificity, as 
a rabbit PV protein was expressed in human cells, the interaction between CRPV E6 and 
MAML1 remains unclear. Therefore, further studies in rabbit cells are needed to elucidate 
this interaction. 
A label free quantification (LFQ) processed by liquid chromatography-mass spectrometry 
(LC-MS/MS) at the core facility Proteome Center of Tübingen (PCT) and subsequent 
bioinformatic analyses were used to select the best interaction candidates. The functional 
analysis showed that pathways, sites of expression and transcription factors point to and 
confirm an oncogenic role of the three baits LE6, SE6 and 38E6. 
In more detail, the interactors identified were, indeed, found to be mostly expressed in 
cancer-associated cell lines. More interestingly, putative interactions with three important 
transcription factors, GABPA, ELK1 and NR4A2, were common to the three viral proteins 
investigated and they were all shown to have an impact in survival [199], poor prognosis 
[200], apoptosis evasion [201] and cell growth [202]. Surprisingly, LE6 and SE6 do not share 
any other interactions with specific transcription factors whereas 38E6 has some in common 
with both of them. In depth analysis showed that 38E6 and LE6 share the transcription 
factors E2F1, CREB1 and SPDEF, which have previously been shown to play a role in 
cellular growth, proliferation, survival and disease progression [203]–[205]. On the other 
hand KLF7, STRA13 and STAT1 are exclusive interactors of 38E6 and SE6 and they are 
associated with growth arrest, apoptosis and senescence in tumor cells [206]–[209]. This 
suggests that, while 38E6 might modulate tumorigenesis on several sides, LE6 and SE6, 
although closely related, might preferentially interfere with proteins involved in oncogenic or 
tumor suppressive mechanisms, respectively. Although additional work is needed to prove 
the putative interactions described so far, it is reasonable to think that the three different E6 
proteins are likely to be involved in tumorigenesis and tumor progression and that the 
mechanisms vary depending on the respective PV. 
In order to consolidate the LFQ results and to obtain a more quantitative insight, SILAC was 
used to perform a second run of LC-MS/MS that enabled us to exclude the detection of 
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unspecific binders. Observing the distribution of the data it was noted that LE6 was well 
expressed and highly reproducible. Therefore, the interactors of LE6 were analyzed more in 
depth. Interestingly, among all the possible candidates of LE6, a group of 5 proteins, all part 
of the NuRD complex, emerged as putative binders. Since, previous findings showed that 
HPV E7 interacts with components of the NuRD complex, such as HDAC1, HDAC2 and Mi2β 
[210], it could be speculated that E6 is also able to bind a component of the complex. 
However, the proteins analyzed in this study did not show any evident interaction with 
KDM1A, HDAC1 or HDAC2. 
Proteins identified in the SILAC approach were compared to the results obtained from the 
LFQ. The comparison took into consideration protein families instead of single isoforms and 
the 17βHSD protein family was found to be represented by several isoforms in both 
approaches. 17βHSD4, an enzyme involved in the steroid hormone metabolism, catalyzes 
the conversion of the active form of estrogen, estradiol, into its inactive form estrone. Several 
studies reported the role of estradiol as a co-factor in HPV-associated cervical tumors [211]–
[218]. Moreover, 17βHSD1, the enzyme catalyzing the reverse reaction leading to the 
conversion of estrone into estradiol, was found to be overexpressed in tumor tissues [219]–
[221]. On the other hand, 17β-estradiol was previously shown to be involved in keratinocyte 
growth in a Cyclin D2-dependent manner [179] and to inhibit apoptosis by promoting Bcl-2 
expression [180]. Since estradiol favors tumor progression, 17βHSD1 is overexpressed in 
tumor tissues and 17βHSD4 does not aid tumor growth, one might hypothesize that an 
inactivation or downregulation of 17βHSD4 could promote tumor progression, favoring the 
increase of estradiol levels. However, further research is necessary to support this thesis. 
In order to validate the interaction of 17βHSD4 with LE6, immunofluorescence (IF) and 
proximity ligation assay (PLA) were performed and supported the interaction. 38E6, one of 
the most studied cutaneous viral oncoprotein, was also analyzed for the interaction with 
17βHSD4, because of its high degree of overlap with LE6 concerning protein interactions. As 
hypothesized, the analysis supported the interaction between 38E6 and 17βHSD4.  
Taken together, these data confirmed the previously reported interactions and point to new 
ones. Even though the screening for LE6 might be incomplete due to mismatched species-
specificity of the expression system, the interaction of LE6 and human 17βHSD4 was 
supported by three independent methods and the results are translatable to the rabbit as 
human 17βHSD4 shares 90% identity with the corresponding rabbit sequence. 
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Further studies are needed to clarify the extent of this interaction, first by quantifying the PLA 
and validating the interaction also via FACS-FRET, and secondly, by expressing LE6 in a 
rabbit system. It could be speculated that the tumorigenic activity of LE6 might be exerted by 
blocking 17βHSD4 activity, thus leading to an accumulation of estradiol, that in turns 
promotes the expression of Cyclin D2 and Bcl-2 favoring tumor progression.  Hence, it would 
also be of great interest to explore the function of this interaction in vivo by using the CRPV 
animal model for instance by measuring the levels of estradiol/estrone, Cyclin D2 and Bcl-2 
in rabbits infected by CRPV and in rabbits where 17βHSD4 is knocked down to verify 
whether this two conditions are comparable and favor tumor progression. In line with the 
previous assumption, the overexpression of 17βHSD4 and/or increased levels of estrone, the 
product of 17βHSD4 metabolism, should impair tumor growth.  
In conclusion, 17βHSD4 could be a novel interactor of the CRPV LE6 protein and it will need 
further investigation to prove its potential role in tumor growth and to demonstrate that 
estradiol/estrone levels play a major role in HPV-associated skin tumors, as already shown 
for other types of tumors [213], [214], [217]–[221]. 
 
6.2 HPV31 intraviral interactome 
All large interaction studies on HPV focused on viral-host protein interactions [59], [197] so 
far. In order to broaden the knowledge of HPV interactions, a flow cytometry-based FRET 
assay (FACS-FRET) [157] was used to unravel HPV31 intra-viral protein interactions. FACS-
FRET has many advantages but the most important one is that interactions can be verified in 
living cells, and therefore in the natural cellular compartment of the protein analyzed. 
Moreover, FACS-FRET is a highly reproducible, non-invasive, standardized and quantitative 
method. Although FRET signals can be easily quantified, signals can be influenced by 
various parameters as the fluorophores selected, their sterical orientation, the distance 
between the two interactors, expression and functionality of the tagged proteins. FRET 
values can be, therefore, over- or under-estimated and measures to minimize possible 
misreading have to be taken. However, FACS-FRET gives a strong hint of protein-protein 
interaction that has to be confirmed using other techniques, but it allows screening of protein 
interactions in thousands of living cells in a small amount of time.  
Pre-analytical experiments showed that all the HPV31 fusion proteins were expressed, 
functional and localized to the cellular compartments where they were previously described. 
Among all the interactions described, the majority of these interactions was confirmed. All the 
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previously reported interactions concerning E2, E8^E2C, E4, E5, E6, L1 and L2, and some of 
E1 and E7 were confirmed. 
For E2 all the interactions between E2 and L2 [194], L1 [193], E1^E4 [186], E6 [189], E7 
[191], E1 [183] and E2-E2 interaction [184] were confirmed. However, the strongest 
interaction, although predicted but never demonstrated, was between E2 and E8^E2C. It is 
important to note that the strength of interaction for E2 relates as follows: E8^E2C>E1>E2. 
Although at low levels, E1 and E8^E2C interact with each other as well, confirming once 
again, that E1, E2 and E8^E2C together finely regulate HPV replication. 
For E1, new interactions emerged with all the proteins investigated except E5. As expected, 
the interaction with E2 was the one with the highest FRET values. The already described E1 
hexamerization [182], instead, could not be confirmed since FRET values were below the 
arbitrary 10% threshold set. 
With the exception of the homodimerization [185], all other interactions observed for E8^E2C 
have not been described so far and comprise E1^E4, E7, L1, L2 and E6.  
Concerning E1^E4, the only two interactions reported in the literature are the formation of 
homodimers [187] and the interaction with E2 [186]. In this work, both interactions were 
confirmed and new interactions were shown with E6, E7 and L1. In addition and most 
interestingly, E1^E4 was the only protein shown to interact with E5. 
Previous studies did not highlight interactions for E5, except for its homodimerization [188], 
that was, however, not confirmed in the present study. Although the cells analyzed were alive 
in the assay, the co-expression of E5 with all the other proteins was not possible leading to 
values that were out of parameters set. The only interaction, never described before, is 
E1^E4. 
The interaction between E6 with E2 [189] and E6 homodimerization [190] were also validated 
in this study. Previously unpublished interactions comprise E1, E1^E4, L1 and L2. However, 
surprisingly the highest FRET values were detected between E6 and E8^E2C and the most 
interesting with E7. This is the first prove that the two oncoproteins of a HR-HPV interact and 
this suggests a cooperation between these two proteins in carcinogenesis. 
Although an E7 dimerization was previously demonstrated [192], we found that the FRET 
signal for E7-E7 interaction was below the 10% threshold that was arbitrarily introduced to 
identify only the relevant interactions. Only the interaction between E7 and E2 [191] was 
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confirmed. New E7 interactions found are with E1, E8^E2C, E1^E4, L1, L2 and the strongest 
one with E6.  
Also the interaction of the capsid proteins, L1 and L2 [195], was confirmed in this work. 
Moreover, this study also confirmed the dimerization of  L1 (Modis et al., 2002) as well as an 
interaction between E2 with both L1 [193] and L2 [194]. In addition, new interactions for the 
viral capsid proteins were identified with E1, E8^E2C, E1^E4, E6 and E7. 
Almost all the proteins, with the exception of E5, were shown to interact with each other 
supporting the idea of a fine regulation of replication, expression and tumorigenesis. 
Although FACS-FRET has the great advantage of analyzing interactions in living cells, it has 
to be considered that proteins are expressed in a temporal, spatial and quantitative pattern 
during a productive HPV infection. Thus some of the detected interactions might not occur in 
the context of an infection. For example, E4 is the only protein demonstrated to be expressed 
during all the phases of the viral life cycle [29], [222], and therefore it can be speculated that 
the interactions found for E4 are close to representative especially considering the interaction 
with the capsid proteins that were reported to be expressed only in E4-positive cells [38]. 
However, the FACS-FRET screening provided a first overview about how the viral proteins 
interact with each other and further research is necessary to validate and evaluate the newly 
discovered interactions. As a first step, the interaction between E6 and E7 was confirmed in 
this work by two independent experiments and methods. 
In addition, although never demonstrated so far, some reports support the idea that HPV31 
E6 and E7 proteins may interact. First, HR-E6 and E7 are thought to derive from a common 
ancestor since the two Cys-X-X-Cys motifs present in the C-terminus of HR-E7 were 
supposed to undergo duplication during evolution. This might have given rise to an HR-E6 
protein that contains four copies of a Cys-X-X-Cys motif, with a sequence similar to the 
motifs present in E7 (McLaughlin-Drubin 2009, Vande pol, 2013). Secondly, E6 and E7 were 
shown to form homodimers [190], [192] so it is reasonable to think that, due to the sequence 
similarities they might interact with each other. At last, the expression of HR-E6 and -E7 in 
keratinocytes was previously shown to be necessary and sufficient for immortalization and 
inhibition of differentiation [55], [56] and, although only E7 can immortalize the keratinocytes 
when expressed alone, it was also reported that the co-expression of E6 and E7 increases 
the efficiency of immortalization [57]. Moreover, the viral oncoproteins were shown to 
cooperate to favor carcinogenesis since they are involved in the regulation of several aspects 
of cancer onset and progression, comprising inhibition of apoptosis and cell proliferation 
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(Bedell et al. 1987; Vousden et al. 1988). Thus, an interaction of both proteins is both likely 
and reasonable. 
Additional studies are needed to further confirm this interaction, using other methods such as 
PLA, deletion mutants to be tested in FACS-FRET and crystallography. In summary, we 
discovered both known and to date unknown interactions and were able to verify for the first 
time an interaction between the two viral oncoproteins E6 and E7. 
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7. Conclusions and Outlook 
Despite the availability of vaccines able to prevent most cases of cervical cancers if given 
before a girl or woman is exposed to the virus, none of the vaccines can treat an existing 
HPV infection  Because of their high prevalence there is, however, an urgent need to find 
new therapeutic alternatives in treating HPV-associated tumors. HPV, as the carcinogene or 
co-carcinogene of different types of cancers, including mucosal and skin tumors, needs to be 
therefore deeply investigated. 
 
In this work, two different approaches to discover protein-protein interactions were used. On 
the one hand, a proteomics approach pointing to shed more light into cutaneous HPV-
associated carcinogenesis mechanisms was used. On the other hand, a flow cytometry-
based FRET assay (FACS-FRET) discovered the intraviral network of the HR type HPV31. 
The data acquired so far provide a better comprehension of the molecular mechanisms by 
which cutaneous PVs interfere with the host. Important results include the confirmation of 
previously reported protein interactions as well as the identification of new interactors, where 
17-Beta-Hydroxysteroid Dehydrogenase isoforms 4 (17βHSD4) looks kike a promising 
protein which seems to be involved in tumorigenesis and, consequently, it may prove to be a 
good treatment target.  
The second part of the work focused on HPV31, one of the representative of the HR-HPV 
types. The results of the FACS-FRET allowed to have the first complete overview on the 
HPV31 intraviral interactome. This needs deeper investigation, but it gives an important 
overview on how viral proteins interact with each other and this knowledge can be translated 
to other HR-HPV. Knowing how viral proteins interact might help in understanding novel 
mechanisms involved in HPV-associated cancers, especially since the two oncoproteins E6 
and E7 were shown to interact with each other for the first time. Further validation is needed 
to prove this interaction, but this novel finding could give new insights in new treatment 
options.  
The findings might be used for future research to understand more in depth how cutaneous 
PVs cause cancer and open new possibilities for therapeutic options of PV-induced 
malignancies. 
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8. Supplementary results 
 
 
Supplementary figure S1. Western blot showing HA-tagged E6 proteins expression in stable 
transfected NIKS cells.  
To investigate viral-host interactions of cutaneous E6 proteins, first, stable cell lines expressing HA-
tagged proteins were established. E6 proteins of HPV 5, 38 and CRPV were C-terminally HA 
(hemagglutinin) tagged. For this, genes were cloned into a retroviral vector containing a linker followed 
by a triple HA tag (Materials and methods, section 4.1.10.1 Expression vectors). CRPVE6 mRNA 
results in two splice-variants encoding for the long (LE6) and the short (SE6) isoforms of E6. 
Previously Dr. Peter Muench generated a vector (pcDNA™3.1(+) CRPVLE6 M98S) containing the 
CRPVE6 gene with a mutation at the splicing site (substitution of methionine with serine at position 
98), which ensures the exclusive production of LE6. The CRPVLE6 M98S (called simply LE6) 
sequence was PCR-amplified and cloned into the 3xHA-containing retroviral vector. For the 
expression of the labeled proteins, normal immortalized keratinocytes (NIKS) were transduced using a 
retroviral infection system and subsequently were kept under constant antibiotic selection, which 
finally resulted in stable E6-expressing cell lines.  In the upper part lysates were probed with an anti-
Hsp90 antibody while in the lower part an anti-HA antibody was used to detect the HA-tagged 
proteins. Although the presence of a housekeeping protein (Hsp90), HPV and CRPV E6 proteins 
could not be detected. +: positive control for HA expression; pMSCV: pMSCV_linker_3xHA empty 
vector; LE6: pMSCV_CRPVLE6_ linker_3xHA; SE6: pMSCV_CRPVSE6_ linker_3xHA; 5E6: 
pMSCV_HPV5E6_ linker_3xHA; 38E6: pMSCV_HPV38E6_ linker_3xHA. On the left, molecular 
weights are indicated in kDa. 
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Supplementary figure S2. Immunofluorescence showing the expression of CRPVLE6 and 
HPV38 E6. Protein expression was examined by immunofluorescence (IF) in NIKS cells stably 
expressing CRPV and HPV 38 E6. Therefore, NIKS cells were stained for the presence of CRPVLE6 
and HPV38 E6 using an anti-HA antibody (green). Cell nuclei were stained with DAPI (blue). Merge 
shows the overlay of HA and the DAPI stainings. In these cells, HA expression was detected, although 
this was confined to a very restricted number of cells. 
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Supplementary Table S3. Label free quantification (LFQ) of LE6 interaction partners. In the table 
are listed: LFQ ratios (LE6/CMV), posterior error probability (PEP), intensity, significance B value (Sig. 
B), Gene names, Protein IDs representing the Uniprot identification numbers and the protein names of 
the significant proteins binding to LE6. Graphical representation in results Fig. 8-A. 
 
LE6/CMV PEP Intensity LE6/CMV Sig. B Gene Names Protein IDs Protein Names 
12,5791 3,48E-63 9,96686 1,52E-120 
 
LE6 
 
4,864 8,67E-28 9,2416 2,17E-20 HME1 P31947 14-3-3 protein sigma 
8,80133 3,80E-04 8,72328 2,54E-18 H3FA P68431 Histone H3.1 
7,68448 1,97E-101 8,62822 1,66E-14 KIAA1321 Q7Z417 
82 kDa FMRP-
interacting protein 
9,20576 1,58E-02 8,37568 5,24E-09 
 
H0Y670 
 
2,65834 3,32E-57 9,11561 1,39E-07 BAP135 P78347 
Bruton tyrosine kinase-
associated protein 135 
2,4433 0,00E+00 10,2862 1,05E-06 G22P2 P13010 
86 kDa subunit of Ku 
antigen 
2,30338 8,24E-278 9,53896 3,61E-06 SAP114 Q15459 SF3a120 
6,92089 3,50E-20 8,17173 8,12E-06 HIST2H2AB Q8IUE6 Histone H2A type 2-B 
2,14906 0,00E+00 9,86804 1,31E-05 PLEC1 Q15149 
Hemidesmosomal 
protein 1 
6,57684 3,54E-135 8,49328 2,08E-05 PABP3 Q9H361 
Polyadenylate-binding 
protein 3 
2,0127 2,06E-177 9,10992 3,84E-05 CORO1C A7MAP1 Coronin-1C_i3 protein 
3,80523 6,09E-57 8,90697 5,19E-05 P53 P04637 Antigen NY-CO-13 
1,95195 4,66E-151 9,14594 6,08E-05 CGI-132 Q9Y3D3 
28S ribosomal protein 
S16, mitochondrial 
1,93494 5,45E-07 9,68152 6,90E-05 RTTN Q86VV8 Rotatin 
5,91065 5,08E-53 8,08221 1,52E-04 AD-001 Q9UI30 TRM112-like protein 
3,46184 6,46E-83 8,82558 1,90E-04 ALDA J3KPS3 
Fructose-bisphosphate 
aldolase A 
5,72686 3,91E-09 7,86207 2,32E-04 PEX14 O75381 Peroxin-14 
4,7913 2,19E-13 7,09548 2,36E-04 H1F3 P16402 Histone H1.3 
5,16901 1,57E-02 7,54616 2,76E-04 AIP Q9NWT8 
Aurora kinase A-
interacting protein 
3,3109 1,25E-30 8,55951 3,25E-04 NDUFA10 E7ESZ7 Complex I-42kD 
1,67761 7,52E-244 9,74603 4,18E-04 ADPRT P09874 
NAD(+) ADP-
ribosyltransferase 1 
5,32215 8,67E-09 8,24655 4,44E-04 MDIG Q8IUF8 
Mineral dust-induced 
gene protein 
3,2159 3,92E-50 8,91431 4,52E-04 DDX6 P26196 
ATP-dependent RNA 
helicase p54 
5,25566 1,92E-27 8,33125 5,14E-04 MAGOH P61326 
Protein mago nashi 
homolog 
1,64535 7,45E-142 9,50864 5,17E-04 SAP61 Q12874 SF3a60 
5,31525 3,18E-09 7,92434 5,72E-04 EIF4E2 O60573 eIF4E-like protein 4E-LP 
1,6214 0,00E+00 10,0114 6,03E-04 HYRC P78527 
DNA-dependent protein 
kinase catalytic subunit 
5,12711 2,83E-20 8,24082 6,80E-04 NOC2L Q9Y3T9 NOC2-like protein 
4,93706 4,89E-04 8,40506 1,02E-03 KIAA1966 J3QR07 
Putative splicing factor 
YT521 
4,54387 5,76E-03 7,31827 1,23E-03 CBP20 P52298 
20 kDa nuclear cap-
binding protein 
4,79271 8,84E-05 8,27969 1,37E-03 NDUFA8 P51970 Complex I-19kD 
4,78859 3,78E-18 8,47748 1,38E-03 SAP62 Q15428 SF3a66 
4,44282 2,21E-03 7,64177 1,54E-03 PROS26 P28070 26 kDa prosomal protein 
4,43791 1,25E-06 7,6203 1,56E-03 OMP25 P57105 
Mitochondrial outer 
membrane protein 25 
2,78404 2,11E-148 8,87237 1,83E-03 UQCRC2 P22695 Complex III subunit 2 
2,75224 3,58E-70 8,68049 2,01E-03 SEC23A Q15436 
Protein transport protein 
Sec23A 
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4,54003 2,62E-30 8,16152 2,25E-03 PYCR2 Q96C36 
Pyrroline-5-carboxylate 
reductase 2 
4,52944 9,23E-07 8,31867 2,30E-03 DBP2 O60231 
ATP-dependent RNA 
helicase #3 
4,56877 4,23E-08 7,93044 2,55E-03 RHOA C9J1T2 
Putative uncharacterized 
protein RHOA 
4,51594 4,70E-16 8,05088 2,81E-03 DNAJB11 Q9UBS4 
APOBEC1-binding 
protein 2 
2,60435 4,74E-60 8,79442 3,12E-03 DDX50 Q9BQ39 
ATP-dependent RNA 
helicase DDX50 
4,3376 2,86E-43 8,39766 3,31E-03 IRA1 Q9BZK7 
F-box-like/WD repeat-
containing protein 
TBL1XR1 
4,28924 2,63E-05 8,21822 3,62E-03 GBAS O75323 
Glioblastoma-amplified 
sequence 
4,03185 2,03E-03 7,57104 3,68E-03 SPT3 O75486 SPT3-like protein 
4,02565 5,04E-05 7,59647 3,73E-03 TTN Q8WZ42-8 Connectin 
3,68588 6,06E-23 7,06807 3,80E-03 
DADB-
118P11.2-006 
A2AB10 Flotillin 1 
3,65753 1,46E-04 6,89485 4,05E-03 CDIPT B3KY94 
cDNA FLJ16129 fis 
highly similar to CDP-
diacylglycerol-inositol3-
phosphatidyltransferase 
3,98471 1,89E-03 7,69854 4,05E-03 MPDU1 O75352 
Mannose-P-dolichol 
utilization defect 1 
protein 
2,50704 1,25E-41 8,6238 4,12E-03 NDUFS1 P28331-2 Complex I-75kD 
3,96544 1,30E-03 7,42667 4,21E-03 INPP5K Q9BT40 
Inositol polyphosphate 
5-phosphatase K 
1,29216 6,72E-160 9,22719 4,22E-03 FACT80 Q08945 
Chromatin-specific 
transcription elongation 
factor 80 kDa subunit 
3,95026 3,24E-06 7,68891 4,34E-03 PRKAR1B P31321 
cAMP-dependent 
protein kinase type I-
beta regulatory subunit 
3,91241 1,27E-02 7,40358 4,68E-03 KIAA0016 Q15388 
Mitochondrial 20 kDa 
outer membrane protein 
3,58018 2,65E-09 7,22937 4,80E-03 
 
P54819-6 
 
3,5659 1,77E-02 7,26252 4,95E-03 NUPL2 C9JYA1 
Putative uncharacterized 
protein NUPL2 
3,86272 9,09E-03 7,33393 5,16E-03 CYB5R3 P00387-3 Diaphorase-1 
3,54532 5,39E-13 6,94077 5,17E-03 H1F2 P16403 Histone H1.2 
4,16565 4,50E-06 7,9301 5,27E-03 VKORC1L1 Q8N0U8 
Vitamin K epoxide 
reductase complex 
subunit 1-like protein 1 
2,38737 3,02E-142 8,5741 5,73E-03 ATP6A1 P38606 
Vacuolar ATPase 
isoform VA68 
3,80382 1,45E-11 7,31601 5,79E-03 MAK16 Q9BXY0 NNP78 
3,78343 1,14E-02 7,66585 6,02E-03 CCDC17 Q96LX7 
Coiled-coil domain-
containing protein 17 
3,71115 1,18E-04 7,66523 6,92E-03 CGI-124 Q9Y3C6 
Peptidyl-prolyl cis-trans 
isomerase-like 1 
3,3881 3,48E-04 7,26708 7,22E-03 BZRP P30536 
Mitochondrial 
benzodiazepine receptor 
3,38743 7,24E-02 7,13271 7,23E-03 ARL5B Q96KC2 
ADP-ribosylation factor-
like protein 5B 
3,37744 3,83E-04 6,67362 7,38E-03 POLR2G P62487 
DNA-directed RNA 
polymerase II subunit G 
3,9659 3,91E-07 7,90927 7,41E-03 SFXN1 Q9H9B4 Sideroflexin-1 
1,18131 4,42E-259 9,62782 7,53E-03 SNRPA1 P09661 
U2 small nuclear 
ribonucleoprotein A 
3,86055 3,63E-04 8,21846 7,74E-03 OGT O15294 
O-GlcNAc transferase 
subunit p110 
3,349 5,91E-17 6,83124 7,82E-03 RAB5 P20339 
Ras-related protein Rab-
5A 
1,16894 2,75E-110 9,13789 8,01E-03 EIF4F E9PFM1 
Eukaryotic translation 
initiation factor 4 gamma 
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1 
3,25536 1,27E-05 7,27235 9,46E-03 ANKRD46 Q86W74 
Ankyrin repeat domain-
containing protein 46 
3,81278 2,52E-09 8,05888 9,54E-03 HSPC114 Q9Y5S9 Binder of OVCA1-1 
3,80298 2,29E-10 7,87272 9,69E-03 RNP24 Q15363 Membrane protein p24A 
3,78453 1,40E-06 7,79759 9,98E-03 PSMB3 P49720 Proteasome chain 13 
3,77018 1,78E-14 8,10531 1,02E-02 NSUN5 Q96P11-4 
NOL1/NOP2/Sun 
domain family member 5 
3,71717 1,38E-07 7,87061 1,11E-02 RNASEP2 E9PB02 
Ribonuclease P protein 
subunit p30 
3,63943 4,14E-08 8,202 1,12E-02 PSMF1 Q92530 
Proteasome inhibitor 
PI31 subunit 
3,63667 9,84E-32 8,27665 1,12E-02 HSD17B12 Q53GQ0 
17-beta-hydroxysteroid 
dehydrogenase 12 
3,629 4,47E-03 8,35034 1,14E-02 CDO1 Q16878 
Cysteine dioxygenase 
type 1 
2,1167 3,92E-84 8,89887 1,16E-02 RO60 P10155 
60 kDa SS-A/Ro 
ribonucleoprotein 
2,11446 8,38E-15 8,78004 1,17E-02 MRP63 Q9BQC6 
Ribosomal protein 63, 
mitochondrial 
3,68267 7,76E-06 7,82563 1,17E-02 RPS21 P63220 
40S ribosomal protein 
S21 
1,08534 9,57E-207 9,82426 1,21E-02 G3BP Q13283 
ATP-dependent DNA 
helicase VIII 
3,6636 2,50E-06 8,03491 1,21E-02 MRPL53 Q96EL3 
39S ribosomal protein 
L53, mitochondrial 
3,3862 1,90E-04 7,5784 1,25E-02 BCDIN3 Q7L2J0 
7SK snRNA 
methylphosphate 
capping enzyme 
3,60524 6,09E-86 7,98692 1,33E-02 MAGED1 Q9Y5V3-2 
MAGE tumor antigen 
CCF 
3,60383 2,75E-14 7,82543 1,33E-02 RCD1 Q92600 
Cell differentiation 
protein RCD1 homolog 
3,59991 1,82E-02 7,99259 1,34E-02 TRAM Q15629 
Translocating chain-
associated membrane 
protein 1 
3,32782 1,70E-05 7,56046 1,39E-02 PMC2 Q9GZR2 Exonuclease XPMC2 
3,31947 1,99E-06 7,63649 1,41E-02 METT11D1 Q9H7H0-3 
False p73 target gene 
protein 
2,03752 1,13E-121 8,73556 1,41E-02 TOP2B Q02880 
DNA topoisomerase 2-
beta 
1,04381 5,59E-68 9,37462 1,47E-02 BAG2 O95816 
BAG family molecular 
chaperone regulator 2 
3,53966 4,72E-03 7,90462 1,47E-02 Nbla11189 Q9BSR8 Protein YIPF4 
3,53135 5,09E-07 7,99257 1,49E-02 THOC3 Q96J01 hTREX45 
2,01582 7,37E-28 8,58048 1,49E-02 KIAA0217 Q92615 
La ribonucleoprotein 
domain family member 
4B 
3,01782 1,73E-03 7,07711 1,50E-02 MYO1C Q12965 Myosin-Ic 
3,26306 1,63E-03 7,69423 1,55E-02 COPS1 Q13098-6 
COP9 signalosome 
complex subunit 1 
3,42107 4,43E-03 8,13293 1,58E-02 KIAA0567 E5KLJ5 
Dynamin-like 120 kDa 
protein, form S1 
3,48818 5,10E-13 7,81296 1,59E-02 DNAJB12 J3KPS0 
DnaJ homolog subfamily 
B member 12 
3,23728 3,10E-12 7,29767 1,62E-02 
 
B4E3L0 
cDNA FLJ54259, highly 
similar to Smu-1 
suppressor of mec-8 
and unc-52 protein 
homolog 
1,97937 6,15E-11 8,75721 1,62E-02 DAD1 P61803 
Defender against cell 
death 1 
3,45163 3,60E-05 7,79649 1,68E-02 IMP3 Q8TCT8 
Intramembrane protease 
3 
3,44448 4,88E-05 8,05588 1,69E-02 MCT1 P53985 
Monocarboxylate 
transporter 1 
3,20968 1,61E-02 7,35168 1,70E-02 WIPF1 C9JB04 Putative uncharacterized 
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protein WIPF1 
1,94899 1,31E-97 8,93848 1,74E-02 HSPC032 Q9Y6C9 
Met-induced 
mitochondrial protein 
3,18694 6,98E-03 7,45388 1,77E-02 FCHO2 J3KNW0 
FCH domain only 
protein 2 
0,997422 0,00E+00 10,1705 1,81E-02 G22P1 P12956 
70 kDa subunit of Ku 
antigen 
3,1688 3,35E-02 7,29763 1,82E-02 GPR112 Q8IZF6 
Probable G-protein 
coupled receptor 112 
1,92081 3,71E-35 8,91995 1,86E-02 THRAP3 Q9Y2W1 
Thyroid hormone 
receptor-associated 
protein 3 
1,91789 1,66E-17 8,8224 1,88E-02 CGI-37 Q9Y221 
60S ribosome subunit 
biogenesis protein NIP7 
homolog 
1,9093 5,26E-134 8,96458 1,92E-02 KIAA0185 Q14690 
NF-kappa-B-binding 
protein 
3,13833 3,43E-04 7,31161 1,92E-02 ITBA4 G3V1N1 
NF-kappa-B-repressing 
factor 
2,87616 1,05E-03 7,25513 1,95E-02 LENG5 E7EQB3 
Leukocyte receptor 
cluster member 5 
1,89884 1,53E-54 9,02152 1,96E-02 POLRMT O00411 
DNA-directed RNA 
polymerase, 
mitochondrial 
2,86842 9,24E-03 7,18927 1,98E-02 DPY19L1 Q2PZI1 Dpy-19-like protein 1 
3,11638 1,01E-03 7,65848 1,99E-02 TOMM34 Q15785 
Mitochondrial import 
receptor subunit TOM34 
2,85361 1,68E-03 5,86589 2,04E-02 GPR107 Q5VW38 
Lung seven 
transmembrane receptor 
1 
2,84926 8,50E-03 7,19901 2,05E-02 TYSND1 Q2T9J0 
Peroxisomal leader 
peptide-processing 
protease 
1,87276 3,38E-08 8,65969 2,08E-02 NDUFS2 O75306 Complex I-49kD 
0,963702 1,25E-98 9,11704 2,11E-02 DDX28 Q9NUL7 
Mitochondrial DEAD box 
protein 28 
2,81653 1,14E-03 7,04242 2,18E-02 JM4 O60831 PRA1 family protein 2 
0,955966 1,18E-20 9,11998 2,18E-02 SFRS2 Q01130 Protein PR264 
3,02414 6,90E-04 7,31025 2,31E-02 CGI-141 Q9Y3E0 
Golgi transport 1 
homolog B 
3,23112 1,81E-20 8,06781 2,32E-02 SAMD1 Q6SPF0 Atherin 
1,82265 9,70E-26 8,92714 2,34E-02 HSP27 P04792 
28 kDa heat shock 
protein 
2,77348 3,24E-04 6,75752 2,35E-02 RBMS3 Q6XE24 
RNA-binding motif, 
single-stranded-
interacting protein 3 
2,77202 2,41E-10 7,16885 2,36E-02 KIAA1483 Q8N680 
Zinc finger and BTB 
domain-containing 
protein 2 
3,143 2,50E-38 8,46705 2,40E-02 HPRT P00492 
Hypoxanthine-guanine 
phosphoribosyltransfera
se 
0,930701 1,38E-172 9,48524 2,43E-02 HSPC075 Q9UQ35 
300 kDa nuclear matrix 
antigen 
3,18545 3,70E-12 8,10687 2,47E-02 AFAR O43488 
AFB1 aldehyde 
reductase 1 
3,17967 2,77E-06 7,93281 2,49E-02 ATAD1 Q8NBU5 
ATPase family AAA 
domain-containing 
protein 1 
2,96876 7,16E-06 7,32434 2,52E-02 UQBP P14927 Complex III subunit 7 
0,919962 4,48E-133 9,2763 2,55E-02 ATP1A1 F5H3A1 
Sodium pump subunit 
alpha-1 
3,08635 8,90E-37 8,33056 2,60E-02 PNO1 Q9NRX1 
RNA-binding protein 
PNO1 
3,14468 4,98E-08 7,84899 2,62E-02 GTF2E2 P29084 
General transcription 
factor IIE subunit 2 
0,912821 4,19E-99 9,15226 2,63E-02 LAPTM4B Q86VI4 
Lysosomal-associated 
transmembrane protein 
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4B 
0,908275 1,47E-46 9,31854 2,68E-02 UBF P17480 Autoantigen NOR-90 
2,92887 2,94E-43 7,28276 2,69E-02 C20orf99 Q9NUD5 
Zinc finger CCHC 
domain-containing 
protein 3 
3,12462 4,34E-21 7,7343 2,69E-02 CCNYL1 Q8N7R7 Cyclin-Y-like protein 1 
1,7544 2,04E-17 8,6172 2,72E-02 PES1 O00541 Pescadillo homolog 
3,05486 6,26E-24 8,14947 2,72E-02 CGI-31 Q9Y320 
Cell proliferation-
inducing gene 26 protein 
2,68842 1,01E-03 6,93221 2,73E-02 HELLS Q9NRZ9 
Lymphoid-specific 
helicase 
2,68196 1,92E-82 7,02584 2,76E-02 HSPC039 Q9Y5U9 
Immediate early 
response 3-interacting 
protein 1 
0,900884 1,49E-124 9,74744 2,76E-02 ACTBL2 Q562R1 Beta-actin-like protein 2 
2,91156 1,12E-03 7,36981 2,76E-02 GLYR1 Q49A26 
3-hydroxyisobutyrate 
dehydrogenase-like 
protein 
2,67655 6,46E-12 6,73242 2,78E-02 
 
F5H0M0 
 
3,03938 2,34E-04 8,31416 2,78E-02 BM-007 Q9NZE8 
39S ribosomal protein 
L35, mitochondrial 
2,90038 1,37E-10 7,57917 2,81E-02 SSR3 B4E2P2 
cDNA FLJ52061, highly 
similar to Translocon-
associated protein 
subunit gamma 
1,73626 8,75E-33 8,72638 2,83E-02 CDC46 P33992 CDC46 homolog 
3,08367 2,47E-06 8,12094 2,85E-02 CGI-64 H0Y8C3 
Mitochondrial carrier 
homolog 1 
3,07133 2,73E-08 7,91616 2,90E-02 POLR2B P30876 
DNA-directed RNA 
polymerase II 140 kDa 
polypeptide 
3,01075 7,73E-12 8,32848 2,90E-02 SMBP Q9HD45 EP70-P-iso 
2,87578 6,74E-06 7,58831 2,92E-02 FMT Q96DP5 
Methionyl-tRNA 
formyltransferase, 
mitochondrial 
2,64561 6,85E-04 6,91704 2,93E-02 CD2BP2 O95400 
CD2 antigen 
cytoplasmic tail-binding 
protein 2 
3,05136 4,38E-03 7,88054 2,98E-02 LSM3 P62310 
U6 snRNA-associated 
Sm-like protein LSm3 
2,86165 5,34E-02 7,42257 2,99E-02 ANKRD18B Q8NF67 
Putative uncharacterized 
protein FLJ00310 
2,97273 7,09E-11 8,29387 3,06E-02 KIAA0650 A6NHR9 
Structural maintenance 
of chromosomes flexible 
hinge domain-containing 
protein 1 
3,02933 6,31E-17 7,95686 3,07E-02 KIAA0090 Q8N766 
Uncharacterized protein 
KIAA0090 
1,6937 4,75E-07 8,60799 3,10E-02 C8orf55 Q8WUY1 
Mesenchymal stem cell 
protein DSCD75 
2,96079 3,35E-09 8,32726 3,11E-02 LMN1 P02545 70 kDa lamin 
2,58272 7,57E-03 6,86276 3,26E-02 SIR2L3 Q9NTG7 
NAD-dependent 
deacetylase sirtuin-3, 
mitochondrial 
0,855271 6,04E-08 10,1452 3,34E-02 
 
P06310 
Ig kappa chain V-II 
region RPMI 6410 
2,78887 6,67E-10 7,62251 3,34E-02 MAP7D2 Q96T17-2 
MAP7 domain-
containing protein 2 
2,90652 1,72E-33 8,37334 3,35E-02 AHAS A1L0T0 
Acetolactate synthase-
like protein 
2,89164 1,58E-36 8,35639 3,42E-02 ADPRT2 Q9UGN5 
NAD(+) ADP-
ribosyltransferase 2 
0,848154 0,00E+00 10,2306 3,43E-02 INA Q16352 
66 kDa neurofilament 
protein 
2,87704 8,45E-76 8,33614 3,49E-02 ZCCHC8 Q6NZY4 
Zinc finger CCHC 
domain-containing 
protein 8 
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1,63856 7,96E-46 8,98526 3,49E-02 A2D Q8WWM7-3 Ataxin-2 domain protein 
1,62197 5,49E-32 9,01595 3,61E-02 NDUFA9 Q16795 Complex I-39kD 
1,61538 2,58E-35 8,56862 3,66E-02 PKR2 P13861 
cAMP-dependent 
protein kinase type II-
alpha regulatory subunit 
2,50474 1,11E-02 6,86248 3,71E-02 BR22 Q9P031 
Coiled-coil domain-
containing protein 59 
0,826828 2,56E-65 10,5165 3,74E-02 H4/A P62805 Histone H4 
2,71138 3,57E-28 7,71162 3,75E-02 POLR1A O95602 A190 
2,80931 1,00E-24 8,15555 3,83E-02 HSPC124 Q9H2U2-2 
Inorganic 
pyrophosphatase 2, 
mitochondrial 
2,48188 3,44E-04 6,70477 3,85E-02 GIPC2 Q8TF65 
PDZ domain-containing 
protein GIPC2 
2,84514 5,91E-09 8,05614 3,93E-02 PSEC0082 Q8NBN7 
Retinol dehydrogenase 
13 
1,58124 1,24E-08 8,78511 3,93E-02 EIF4E P06730-2 eIF-4F 25 kDa subunit 
2,82651 4,67E-07 7,89478 4,02E-02 ARC77 Q9NVC6 
Activator-recruited 
cofactor 77 kDa 
component 
0,807116 2,14E-27 9,37297 4,05E-02 SNRPB2 P08579 
U2 small nuclear 
ribonucleoprotein B 
2,78703 3,27E-14 7,81206 4,24E-02 KIAA0117 P42696 
RNA-binding motif 
protein 34 
0,792693 6,42E-139 9,28639 4,28E-02 CATX11 O76021 CATX-11 
0,791174 2,11E-136 9,32457 4,31E-02 IARS P41252 Isoleucine--tRNA ligase 
2,40525 1,33E-03 7,04821 4,35E-02 CCDC127 Q96BQ5 
Coiled-coil domain-
containing protein 127 
2,70715 1,12E-11 8,24932 4,38E-02 NDUFV1 P49821 Complex I-51kD 
2,37872 3,14E-16 7,25563 4,54E-02 RIF1 Q5UIP0 
Rap1-interacting factor 1 
homolog 
2,57778 1,82E-06 7,29776 4,56E-02 AAG P29372 
3-alkyladenine DNA 
glycosylase 
0,773697 0,00E+00 9,79227 4,61E-02 DBC1 Q8N163 
Deleted in breast cancer 
gene 1 protein 
2,64973 8,65E-19 8,1233 4,72E-02 CYC1 P08574 Complex III subunit 4 
2,64121 7,60E-38 8,35307 4,77E-02 NOL6 Q9H6R4 Nucleolar protein 6 
2,34292 3,02E-21 7,12946 4,80E-02 BT2.1 Q7KYR7-1 
Butyrophilin subfamily 2 
member A1 
2,67919 3,99E-37 8,07478 4,86E-02 AD-005 A5YKK6 
CCR4-associated factor 
1 
0,758771 7,16E-76 9,37927 4,88E-02 VDAC3 F5H740 
Outer mitochondrial 
membrane protein porin 
3 
1,46791 7,60E-109 8,58132 4,94E-02 MKI67 P46013 Antigen KI-67 
1,46543 6,72E-34 8,7788 4,97E-02 EIF4G2 D3DQV9 
Eukaryotic translation 
initiation factor 4 
gamma, 2, isoform 
CRA_b 
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Supplementary Table S4. Label free quantification (LFQ) of SE6 interaction partners. In the table 
are listed: LFQ ratios (SE6/CMV), posterior error probability (PEP), intensity, significance B value (Sig. 
B), Gene names, Protein IDs representing the Uniprot identification numbers and the protein names of 
the significant proteins binding to SE6. Graphical representation in results Fig. 8-B. 
 
SE6/CMV PEP Intensity LE6/CMV Sig. B Gene Names Protein IDs Protein Names 
10,975 3,48E-63 9,96686 1,01E-25 
 
LE6 
 
10,5616 6,59E-69 8,6343 2,75E-16 
 
SE6 
 
8,89299 6,71E-31 8,98318 3,98E-12 HSPE1 P61604 10 kDa chaperonin 
4,54067 1,90E-125 9,56785 9,69E-07 MDH2 P40926 
Malate dehydrogenase, 
mitochondrial 
5,43301 1,18E-03 6,84012 5,22E-06 TMEM127 C9J4H2 
Putative uncharacterized 
protein TMEM127 
3,89628 8,24E-278 9,53896 1,38E-05 SAP114 Q15459 SF3a120 
6,05015 8,22E-06 7,63276 4,75E-05 LSM8 O95777 
N-alpha-
acetyltransferase 38, 
NatC auxiliary subunit 
4,97634 1,45E-43 8,69873 5,23E-05 OAT P04181 
Ornithine 
aminotransferase, 
hepatic form 
4,96859 2,82E-55 8,55398 5,35E-05 ACO2 A2A274 
Aconitase 2, 
mitochondrial 
4,70771 3,02E-142 8,5741 1,18E-04 ATP6A1 P38606 
Vacuolar ATPase 
isoform VA68 
4,69258 5,84E-95 8,6778 1,23E-04 SHMT2 P34897 
Glycine 
hydroxymethyltransferas
e 
4,55594 5,08E-36 8,9758 1,84E-04 GOT2 P00505 
Aspartate 
aminotransferase, 
mitochondrial 
4,47663 5,02E-30 8,55332 2,31E-04 ERO1L Q96HE7 
Endoplasmic 
oxidoreductin-1-like 
protein 
5,43058 8,61E-09 7,53728 2,38E-04 NPDC1 Q5SPY9 
Neural proliferation, 
differentiation and 
control, 1 
4,43814 8,13E-60 8,99234 2,57E-04 CS O75390 
Citrate synthase, 
mitochondrial 
4,41753 1,25E-30 8,55951 2,72E-04 NDUFA10 E7ESZ7 Complex I-42kD 
4,19393 5,64E-17 7,1697 2,93E-04 LSM5 Q9Y4Y9 
U6 snRNA-associated 
Sm-like protein LSm5 
4,10401 1,27E-05 7,27235 3,79E-04 ANKRD46 Q86W74 
Ankyrin repeat domain-
containing protein 46 
5,22209 2,49E-07 7,64966 3,95E-04 C19orf27 Q96GS6-2 
Abhydrolase domain-
containing protein 
FAM108A1 
6,81918 3,78E-18 8,47748 4,11E-04 SAP62 Q15428 SF3a66 
2,92932 7,45E-142 9,50864 4,15E-04 SAP61 Q12874 SF3a60 
5,07866 3,03E-06 7,30593 5,55E-04 BRI3 O95415 Brain protein I3 
4,10706 1,97E-101 8,62822 6,34E-04 KIAA1321 Q7Z417 
82 kDa FMRP-
interacting protein 
3,86299 2,50E-05 6,78708 7,38E-04 SNX12 Q9UMY4 Sorting nexin-12 
4,92716 3,13E-03 7,41581 7,86E-04 LSM4 Q9Y4Z0 Glycine-rich protein 
4,88343 1,51E-14 7,54209 8,68E-04 FN14 Q9NP84 
Fibroblast growth factor-
inducible immediate-
early response protein 
14 
3,98084 6,46E-83 8,82558 8,81E-04 ALDA J3KPS3 
Fructose-bisphosphate 
aldolase A 
3,86201 2,64E-20 8,62974 1,19E-03 MPPB O75439 Beta-MPP 
3,7933 2,49E-24 8,61982 1,41E-03 GLUD P00367 
Glutamate 
dehydrogenase 1, 
mitochondrial 
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6,05333 1,95E-27 8,30276 1,50E-03 CYC P99999 Cytochrome c 
3,75475 6,07E-74 8,92925 1,55E-03 ALDH7A1 P49419 
Aldehyde 
dehydrogenase family 7 
member A1 
3,55883 4,32E-03 7,21043 1,64E-03 CCM3 Q9BUL8 
Cerebral cavernous 
malformations 3 protein 
3,55785 3,48E-04 7,26708 1,64E-03 BZRP P30536 
Mitochondrial 
benzodiazepine receptor 
5,91233 1,92E-27 8,33125 1,87E-03 MAGOH P61326 
Protein mago nashi 
homolog 
6,45681 1,40E-03 7,75374 1,97E-03 MAP2K1IP1 Q9UHA4 MEK-binding partner 1 
6,34976 1,70E-18 7,99084 2,31E-03 C6orf28 Q9Y333 Protein G7b 
6,30676 1,23E-07 7,77732 2,46E-03 HSPC119 Q9UDW1 Complex III subunit 9 
2,29287 8,66E-131 9,13615 2,70E-03 ME2 P23368 Malic enzyme 2 
3,3219 2,12E-22 7,00779 2,93E-03 ATP6G O75348 
Vacuolar proton pump 
subunit G 1 
3,31805 7,24E-02 7,13271 2,96E-03 ARL5B Q96KC2 
ADP-ribosylation factor-
like protein 5B 
3,29707 1,67E-22 7,01397 3,11E-03 HIAT1 Q96MC6 
Hippocampus abundant 
transcript 1 protein 
6,12232 3,45E-07 7,74262 3,22E-03 GAP43 P17677-2 
Axonal membrane 
protein GAP-43 
4,26284 1,89E-03 7,69854 3,24E-03 MPDU1 O75352 
Mannose-P-dolichol 
utilization defect 1 
protein 
3,24959 4,00E-03 7,13223 3,48E-03 HLC1 O95298 Complex I-B14.5b 
6,06313 1,71E-05 7,97103 3,51E-03 LSM6 P62312 
U6 snRNA-associated 
Sm-like protein LSm6 
6,05288 2,54E-10 7,99493 3,56E-03 NIF3L1BP1 Q6I9Y2 
Functional spliceosome-
associated protein 24 
3,223 9,23E-03 6,85831 3,70E-03 C18orf2 Q7LBR1 
Charged multivesicular 
body protein 1b 
3,35566 1,87E-27 8,90909 3,96E-03 BCLAF1 Q9NYF8 
Bcl-2-associated 
transcription factor 1 
3,19144 3,97E-04 7,24988 3,98E-03 EPN3 F6QWW5 
EPS-15-interacting 
protein 3 
3,16721 8,64E-04 7,15924 4,21E-03 KIAA1115 Q9UPN7 
SAPS domain family 
member 1 
2,11872 6,78E-106 9,21155 4,28E-03 QARS P47897 Glutamine--tRNA ligase 
4,10498 5,04E-05 7,59647 4,43E-03 TTN Q8WZ42-8 Connectin 
5,32607 3,69E-10 8,42379 4,52E-03 ETFB P38117-2 
Electron transfer 
flavoprotein subunit beta 
3,29315 9,07E-119 8,66849 4,55E-03 ACAT P24752 
Acetoacetyl-CoA 
thiolase 
3,29044 1,91E-56 8,64715 4,58E-03 EBP1 Q9UQ80 
Cell cycle protein p38-
2G4 homolog 
5,8402 2,52E-09 8,05888 4,80E-03 HSPC114 Q9Y5S9 Binder of OVCA1-1 
3,25983 6,09E-57 8,90697 4,90E-03 P53 P04637 Antigen NY-CO-13 
2,05592 3,32E-57 9,11561 5,03E-03 BAP135 P78347 
Bruton tyrosine kinase-
associated protein 135 
5,79668 5,09E-07 7,99257 5,09E-03 THOC3 Q96J01 hTREX45 
3,05457 2,39E-05 7,19195 5,44E-03 NEXN Q0ZGT2 F-actin-binding protein 
3,15304 2,11E-148 8,87237 6,17E-03 UQCRC2 P22695 Complex III subunit 2 
2,98978 7,66E-03 7,19287 6,28E-03 ASCC2 B1AH60 
Activating signal 
cointegrator 1 complex 
subunit 2 
2,97224 3,05E-27 7,0454 6,53E-03 RAB6B Q9NRW1 
Ras-related protein Rab-
6B 
3,8955 1,66E-05 7,57731 6,58E-03 JTK5A P34925-2 
Tyrosine-protein kinase 
RYK 
3,89146 2,20E-08 7,47293 6,63E-03 ATP6V1H Q9UI12 Nef-binding protein 1 
3,88441 8,55E-03 7,63737 6,72E-03 TXNDC17 Q9BRA2 
14 kDa thioredoxin-
related protein 
5,55456 4,38E-03 7,88054 7,05E-03 LSM3 P62310 
U6 snRNA-associated 
Sm-like protein LSm3 
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1,91106 5,21E-130 9,59145 7,21E-03 DBN1 A8MV58 
Putative uncharacterized 
protein DBN1 
3,07754 6,15E-11 8,75721 7,24E-03 DAD1 P61803 
Defender against cell 
death 1 
4,98854 8,84E-05 8,27969 7,25E-03 NDUFA8 P51970 Complex I-19kD 
3,07372 7,50E-18 8,53145 7,30E-03 GLUR P00390 
Glutathione reductase, 
mitochondrial 
1,90433 9,14E-21 9,31035 7,33E-03 hCG_2001850 Q32Q12 
Nucleoside diphosphate 
kinase 
1,87883 4,42E-259 9,62782 7,80E-03 SNRPA1 P09661 
U2 small nuclear 
ribonucleoprotein A 
3,79063 2,16E-05 7,48766 7,98E-03 GGH Q92820 Conjugase 
2,97973 1,25E-41 8,6238 8,86E-03 NDUFS1 P28331-2 Complex I-75kD 
4,81696 1,58E-02 8,37568 9,13E-03 
 
H0Y670 
 
2,75734 4,85E-09 7,23739 1,03E-02 SOD1 P00441 
Superoxide dismutase 
[Cu-Zn] 
2,89509 3,77E-113 8,76907 1,05E-02 ACTR3 P61158 Actin-like protein 3 
4,67305 6,09E-10 8,3582 1,10E-02 ADK2 P54819 
Adenylate kinase 2, 
mitochondrial 
2,85157 1,56E-18 8,65379 1,15E-02 C12orf8 P30040 
Endoplasmic reticulum 
resident protein 28 
2,70029 3,09E-03 7,06524 1,16E-02 
RP11-
545E17.12-003 
Q96GR4-3 
Zinc finger, DHHC-type 
containing 12 
4,60682 8,28E-19 8,3827 1,20E-02 PROS27 G3V5Z7 27 kDa prosomal protein 
4,60427 4,47E-03 8,35034 1,20E-02 CDO1 Q16878 
Cysteine dioxygenase 
type 1 
5,13251 3,91E-09 7,86207 1,21E-02 PEX14 O75381 Peroxin-14 
3,55153 2,03E-03 7,57104 1,22E-02 SPT3 O75486 SPT3-like protein 
2,80311 1,39E-57 8,76926 1,26E-02 C22orf19 Q13769 
Functional spliceosome-
associated protein 79 
3,51482 3,99E-08 7,50174 1,29E-02 EPN2 O95208 
EPS-15-interacting 
protein 2 
5,07639 4,72E-03 7,90462 1,30E-02 Nbla11189 Q9BSR8 Protein YIPF4 
1,65445 1,29E-53 9,2223 1,32E-02 hCG_39182 A7YIJ8 Radixin isoform b 
1,64947 6,16E-106 9,3293 1,33E-02 DDX48 P38919 
ATP-dependent RNA 
helicase DDX48 
2,60402 3,53E-07 7,17834 1,41E-02 SDF2L1 Q9HCN8 
PWP1-interacting 
protein 8 
3,442 9,15E-04 7,72908 1,46E-02 D3S1231E B4DXJ1 
cDNA FLJ56334, highly 
similar to SEC13-related 
protein 
2,55086 9,68E-13 6,455 1,57E-02 BTF3 P20290 
RNA polymerase B 
transcription factor 3 
3,3772 5,58E-04 7,29953 1,63E-02 C6orf120 J3KQ97 
UPF0669 protein 
C6orf120 
1,53972 2,12E-154 9,1365 1,70E-02 VCP P55072 
15S Mg(2+)-ATPase 
p97 subunit 
1,539 2,06E-177 9,10992 1,70E-02 CORO1C A7MAP1 Coronin-1C_i3 protein 
4,31299 2,25E-53 8,35944 1,73E-02 DHRS8 Q8NBQ5 
17-beta-hydroxysteroid 
dehydrogenase 11 
4,27672 2,62E-30 8,16152 1,81E-02 PYCR2 Q96C36 
Pyrroline-5-carboxylate 
reductase 2 
4,7938 3,67E-07 7,90116 1,81E-02 ACOT13 Q9NPJ3 
Acyl-coenzyme A 
thioesterase 13 
4,27281 4,40E-07 8,34739 1,82E-02 CPO P36551 
Coproporphyrinogen-III 
oxidase, mitochondrial 
1,50639 1,51E-29 9,12031 1,83E-02 C1orf8 Q9BXS4 
Liver membrane-bound 
protein 
2,46794 5,85E-03 6,55302 1,84E-02 DIRC2 Q96SL1 
Disrupted in renal 
cancer protein 2 
2,57601 8,83E-32 8,55563 1,94E-02 SUCLG2 Q96I99 
GTP-specific succinyl-
CoA synthetase subunit 
beta 
3,22815 5,11E-03 7,52298 2,08E-02 GCSH P23434 
Glycine cleavage 
system H protein, 
mitochondrial 
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4,15581 2,50E-38 8,46705 2,09E-02 HPRT P00492 
Hypoxanthine-guanine 
phosphoribosyltransfera
se 
2,37266 9,05E-03 6,77243 2,21E-02 SECTM1 Q8WVN6 Protein K12 
2,50177 3,71E-35 8,91995 2,22E-02 THRAP3 Q9Y2W1 
Thyroid hormone 
receptor-associated 
protein 3 
3,17761 1,09E-04 7,63304 2,25E-02 C14orf87 Q86SX6 
Glutaredoxin-related 
protein 5, mitochondrial 
2,35878 1,63E-06 6,60762 2,26E-02 SDC4 P31431 Amphiglycan 
1,40397 2,69E-229 9,59359 2,27E-02 ATP5B P06576 
ATP synthase subunit 
beta, mitochondrial 
1,40361 1,87E-64 9,52492 2,27E-02 BAT1 F8VQ10 
56 kDa U2AF65-
associated protein 
3,16635 3,33E-08 7,43345 2,29E-02 GNA14 O95837 
Guanine nucleotide-
binding protein subunit 
alpha-14 
3,16188 3,87E-07 7,40922 2,30E-02 LIN7C Q9NUP9 
Mammalian lin-seven 
protein 3 
2,47707 9,80E-103 9,061 2,32E-02 HPR1 Q96FV9 hTREX84 
4,05929 4,85E-09 8,24259 2,34E-02 IDH3A P50213 
Isocitrate 
dehydrogenase [NAD] 
subunit alpha, 
mitochondrial 
2,33609 1,59E-02 7,21018 2,36E-02 FABP5 Q01469 
Epidermal-type fatty 
acid-binding protein 
2,45319 7,47E-55 8,72385 2,42E-02 CXorf3 Q8NI27 hTREX120 
4,50569 2,02E-37 8,04906 2,52E-02 ANP32B Q92688 
Acidic leucine-rich 
nuclear phosphoprotein 
32 family member B 
3,10018 1,80E-02 7,56618 2,54E-02 WHIP Q96S55 ATPase WRNIP1 
3,98298 5,79E-13 8,48173 2,56E-02 PCNA P12004 Cyclin 
2,2737 9,44E-03 6,39503 2,65E-02 KIAA0257 Q92545 Protein RW1 
3,9492 3,74E-33 8,19056 2,66E-02 LETM1 O95202 
LETM1 and EF-hand 
domain-containing 
protein 1, mitochondrial 
1,32349 1,96E-197 9,11123 2,68E-02 C20orf14 O94906 
Pre-mRNA-processing 
factor 6 
2,38742 6,77E-117 8,56886 2,72E-02 ECHS1 P30084 Enoyl-CoA hydratase 1 
3,03678 4,02E-06 7,72447 2,80E-02 CDK4 P11802 
Cell division protein 
kinase 4 
3,9014 1,41E-23 8,48427 2,81E-02 ACADM Q5T4U5 
Acyl-Coenzyme A 
dehydrogenase, C-4 to 
C-12 straight chain 
3,89118 4,31E-04 8,15272 2,84E-02 DER1 Q9BUN8 
Degradation in 
endoplasmic reticulum 
protein 1 
2,23258 4,53E-13 6,83139 2,85E-02 FAM108C1 Q6PCB6 
Abhydrolase domain-
containing protein 
FAM108C1 
2,22965 1,63E-03 6,98397 2,87E-02 MER Q12866 Proto-oncogene c-Mer 
2,22028 1,17E-03 7,22889 2,91E-02 SGMS2 Q8NHU3 
Phosphatidylcholine:cer
amide 
cholinephosphotransfera
se 2 
3,00662 6,70E-05 7,57885 2,93E-02 TM9SF1 E9PSI1 
MP70 protein family 
member 
2,21562 3,13E-03 6,64125 2,94E-02 ARFRP1 Q13795 
ADP-ribosylation factor-
related protein 1 
2,21382 1,25E-05 6,94675 2,95E-02 DRIP92 Q9Y2X0 
Mediator complex 
subunit 16 
2,32915 1,99E-34 8,79709 3,01E-02 ACADVL F5H2A9 
Very long-chain specific 
acyl-CoA 
dehydrogenase, 
mitochondrial 
3,82748 4,33E-21 8,24239 3,05E-02 ATP6E P36543 
Vacuolar proton pump 
subunit E 1 
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3,80811 1,00E-24 8,15555 3,12E-02 HSPC124 Q9H2U2-2 
Inorganic 
pyrophosphatase 2, 
mitochondrial 
4,30421 1,86E-11 8,0136 3,14E-02 GOSR1 O95249 
28 kDa cis-Golgi 
SNARE p28 
4,30009 3,91E-07 7,90927 3,15E-02 SFXN1 Q9H9B4 Sideroflexin-1 
2,29522 4,96E-113 8,78671 3,19E-02 FER1L3 F8W8J4 Fer-1-like protein 3 
1,23662 0,00E+00 10,1904 3,19E-02 CLH17 Q00610 Clathrin heavy chain 1 
2,94361 6,90E-04 7,31025 3,21E-02 CGI-141 Q9Y3E0 
Golgi transport 1 
homolog B 
2,28748 7,82E-90 8,67041 3,23E-02 DLD P09622 
Dihydrolipoamide 
dehydrogenase 
2,15944 3,31E-04 7,09975 3,25E-02 CERK Q8TCT0 Acylsphingosine kinase 
2,27131 4,03E-17 8,56604 3,32E-02 ACR1 P30044 Alu corepressor 1 
1,20681 2,11E-136 9,32457 3,38E-02 IARS P41252 Isoleucine--tRNA ligase 
2,24077 8,11E-47 8,78309 3,49E-02 ABCD3 E7EUE1 
70 kDa peroxisomal 
membrane protein 
2,23722 1,06E-33 8,70361 3,51E-02 INPP5E Q10713 Alpha-MPP 
2,10653 9,13E-04 7,22853 3,56E-02 MTX Q13505 Metaxin-1 
3,68244 2,86E-43 8,39766 3,58E-02 IRA1 Q9BZK7 
F-box-like/WD repeat-
containing protein 
TBL1XR1 
4,17027 2,29E-10 7,87272 3,61E-02 RNP24 Q15363 Membrane protein p24A 
2,85632 1,06E-07 7,35763 3,65E-02 GLXR Q9UBQ7 
Glyoxylate 
reductase/hydroxypyruv
ate reductase 
2,85252 3,89E-03 7,50312 3,67E-02 PPT P50897 
Palmitoyl-protein 
hydrolase 1 
3,65219 1,67E-09 8,14724 3,69E-02 DECR Q16698 
2,4-dienoyl-CoA 
reductase [NADPH] 
3,64903 4,43E-03 8,13293 3,71E-02 KIAA0567 E5KLJ5 
Dynamin-like 120 kDa 
protein, form S1 
2,08216 9,30E-04 7,12746 3,71E-02 DYNLT1 P63172 
Dynein light chain Tctex-
type 1 
2,83795 2,33E-04 7,30516 3,75E-02 IST1 A8KAH5 
cDNA FLJ32696 fis, 
clone TESTI2000358 
4,13197 3,63E-02 7,99647 3,76E-02 CXorf5 O75665 
Oral-facial-digital 
syndrome 1 protein 
2,8343 7,53E-21 7,63556 3,77E-02 IL1RL1L Q13445 
Interleukin-1 receptor-
like 1 ligand 
1,15052 7,44E-108 9,45281 3,77E-02 N4WBP5 Q9BT67 
Breast cancer-
associated protein SGA-
1M 
1,14485 3,00E-144 9,21492 3,81E-02 DREG Q86SQ4 
Developmentally 
regulated G-protein-
coupled receptor 
3,62111 2,27E-14 8,19973 3,82E-02 VAT1 Q99536 
Synaptic vesicle 
membrane protein VAT-
1 homolog 
2,18568 1,68E-34 8,63781 3,83E-02 ETFA P13804 
Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 
4,10857 9,33E-10 7,89052 3,85E-02 
DASS-38L18.1-
001 
Q96QC4 
cDNA FLJ60820, highly 
similar to Homo sapiens 
MHC class I 
polypeptide-related 
sequence A (MICA), 
mRNA 
3,59042 5,05E-07 8,12519 3,95E-02 DXS423E Q14683 Sb1.8 
2,04376 1,38E-04 7,20082 3,96E-02 SOD2 P04179 
Superoxide dismutase 
[Mn], mitochondrial 
1,12051 5,80E-84 9,12574 4,00E-02 GA11 P29992 
Guanine nucleotide-
binding protein G(y) 
subunit alpha 
2,7735 0,00E+00 7,46343 4,11E-02 TUBA1 P68366 Alpha-tubulin 1 
2,14066 3,43E-12 8,65706 4,12E-02 ACAA2 P42765 
3-ketoacyl-CoA thiolase, 
mitochondrial 
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2,76387 6,84E-03 7,33258 4,17E-02 UBC12 P61081 NEDD8 carrier protein 
2,13266 3,38E-08 8,65969 4,17E-02 NDUFS2 O75306 Complex I-49kD 
3,53585 2,63E-05 8,21822 4,18E-02 GBAS O75323 
Glioblastoma-amplified 
sequence 
2,75815 1,54E-02 7,5023 4,20E-02 ABHD10 Q9NUJ1 
Abhydrolase domain-
containing protein 10, 
mitochondrial 
4,00886 2,76E-13 7,7432 4,26E-02 ATP6C P21283 
Vacuolar proton pump 
subunit C 1 
1,998 2,01E-42 7,20303 4,28E-02 ARC100 F5GY88 
Activator-recruited 
cofactor 100 kDa 
component 
2,1071 9,02E-13 8,60011 4,35E-02 MIG10 P00558 
Cell migration-inducing 
gene 10 protein 
2,72869 2,29E-28 7,31608 4,38E-02 ATP6M Q9Y5K8 
Vacuolar proton pump 
subunit D 
3,48393 8,32E-18 8,26487 4,41E-02 ARC21 O15145 
Actin-related protein 2/3 
complex subunit 3 
1,97274 7,83E-04 7,04072 4,46E-02 MPST J3KPV7 
3-mercaptopyruvate 
sulfurtransferase 
2,70406 2,14E-05 7,65473 4,53E-02 ARL10C Q9NVJ2 
ADP-ribosylation factor-
like protein 10C 
2,69598 1,81E-24 7,42354 4,58E-02 TYK2 P29597 
Non-receptor tyrosine-
protein kinase TYK2 
1,94176 8,87E-03 7,12665 4,69E-02 C3orf28 Q96A26 
E2-induced gene 5 
protein 
2,0579 2,58E-35 8,56862 4,70E-02 PKR2 P13861 
cAMP-dependent 
protein kinase type II-
alpha regulatory subunit 
1,02727 1,39E-116 9,48637 4,75E-02 RARS P54136 Arginine--tRNA ligase 
1,02165 3,42E-148 9,35522 4,80E-02 HSP75 Q12931 
Heat shock protein 75 
kDa, mitochondrial 
3,888 9,75E-05 8,0054 4,81E-02 EPHX P07099 Epoxide hydratase 
3,39303 1,81E-09 8,1758 4,85E-02 HMOX2 P30519 Heme oxygenase 2 
1,01557 2,14E-27 9,37297 4,86E-02 SNRPB2 P08579 
U2 small nuclear 
ribonucleoprotein B 
1,91022 2,69E-06 7,13827 4,94E-02 HBP Q9NRV9 Heme-binding protein 1 
1,90774 7,57E-03 6,86276 4,96E-02 SIR2L3 Q9NTG7 
NAD-dependent 
deacetylase sirtuin-3, 
mitochondrial 
1,0021 0,00E+00 10,3535 4,98E-02 HSP60 P10809 60 kDa chaperonin 
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Supplementary Table S5. Label free quantification (LFQ) of 38E6 interaction partners. In the 
table are listed: LFQ ratios (38E6/CMV), posterior error probability (PEP), intensity, significance B 
value (Sig. B), Gene names, Protein IDs representing the Uniprot identification numbers and the 
protein names of the significant proteins binding to 38E6. Graphical representation in results Fig. 8-C. 
 
38E6/CMV PEP Intensity 38E6/CMV Sig. B Gene Names Protein IDs Protein Names 
12,7027 1,70E-122 9,76094 4,86E-47 
 
38E6 
 
8,76375 6,09E-57 8,90697 4,18E-10 P53 P04637 Antigen NY-CO-13 
3,924 8,24E-278 9,53896 1,93E-07 SAP114 Q15459 SF3a120 
6,35757 6,71E-31 8,98318 3,51E-06 HSPE1 P61604 10 kDa chaperonin 
5,99199 1,92E-82 7,02584 5,37E-06 HSPC039 Q9Y5U9 
Immediate early 
response 3-interacting 
protein 1 
6,04021 4,38E-150 8,70875 9,50E-06 KIAA1481 Q8TF72 Protein Shroom3 
6,0107 1,76E-94 8,87462 1,04E-05 CVAK104 Q6P3W7 
Coated vesicle-
associated kinase of 
104 kDa 
3,11766 7,45E-142 9,50864 1,20E-05 SAP61 Q12874 SF3a60 
2,99617 1,90E-125 9,56785 2,11E-05 MDH2 P40926 
Malate 
dehydrogenase, 
mitochondrial 
5,56178 8,09E-150 9,10151 3,92E-05 SF1 Q15637-6 
Mammalian branch 
point-binding protein 
4,96885 1,75E-15 7,17886 1,18E-04 
 
H7C0N4 
 
4,8977 5,57E-03 7,19731 1,43E-04 C17orf35 P17152 Protein PM1 
2,54517 1,47E-249 9,35892 1,48E-04 XRN2 Q9H0D6 5-3 exoribonuclease 2 
4,8185 1,38E-02 7,27316 1,78E-04 C11orf10 P61165 
UPF0197 
transmembrane 
protein C11orf10 
2,49778 3,32E-57 9,11561 1,80E-04 BAP135 P78347 
Bruton tyrosine 
kinase-associated 
protein 135 
4,67835 2,62E-03 7,18475 2,59E-04 ATP5I P56385 
ATP synthase subunit 
e, mitochondrial 
7,29957 3,78E-18 8,47748 2,74E-04 SAP62 Q15428 SF3a66 
2,31901 6,78E-106 9,21155 3,64E-04 QARS P47897 
Glutamine--tRNA 
ligase 
4,53979 5,64E-17 7,1697 3,71E-04 LSM5 Q9Y4Y9 
U6 snRNA-associated 
Sm-like protein LSm5 
4,70734 7,37E-28 8,58048 3,82E-04 KIAA0217 Q92615 
La ribonucleoprotein 
domain family 
member 4B 
2,21974 2,11E-136 9,32457 5,30E-04 IARS P41252 
Isoleucine--tRNA 
ligase 
4,39671 1,97E-03 7,13707 5,34E-04 CCDC56 Q9Y2R0 
Coiled-coil domain-
containing protein 56 
6,8338 2,86E-43 8,39766 6,03E-04 IRA1 Q9BZK7 
F-box-like/WD repeat-
containing protein 
TBL1XR1 
6,72286 8,45E-76 8,33614 7,23E-04 ZCCHC8 Q6NZY4 
Zinc finger CCHC 
domain-containing 
protein 8 
4,345 1,87E-27 8,90909 9,12E-04 BCLAF1 Q9NYF8 
Bcl-2-associated 
transcription factor 1 
2,04313 6,16E-106 9,3293 1,01E-03 DDX48 P38919 
ATP-dependent RNA 
helicase DDX48 
5,36508 2,23E-26 7,6464 1,04E-03 CDKN2AIPNL Q96HQ2 
CDKN2A-interacting 
protein N-terminal-like 
protein 
6,67635 2,52E-09 8,05888 1,26E-03 HSPC114 Q9Y5S9 Binder of OVCA1-1 
6,33469 1,92E-27 8,33125 1,34E-03 MAGOH P61326 
Protein mago nashi 
homolog 
4,15562 1,91E-56 8,64715 1,40E-03 EBP1 Q9UQ80 
Cell cycle protein p38-
2G4 homolog 
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4,13508 1,25E-30 8,55951 1,47E-03 NDUFA10 E7ESZ7 Complex I-42kD 
6,5643 1,23E-07 7,77732 1,50E-03 HSPC119 Q9UDW1 Complex III subunit 9 
6,25869 3,02E-20 8,12801 1,50E-03 CNOT4 F8VQP3 
CCR4-associated 
factor 4 
5,14623 2,09E-03 7,42545 1,58E-03 SEC61G P60059 
Protein transport 
protein Sec61 subunit 
gamma 
3,94796 5,84E-95 8,6778 2,21E-03 SHMT2 P34897 
Glycine 
hydroxymethyltransfer
ase 
3,78836 5,74E-09 6,75735 2,25E-03 C21orf51 P58511 Protein FAM165B 
3,89361 3,02E-142 8,5741 2,48E-03 ATP6A1 P38606 
Vacuolar ATPase 
isoform VA68 
3,84649 1,97E-101 8,62822 2,74E-03 KIAA1321 Q7Z417 
82 kDa FMRP-
interacting protein 
6,09745 1,70E-18 7,99084 2,99E-03 C6orf28 Q9Y333 Protein G7b 
5,78917 8,84E-05 8,27969 3,01E-03 NDUFA8 P51970 Complex I-19kD 
3,78228 1,45E-43 8,69873 3,14E-03 OAT P04181 
Ornithine 
aminotransferase, 
hepatic form 
6,01797 1,71E-05 7,97103 3,35E-03 LSM6 P62312 
U6 snRNA-associated 
Sm-like protein LSm6 
3,55271 2,12E-22 7,00779 3,74E-03 ATP6G O75348 
Vacuolar proton pump 
subunit G 1 
1,65172 4,42E-259 9,62782 3,75E-03 SNRPA1 P09661 
U2 small nuclear 
ribonucleoprotein A 
3,68872 2,82E-55 8,55398 3,80E-03 ACO2 A2A274 
Aconitase 2, 
mitochondrial 
4,62087 1,37E-10 7,57917 4,07E-03 SSR3 B4E2P2 
cDNA FLJ52061, 
highly similar to 
Translocon-
associated protein 
subunit gamma 
5,48408 6,26E-24 8,14947 4,61E-03 CGI-31 Q9Y320 
Cell proliferation-
inducing gene 26 
protein 
4,52827 3,78E-04 7,34988 4,76E-03 
 
Q8WVI0 UPF0640 protein 
3,42972 1,67E-22 7,01397 4,83E-03 HIAT1 Q96MC6 
Hippocampus 
abundant transcript 1 
protein 
4,49094 3,03E-06 7,30593 5,07E-03 BRI3 O95415 Brain protein I3 
3,52242 2,11E-148 8,87237 5,30E-03 UQCRC2 P22695 Complex III subunit 2 
5,33011 4,89E-04 8,40506 5,68E-03 KIAA1966 J3QR07 
Putative splicing 
factor YT521 
5,61692 1,40E-03 7,75374 5,82E-03 MAP2K1IP1 Q9UHA4 
MEK-binding partner 
1 
3,31644 5,37E-03 7,09202 6,08E-03 199G4 Q9NW64 
Pre-mRNA-splicing 
factor RBM22 
4,36876 7,16E-06 7,32434 6,21E-03 UQBP P14927 Complex III subunit 7 
4,36722 8,22E-06 7,63276 6,23E-03 LSM8 O95777 
N-alpha-
acetyltransferase 38, 
NatC auxiliary subunit 
3,26783 1,49E-15 7,19687 6,70E-03 
 
Q70UQ0-4 
 
3,37571 3,68E-19 8,74904 7,04E-03 PRC1 O43663 
Protein regulator of 
cytokinesis 1 
5,47004 4,38E-03 7,88054 7,07E-03 LSM3 P62310 
U6 snRNA-associated 
Sm-like protein LSm3 
3,33242 1,25E-41 8,6238 7,64E-03 NDUFS1 P28331-2 Complex I-75kD 
3,19884 2,13E-03 6,64181 7,67E-03 JAGN1 Q8N5M9 
Protein jagunal 
homolog 1 
5,39877 3,97E-08 7,81246 7,75E-03 HCC1 F8VZQ9 
Cytokine-induced 
protein of 29 kDa 
3,30556 8,13E-60 8,99234 8,04E-03 CS O75390 
Citrate synthase, 
mitochondrial 
1,39268 2,69E-229 9,59359 8,21E-03 ATP5B P06576 
ATP synthase subunit 
beta, mitochondrial 
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3,16084 1,14E-03 7,04242 8,26E-03 JM4 O60831 PRA1 family protein 2 
4,1589 6,99E-03 7,70936 8,71E-03 FAM51A1 Q9NWZ8 
Gem-associated 
protein 8 
3,26227 2,58E-35 8,56862 8,71E-03 PKR2 P13861 
cAMP-dependent 
protein kinase type II-
alpha regulatory 
subunit 
1,35215 1,87E-64 9,52492 9,22E-03 BAT1 F8VQ10 
56 kDa U2AF65-
associated protein 
1,34641 9,14E-21 9,31035 9,37E-03 hCG_2001850 Q32Q12 
Nucleoside 
diphosphate kinase 
4,07129 1,18E-04 7,66523 9,99E-03 CGI-124 Q9Y3C6 
Peptidyl-prolyl cis-
trans isomerase-like 1 
1,31924 1,39E-116 9,48637 1,01E-02 RARS P54136 Arginine--tRNA ligase 
4,84647 6,56E-99 8,50745 1,06E-02 KIAA1671 Q9BY89 
Uncharacterized 
protein KIAA1671 
1,30027 5,21E-130 9,59145 1,07E-02 DBN1 A8MV58 
Putative 
uncharacterized 
protein DBN1 
4,02035 6,90E-04 7,31025 1,08E-02 CGI-141 Q9Y3E0 
Golgi transport 1 
homolog B 
3,0186 4,10E-17 7,20003 1,08E-02 C6orf53 Q9P0S9 
Transmembrane 
protein 14C 
3,13428 3,24E-48 8,60766 1,10E-02 MCM3 P25205 
DNA polymerase 
alpha holoenzyme-
associated protein P1 
5,1054 9,43E-14 7,77305 1,12E-02 ERS25 Q7Z7H5 
Endoplasmic 
reticulum stress-
response protein 25 
5,09578 3,18E-09 7,92434 1,14E-02 EIF4E2 O60573 
eIF4E-like protein 4E-
LP 
3,11024 3,71E-35 8,91995 1,15E-02 THRAP3 Q9Y2W1 
Thyroid hormone 
receptor-associated 
protein 3 
4,76335 1,95E-27 8,30276 1,17E-02 CYC P99999 Cytochrome c 
2,95714 1,56E-02 7,04356 1,21E-02 SFXN3 Q9BWM7 Sideroflexin-3 
2,95415 9,38E-04 7,15576 1,22E-02 GSTK1 Q9Y2Q3-2 
Glutathione S-
transferase kappa 1 
3,83566 1,25E-06 7,6203 1,43E-02 OMP25 P57105 
Mitochondrial outer 
membrane protein 25 
2,8652 4,32E-03 7,21043 1,43E-02 CCM3 Q9BUL8 
Cerebral cavernous 
malformations 3 
protein 
4,58042 1,81E-09 8,1758 1,46E-02 HMOX2 P30519 Heme oxygenase 2 
1,17753 3,37E-44 9,18053 1,49E-02 DARS P14868 
Aspartate--tRNA 
ligase 
2,95337 6,15E-11 8,75721 1,51E-02 DAD1 P61803 
Defender against cell 
death 1 
4,85084 2,54E-10 7,99493 1,53E-02 NIF3L1BP1 Q6I9Y2 
Functional 
spliceosome-
associated protein 24 
2,94006 2,64E-20 8,62974 1,55E-02 MPPB O75439 Beta-MPP 
2,9318 5,08E-36 8,9758 1,57E-02 GOT2 P00505 
Aspartate 
aminotransferase, 
mitochondrial 
1,15704 3,42E-148 9,35522 1,58E-02 HSP75 Q12931 
Heat shock protein 75 
kDa, mitochondrial 
2,92153 5,02E-30 8,55332 1,60E-02 ERO1L Q96HE7 
Endoplasmic 
oxidoreductin-1-like 
protein 
1,14576 8,66E-131 9,13615 1,62E-02 ME2 P23368 Malic enzyme 2 
4,79258 5,09E-07 7,99257 1,64E-02 THOC3 Q96J01 hTREX45 
4,78764 3,91E-09 7,86207 1,64E-02 PEX14 O75381 Peroxin-14 
4,77135 4,72E-03 7,90462 1,68E-02 Nbla11189 Q9BSR8 Protein YIPF4 
2,7677 1,62E-02 7,18761 1,71E-02 NDUFB7 P17568 
Cell adhesion protein 
SQM1 
2,87009 6,07E-74 8,92925 1,75E-02 ALDH7A1 P49419 Aldehyde 
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dehydrogenase family 
7 member A1 
2,74134 5,95E-02 7,03711 1,79E-02 CGI-89 Q9Y397 
Palmitoyltransferase 
ZDHHC9 
4,39665 2,62E-30 8,16152 1,82E-02 PYCR2 Q96C36 
Pyrroline-5-
carboxylate reductase 
2 
1,10049 7,16E-76 9,37927 1,83E-02 VDAC3 F5H740 
Outer mitochondrial 
membrane protein 
porin 3 
1,08937 1,29E-53 9,2223 1,88E-02 hCG_39182 A7YIJ8 Radixin isoform b 
4,35556 3,69E-10 8,42379 1,90E-02 ETFB P38117-2 
Electron transfer 
flavoprotein subunit 
beta 
3,62722 5,04E-05 7,59647 1,93E-02 TTN Q8WZ42-8 Connectin 
4,64543 7,76E-06 7,82563 1,94E-02 RPS21 P63220 
40S ribosomal protein 
S21 
4,33184 2,25E-53 8,35944 1,96E-02 DHRS8 Q8NBQ5 
17-beta-
hydroxysteroid 
dehydrogenase 11 
1,07256 2,06E-177 9,10992 1,96E-02 CORO1C A7MAP1 Coronin-1C_i3 protein 
2,68015 4,08E-04 6,8247 1,99E-02 CSTF2 E7EWR4 CF-1 64 kDa subunit 
1,06417 0,00E+00 10,0419 2,01E-02 CG1 Q86UP2 CG-1 antigen 
2,6731 8,54E-06 7,07313 2,01E-02 
RP5-
894H24.1-001 
B1ALM5 
Transmembrane 
protein 9 
2,67194 7,55E-08 7,238 2,01E-02 EPT1 Q9C0D9 
Ethanolaminephospho
transferase 1 
4,2922 1,09E-14 8,42698 2,05E-02 KIAA1470 Q9P258 Protein RCC2 
4,56078 4,50E-06 7,9301 2,13E-02 VKORC1L1 Q8N0U8 
Vitamin K epoxide 
reductase complex 
subunit 1-like protein 
1 
2,74234 9,07E-119 8,66849 2,16E-02 ACAT P24752 
Acetoacetyl-CoA 
thiolase 
1,03507 1,04E-91 9,19921 2,16E-02 CANX B4DGP8 
cDNA FLJ55574, 
highly similar to 
Calnexin 
2,73211 6,46E-83 8,82558 2,19E-02 ALDA J3KPS3 
Fructose-
bisphosphate aldolase 
A 
1,02388 2,14E-27 9,37297 2,22E-02 SNRPB2 P08579 
U2 small nuclear 
ribonucleoprotein B 
1,02379 4,48E-133 9,2763 2,22E-02 ATP1A1 F5H3A1 
Sodium pump subunit 
alpha-1 
2,60114 3,83E-04 6,67362 2,27E-02 POLR2G P62487 
DNA-directed RNA 
polymerase II subunit 
G 
3,5098 2,64E-11 7,44781 2,27E-02 HTRA2 O43464 
High temperature 
requirement protein 
A2 
1,00573 2,08E-189 9,38518 2,33E-02 EPRS P07814 
Bifunctional 
aminoacyl-tRNA 
synthetase 
2,69422 2,49E-24 8,61982 2,33E-02 GLUD P00367 
Glutamate 
dehydrogenase 1, 
mitochondrial 
2,69223 3,92E-50 8,91431 2,34E-02 DDX6 P26196 
ATP-dependent RNA 
helicase p54 
4,15662 2,34E-04 8,31416 2,38E-02 BM-007 Q9NZE8 
39S ribosomal protein 
L35, mitochondrial 
2,54977 2,56E-14 7,19601 2,47E-02 ECE1 P42892 
Endothelin-converting 
enzyme 1 
4,10283 4,31E-04 8,15272 2,53E-02 DER1 Q9BUN8 
Degradation in 
endoplasmic reticulum 
protein 1 
3,42629 2,09E-11 7,37433 2,55E-02 MBD2 Q9UBB5 Demethylase 
3,42111 1,80E-02 7,56618 2,57E-02 WHIP Q96S55 ATPase WRNIP1 
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0,964725 0,00E+00 10,0114 2,58E-02 HYRC P78527 
DNA-dependent 
protein kinase 
catalytic subunit 
0,962739 6,04E-174 9,52214 2,59E-02 BAP J3KPX7 
B-cell receptor-
associated protein 
BAP37 
3,40722 1,27E-02 7,40358 2,62E-02 KIAA0016 Q15388 
Mitochondrial 20 kDa 
outer membrane 
protein 
2,50515 1,46E-04 6,89485 2,66E-02 CDIPT B3KY94 
cDNA FLJ16129 fis 
highly similar to CDP-
diacylglycerol-
inositol3-
phosphatidyltransfera
se 
0,943297 2,12E-154 9,1365 2,71E-02 VCP P55072 
15S Mg(2+)-ATPase 
p97 subunit 
4,02986 2,63E-05 8,21822 2,73E-02 GBAS O75323 
Glioblastoma-
amplified sequence 
2,4868 2,74E-04 6,82791 2,74E-02 BTS Q13286 Batten disease protein 
4,01272 8,32E-18 8,26487 2,79E-02 ARC21 O15145 
Actin-related protein 
2/3 complex subunit 3 
4,00599 8,28E-19 8,3827 2,81E-02 PROS27 G3V5Z7 
27 kDa prosomal 
protein 
4,31222 5,35E-20 8,06198 2,81E-02 KIAA1230 Q86W92 hSGT2 
0,929025 6,55E-100 9,51968 2,81E-02 PHB P35232 Prohibitin 
2,46913 1,63E-10 7,26503 2,82E-02 SENP1 Q9P0U3 
Sentrin/SUMO-
specific protease 
SENP1 
3,34561 1,89E-03 7,69854 2,84E-02 MPDU1 O75352 
Mannose-P-dolichol 
utilization defect 1 
protein 
0,920861 4,23E-92 9,42467 2,87E-02 MDU1 P08195-4 
4F2 cell-surface 
antigen heavy chain 
3,33263 5,03E-03 7,37603 2,89E-02 SLC35F2 Q8IXU6 
Solute carrier family 
35 member F2 
3,96729 2,50E-38 8,46705 2,93E-02 HPRT P00492 
Hypoxanthine-
guanine 
phosphoribosyltransfe
rase 
4,22008 2,13E-23 7,78453 3,10E-02 KIAA0103 Q15006 
Tetratricopeptide 
repeat protein 35 
4,21117 6,32E-32 7,91628 3,13E-02 CARF Q9NXV6 
CDKN2A-interacting 
protein 
3,2383 9,15E-04 7,72908 3,27E-02 D3S1231E B4DXJ1 
cDNA FLJ56334, 
highly similar to 
SEC13-related protein 
0,854112 2,88E-107 9,90612 3,36E-02 ATAD3A Q9NVI7-2 
ATPase family AAA 
domain-containing 
protein 3A 
0,852194 6,73E-245 9,4987 3,38E-02 PDIA6 Q15084-2 
Protein disulfide 
isomerase P5 
0,841658 1,79E-67 9,40678 3,46E-02 SNRPD1 P62314 
Small nuclear 
ribonucleoprotein Sm 
D1 
3,78978 1,12E-11 8,24932 3,53E-02 NDUFV1 P49821 Complex I-51kD 
4,07352 2,41E-85 7,96619 3,61E-02 KIAA0095 H3BVG0 93 kDa nucleoporin 
4,06671 3,45E-07 7,74262 3,63E-02 GAP43 P17677-2 
Axonal membrane 
protein GAP-43 
4,0625 2,02E-37 8,04906 3,65E-02 ANP32B Q92688 
Acidic leucine-rich 
nuclear 
phosphoprotein 32 
family member B 
4,04767 1,91E-03 7,89165 3,71E-02 ASF1B Q9NVP2 
Anti-silencing function 
protein 1 homolog B 
2,39456 3,38E-08 8,65969 3,72E-02 NDUFS2 O75306 Complex I-49kD 
2,37265 7,50E-18 8,53145 3,84E-02 GLUR P00390 
Glutathione 
reductase, 
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mitochondrial 
3,11061 2,38E-100 7,65889 3,85E-02 EEF1A2 Q05639 
Elongation factor 1-
alpha 2 
0,791017 0,00E+00 10,3535 3,89E-02 HSP60 P10809 60 kDa chaperonin 
3,68352 4,85E-09 8,24259 3,93E-02 IDH3A P50213 
Isocitrate 
dehydrogenase [NAD] 
subunit alpha, 
mitochondrial 
3,67997 4,40E-07 8,34739 3,95E-02 CPO P36551 
Coproporphyrinogen-
III oxidase, 
mitochondrial 
3,08583 5,58E-04 7,29953 3,97E-02 C6orf120 J3KQ97 
UPF0669 protein 
C6orf120 
3,6699 3,50E-20 8,17173 3,99E-02 HIST2H2AB Q8IUE6 Histone H2A type 2-B 
3,07004 1,34E-26 7,52054 4,05E-02 KIAA1418 Q9NXE4-4 
Neutral 
sphingomyelinase 3 
2,30867 3,58E-70 8,68049 4,22E-02 SEC23A Q15436 
Protein transport 
protein Sec23A 
3,60578 4,03E-15 8,33149 4,25E-02 TIAL1 Q01085-2 Nucleolysin TIAR 
2,2985 4,03E-17 8,56604 4,28E-02 ACR1 P30044 Alu corepressor 1 
3,90448 4,96E-85 8,09733 4,28E-02 MDH1 F5H098 
Cytosolic malate 
dehydrogenase 
3,58667 1,21E-32 8,26975 4,33E-02 HRIHFB2436 Q5VUA4 
Endocrine regulatory 
protein 
2,2838 1,03E-02 8,55751 4,37E-02 RPL39 P62891 
60S ribosomal protein 
L39 
3,88289 1,86E-11 8,0136 4,38E-02 GOSR1 O95249 
28 kDa cis-Golgi 
SNARE p28 
2,18412 8,46E-43 7,04171 4,40E-02 TBL1 O60907 
F-box-like/WD repeat-
containing protein 
TBL1X 
3,00152 5,11E-03 7,52298 4,41E-02 GCSH P23434 
Glycine cleavage 
system H protein, 
mitochondrial 
3,56522 6,09E-10 8,3582 4,43E-02 ADK2 P54819 
Adenylate kinase 2, 
mitochondrial 
3,86444 4,23E-04 8,00424 4,46E-02 ADAM9 Q13443 
Cellular disintegrin-
related protein 
0,728565 0,00E+00 9,98268 4,48E-02 VDAC P21796 
Outer mitochondrial 
membrane protein 
porin 1 
2,98467 3,87E-07 7,40922 4,50E-02 LIN7C Q9NUP9 
Mammalian lin-seven 
protein 3 
0,726183 0,00E+00 10,0907 4,50E-02 MYH10 F8VTL3 
Cellular myosin heavy 
chain, type B 
0,722053 2,02E-75 9,18298 4,55E-02 ALDH10 P51648-2 
Aldehyde 
dehydrogenase 10 
3,52267 7,09E-11 8,29387 4,62E-02 KIAA0650 A6NHR9 
Structural 
maintenance of 
chromosomes flexible 
hinge domain-
containing protein 1 
0,714552 2,72E-79 9,47384 4,62E-02 NIPSNAP1 Q9BPW8 
Protein NipSnap 
homolog 1 
2,95263 3,44E-02 7,51614 4,68E-02 NDUFB3 O43676 Complex I-B12 
0,700503 0,00E+00 10,1904 4,77E-02 CLH17 Q00610 Clathrin heavy chain 1 
2,11952 1,68E-06 6,66083 4,85E-02 HIST1H2BA Q96A08 Histone H2B type 1-A 
2,11683 6,22E-09 6,33383 4,87E-02 PIGL Q9Y2B2 
N-acetylglucosaminyl-
phosphatidylinositol 
de-N-acetylase 
3,44942 5,79E-13 8,48173 4,96E-02 PCNA P12004 Cyclin 
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Supplementary Table S6. Label free quantification (LFQ) of differential interaction partners of 
LE6 and SE6. In the table are listed: LFQ ratios (LE6/SE6), posterior error probability (PEP), intensity, 
significance B value (Sig. B), Gene names, Protein IDs representing the Uniprot identification numbers 
and the protein names of the significant proteins binding to both LE6 and SE6, or exclusively LE6 or 
SE6. Graphical representation in results Fig. 9. 
 
LE6/SE6 PEP Intensity LE6/SE6 Sig. B Gene Names Protein IDs Protein Names 
10,1324 1,49E-124 9,74744 4,14E-18 ACTBL2 Q562R1 Beta-actin-like protein 2 
11,3192 3,80E-04 8,72328 1,02E-12 H3FA P68431 Histone H3.1 
-9,45144 6,59E-69 8,6343 1,11E-10 
 
SE6 
 
-6,55435 1,90E-125 9,56785 9,04E-10 MDH2 P40926 
Malate dehydrogenase, 
mitochondrial 
6,82679 4,43E-44 9,13296 1,71E-08 FBL P22087 
34 kDa nucleolar 
scleroderma antigen 
8,75709 1,03E-02 8,55751 3,12E-08 RPL39 P62891 
60S ribosomal protein 
L39 
-7,97383 6,71E-31 8,98318 5,71E-08 HSPE1 P61604 10 kDa chaperonin 
-7,60818 3,63E-02 8,73607 2,29E-07 CASP7 P55210-2 
Caspase 7, apoptosis-
related cysteine 
peptidase 
6,07051 6,01E-12 9,34756 7,65E-07 BTF2P44 Q13888 
Basic transcription factor 
2 44 kDa subunit 
5,80357 7,67E-07 9,1554 2,62E-06 RPS29 P62273 
40S ribosomal protein 
S29 
-6,15742 8,13E-60 8,99234 3,06E-05 CS O75390 
Citrate synthase, 
mitochondrial 
-5,3629 5,64E-17 7,1697 8,49E-05 LSM5 Q9Y4Y9 
U6 snRNA-associated 
Sm-like protein LSm5 
5,44432 3,46E-03 7,2179 1,35E-04 NOLA3 Q9NPE3 
H/ACA ribonucleoprotein 
complex subunit 3 
-5,132 1,18E-03 6,84012 1,63E-04 TMEM127 C9J4H2 
Putative uncharacterized 
protein TMEM127 
-7,26709 8,83E-07 8,17929 2,71E-04 SYBL1 P51809 
Synaptobrevin-like 
protein 1 
5,70268 6,13E-80 8,69808 2,78E-04 KIAA0179 Q14684 
Ribosomal RNA 
processing protein 1 
homolog B 
5,19307 7,81E-05 7,16859 2,84E-04 GNG5 P63218 
Guanine nucleotide-
binding protein 
G(I)/G(S)/G(O) subunit 
gamma-5 
4,9535 1,63E-03 7,04195 5,57E-04 ATP6 P00846 ATP synthase subunit a 
-4,62901 7,66E-03 7,19287 6,21E-04 ASCC2 B1AH60 
Activating signal 
cointegrator 1 complex 
subunit 2 
7,16313 1,18E-02 8,38791 7,71E-04 IFITM3 Q01628 
Interferon-induced 
transmembrane protein 3 
5,22807 5,26E-134 8,96458 8,38E-04 KIAA0185 Q14690 
NF-kappa-B-binding 
protein 
4,68621 2,19E-13 7,09548 1,14E-03 H1F3 P16402 Histone H1.3 
-6,20607 9,68E-08 7,58399 1,18E-03 UBTD1 Q9HAC8 
Ubiquitin domain-
containing protein 1 
4,20713 8,67E-28 9,2416 1,23E-03 HME1 P31947 14-3-3 protein sigma 
5,00624 7,60E-109 8,58132 1,37E-03 MKI67 P46013 Antigen KI-67 
-4,74916 5,08E-36 8,9758 1,41E-03 GOT2 P00505 
Aspartate 
aminotransferase, 
mitochondrial 
-4,69406 5,02E-30 8,55332 1,61E-03 ERO1L Q96HE7 
Endoplasmic 
oxidoreductin-1-like 
protein 
4,53126 1,46E-04 6,89485 1,70E-03 CDIPT B3KY94 
cDNA FLJ16129 fis highly 
similar to CDP-
diacylglycerol-inositol3-
phosphatidyltransferase 
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-4,66789 1,68E-34 8,63781 1,71E-03 ETFA P13804 
Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 
-4,6315 1,56E-18 8,65379 1,86E-03 C12orf8 P30040 
Endoplasmic reticulum 
resident protein 28 
6,61691 1,00E-49 8,47506 1,89E-03 SMNDC1 O75940 
30 kDa splicing factor 
SMNrp 
6,57773 3,35E-09 8,32726 2,01E-03 LMN1 P02545 70 kDa lamin 
-6,14609 1,46E-12 8,42715 2,08E-03 CALU O43852-3 Calumenin 
-4,52422 4,39E-24 8,75897 2,39E-03 LONP1 P36776 
Lon protease homolog, 
mitochondrial 
4,72268 1,75E-17 8,87437 2,48E-03 COX5A P20674 
Cytochrome c oxidase 
polypeptide Va 
-6,72801 1,71E-05 7,97103 2,50E-03 LSM6 P62312 
U6 snRNA-associated 
Sm-like protein LSm6 
-5,99833 4,33E-21 8,24239 2,67E-03 ATP6E P36543 
Vacuolar proton pump 
subunit E 1 
6,20764 9,98E-03 7,60373 2,71E-03 CGI-108 Q9Y3B2 
3-5 exoribonuclease 
CSL4 homolog 
-4,46487 2,82E-55 8,55398 2,74E-03 ACO2 A2A274 
Aconitase 2, 
mitochondrial 
5,64784 2,50E-08 7,83426 2,90E-03 MRPL54 Q6P161 
39S ribosomal protein 
L54, mitochondrial 
-6,62986 5,22E-10 8,09384 2,92E-03 TM4SF8 O60637 Tetraspanin TM4-A 
-6,59284 1,34E-03 7,9894 3,10E-03 ATP6C P27449 
Vacuolar proton pump 16 
kDa proteolipid subunit 
6,26069 3,54E-135 8,49328 3,27E-03 PABP3 Q9H361 
Polyadenylate-binding 
protein 3 
-6,5531 1,40E-03 7,75374 3,29E-03 MAP2K1IP1 Q9UHA4 MEK-binding partner 1 
4,2415 5,39E-13 6,94077 3,48E-03 H1F2 P16403 Histone H1.2 
6,16828 2,69E-33 8,36372 3,76E-03 TCEB1 Q15369 Elongin 15 kDa subunit 
4,5048 1,65E-15 8,63329 3,85E-03 HSPC250 Q9P0M9 
39S ribosomal protein 
L27, mitochondrial 
-4,28016 1,20E-166 8,82929 4,13E-03 CDHF7 Q14517 
Cadherin family member 
7 
4,14825 1,03E-02 6,38254 4,34E-03 TAF13 Q15543 
Transcription initiation 
factor TFIID 18 kDa 
subunit 
5,89416 2,32E-05 7,33216 4,42E-03 C12orf31 Q9BRT6 Protein LAPS18-like 
-5,68055 5,36E-10 8,26152 4,45E-03 GLIF P14174 
Glycosylation-inhibiting 
factor 
-4,2371 7,82E-90 8,67041 4,54E-03 DLD P09622 
Dihydrolipoamide 
dehydrogenase 
4,11498 2,65E-09 7,22937 4,69E-03 
 
P54819-6 
 
-4,21686 6,77E-117 8,56886 4,74E-03 ECHS1 P30084 Enoyl-CoA hydratase 1 
5,33139 7,53E-70 8,00937 4,75E-03 RPL10L F8W7C6 
60S ribosomal protein 
L10-like 
5,83257 5,34E-26 7,6445 4,86E-03 MRPL55 Q7Z7F7-2 
39S ribosomal protein 
L55, mitochondrial 
5,99174 1,55E-98 8,26236 4,88E-03 CGI-102 Q9NQT5 
Exosome complex 
exonuclease RRP40 
-5,59476 1,95E-27 8,30276 5,10E-03 CYC P99999 Cytochrome c 
3,73628 0,00E+00 10,2862 5,11E-03 G22P2 P13010 
86 kDa subunit of Ku 
antigen 
-4,14737 2,00E-52 8,8564 5,51E-03 AHSA1 O95433 
Activator of 90 kDa heat 
shock protein ATPase 
homolog 1 
-4,1428 2,64E-20 8,62974 5,56E-03 MPPB O75439 Beta-MPP 
-4,10423 9,02E-13 8,60011 6,03E-03 MIG10 P00558 
Cell migration-inducing 
gene 10 protein 
5,82991 3,73E-33 8,2675 6,16E-03 PCMT1 H7BY58 
L-isoaspartyl protein 
carboxyl 
methyltransferase 
-4,07691 6,07E-74 8,92925 6,39E-03 ALDH7A1 P49419 
Aldehyde dehydrogenase 
family 7 member A1 
-5,41876 5,79E-13 8,48173 6,68E-03 PCNA P12004 Cyclin 
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-4,05056 9,07E-119 8,66849 6,75E-03 ACAT P24752 Acetoacetyl-CoA thiolase 
5,06855 4,88E-05 8,05588 7,03E-03 MCT1 P53985 
Monocarboxylate 
transporter 1 
5,72257 6,07E-13 8,26604 7,16E-03 BAF O75531 
Barrier-to-autointegration 
factor 
-3,50326 1,17E-03 7,22889 8,22E-03 SGMS2 Q8NHU3 
Phosphatidylcholine:cera
mide 
cholinephosphotransferas
e 2 
-5,04541 1,51E-14 7,54209 8,22E-03 FN14 Q9NP84 
Fibroblast growth factor-
inducible immediate-early 
response protein 14 
4,09435 5,44E-34 8,94621 8,42E-03 BUB3 O43684 
Mitotic checkpoint protein 
BUB3 
-5,90888 2,54E-10 7,99493 8,57E-03 NIF3L1BP1 Q6I9Y2 
Functional spliceosome-
associated protein 24 
5,58342 2,30E-11 8,27142 8,69E-03 TWISTNB Q3B726 
DNA-directed RNA 
polymerase I subunit 
RPA43 
4,91767 2,06E-12 7,8117 8,76E-03 CNN3 Q15417 Calponin, acidic isoform 
3,8302 9,24E-03 7,18927 8,90E-03 DPY19L1 Q2PZI1 Dpy-19-like protein 1 
3,82689 8,21E-03 7,25356 8,97E-03 CHCHD6 J3QTA6 
Coiled-coil-helix-coiled-
coil-helix domain-
containing protein 6 
5,40311 9,09E-03 7,33393 9,15E-03 CYB5R3 P00387-3 Diaphorase-1 
3,81342 3,77E-10 7,22978 9,23E-03 KCP2 Q8N6L1 
Keratinocyte-associated 
protein 2 
-5,85415 1,70E-18 7,99084 9,25E-03 C6orf28 Q9Y333 Protein G7b 
5,53264 1,85E-20 8,30735 9,31E-03 CGI-117 Q9Y3C1 
HBV pre-S2 trans-
regulated protein 3 
-4,95483 5,58E-04 7,29953 9,43E-03 C6orf120 J3KQ97 
UPF0669 protein 
C6orf120 
-3,88166 5,84E-95 8,6778 9,55E-03 SHMT2 P34897 
Glycine 
hydroxymethyltransferase 
5,36266 1,29E-03 7,69901 9,69E-03 MRPL34 Q9BQ48 
39S ribosomal protein 
L34, mitochondrial 
4,84288 1,83E-31 8,02865 9,74E-03 DCAF7 P61962 
DDB1- and CUL4-
associated factor 7 
5,47086 8,65E-03 8,23414 1,01E-02 DNAJA4 Q8WW22-2 
DnaJ homolog subfamily 
A member 4 
4,80944 3,51E-43 7,76694 1,02E-02 CCDC137 I3L0U5 
Coiled-coil domain-
containing protein 137 
-3,84445 3,65E-53 8,6911 1,03E-02 AE2 P04920 Anion exchange protein 2 
-3,38217 2,12E-22 7,00779 1,05E-02 ATP6G O75348 
Vacuolar proton pump 
subunit G 1 
4,71063 9,27E-03 7,78385 1,17E-02 
 
F5GZ99 
 
3,42336 0,00E+00 9,86804 1,20E-02 PLEC1 Q15149 
Hemidesmosomal protein 
1 
5,34314 1,08E-15 8,23634 1,20E-02 HDCMA18P Q4G0J3 
La ribonucleoprotein 
domain family member 7 
5,30032 9,23E-07 8,31867 1,27E-02 DBP2 O60231 
ATP-dependent RNA 
helicase #3 
3,86255 1,75E-118 9,04328 1,28E-02 PAF53 Q9GZS1-2 
DNA-directed RNA 
polymerase I subunit E 
-4,7386 3,13E-03 7,41581 1,30E-02 LSM4 Q9Y4Z0 Glycine-rich protein 
-3,27254 5,73E-04 7,15975 1,30E-02 CGI-84 Q9UQN3 
Charged multivesicular 
body protein 2b 
4,62893 7,88E-12 8,00243 1,31E-02 NOC4L Q9BVI4 NOC4-like protein 
-5,57053 1,03E-54 8,10724 1,37E-02 CMIP Q8IY22 C-Maf-inducing protein 
-3,24545 9,30E-04 7,12746 1,37E-02 DYNLT1 P63172 
Dynein light chain Tctex-
type 1 
-4,91514 1,88E-15 8,37016 1,39E-02 CDC10 Q16181 CDC10 protein homolog 
4,5805 5,15E-04 7,98945 1,40E-02 EDR Q86TG7 
Embryonal carcinoma 
differentiation-regulated 
protein 
-2,21556 4,19E-152 9,38929 1,41E-02 A4 P05067 ABPP 
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-3,22653 1,28E-16 6,99954 1,42E-02 PNSC1 O95164 
Membrane-anchored 
ubiquitin-fold protein 
4,53983 3,27E-14 7,81206 1,48E-02 KIAA0117 P42696 
RNA-binding motif protein 
34 
-3,6557 4,96E-113 8,78671 1,49E-02 FER1L3 F8W8J4 Fer-1-like protein 3 
-4,867 1,41E-23 8,48427 1,49E-02 ACADM Q5T4U5 
Acyl-Coenzyme A 
dehydrogenase, C-4 to C-
12 straight chain 
-4,62579 2,33E-04 7,30516 1,53E-02 IST1 A8KAH5 
cDNA FLJ32696 fis, 
clone TESTI2000358 
4,9775 8,43E-04 7,71574 1,65E-02 HSPC283 Q9BYC8 
39S ribosomal protein 
L32, mitochondrial 
3,29517 0,00E+00 10,1705 1,66E-02 G22P1 P12956 
70 kDa subunit of Ku 
antigen 
5,08109 1,94E-20 8,40931 1,69E-02 ASH P62993 Adapter protein GRB2 
4,95385 1,14E-02 7,42962 1,70E-02 FLC3A P60520 
GABA(A) receptor-
associated protein-like 2 
-3,12585 3,09E-03 7,06524 1,72E-02 
RP11-
545E17.12-
003 
Q96GR4-3 
Zinc finger, DHHC-type 
containing 12 
-3,56239 1,45E-43 8,69873 1,78E-02 OAT P04181 
Ornithine 
aminotransferase, hepatic 
form 
-4,51698 8,22E-06 7,63276 1,78E-02 LSM8 O95777 
N-alpha-acetyltransferase 
38, NatC auxiliary subunit 
5,03827 1,30E-127 8,51868 1,78E-02 EBNA1BP2 H7C2Q8 EBNA1-binding protein 2 
4,91179 7,40E-15 7,62185 1,79E-02 PP1201 Q969X1 Protein RECS1 homolog 
4,38393 2,62E-15 7,96521 1,82E-02 C21orf70 Q9NSI2 
Uncharacterized protein 
C21orf70 
-4,48628 3,03E-06 7,30593 1,86E-02 BRI3 O95415 Brain protein I3 
4,87594 1,57E-02 7,54616 1,88E-02 AIP Q9NWT8 
Aurora kinase A-
interacting protein 
3,44372 6,85E-04 6,91704 1,99E-02 CD2BP2 O95400 
CD2 antigen cytoplasmic 
tail-binding protein 2 
4,31484 7,76E-06 7,82563 2,00E-02 RPS21 P63220 
40S ribosomal protein 
S21 
4,82803 1,45E-11 7,31601 2,00E-02 MAK16 Q9BXY0 NNP78 
-3,48681 1,99E-34 8,79709 2,04E-02 ACADVL F5H2A9 
Very long-chain specific 
acyl-CoA dehydrogenase, 
mitochondrial 
-4,40983 2,20E-08 7,47293 2,07E-02 ATP6V1H Q9UI12 Nef-binding protein 1 
-3,02713 5,68E-03 7,16212 2,07E-02 SRCASM O75674 
Src-activating and 
signaling molecule 
protein 
3,57742 1,97E-101 8,62822 2,07E-02 KIAA1321 Q7Z417 
82 kDa FMRP-interacting 
protein 
3,56398 7,29E-63 8,82316 2,12E-02 SALL4 Q9UJQ4 Sal-like protein 4 
-4,36707 6,99E-07 7,48139 2,19E-02 BM-008 Q12974 HU-PP-1 
-4,3664 2,49E-07 7,64966 2,19E-02 C19orf27 Q96GS6-2 
Abhydrolase domain-
containing protein 
FAM108A1 
-2,99341 3,57E-03 7,16542 2,20E-02 IL17R Q96F46 CDw217 
-2,01703 3,00E-144 9,21492 2,21E-02 DREG Q86SQ4 
Developmentally 
regulated G-protein-
coupled receptor 
3,17136 6,05E-78 9,3369 2,25E-02 RIG P62841 
40S ribosomal protein 
S15 
-5,18215 7,39E-30 8,11025 2,27E-02 ARC41 O15143 
Actin-related protein 2/3 
complex subunit 1B 
3,37091 2,41E-10 7,16885 2,30E-02 KIAA1483 Q8N680 
Zinc finger and BTB 
domain-containing protein 
2 
4,19647 1,16E-18 7,98034 2,33E-02 DNAJC7 Q99615 
DnaJ homolog subfamily 
C member 7 
4,70904 1,25E-06 7,6203 2,33E-02 OMP25 P57105 
Mitochondrial outer 
membrane protein 25 
 132 
 
-4,3198 8,61E-09 7,53728 2,34E-02 NPDC1 Q5SPY9 
Neural proliferation, 
differentiation and control, 
1 
4,81125 5,92E-50 8,21307 2,36E-02 WDR36 Q8NI36 
T-cell activation WD 
repeat-containing protein 
3,35033 1,73E-03 7,07711 2,39E-02 MYO1C Q12965 Myosin-Ic 
-4,51361 1,54E-47 8,31479 2,40E-02 LRP12 Q9Y561 
Low-density lipoprotein 
receptor-related protein 
12 
-2,94208 3,37E-07 7,08318 2,42E-02 ZDHHC18 Q9NUE0 
Palmitoyltransferase 
ZDHHC18 
3,13854 2,90E-55 9,26364 2,44E-02 C1orf33 Q9UKD2 
mRNA turnover protein 4 
homolog 
-4,49011 6,09E-10 8,3582 2,47E-02 ADK2 P54819 
Adenylate kinase 2, 
mitochondrial 
4,66169 6,33E-05 7,66304 2,48E-02 MRPS12 O15235 
28S ribosomal protein 
S12, mitochondrial 
4,6563 1,18E-04 7,66523 2,50E-02 CGI-124 Q9Y3C6 
Peptidyl-prolyl cis-trans 
isomerase-like 1 
-5,08313 8,06E-27 8,11448 2,56E-02 ECH1 Q13011 
Delta(3,5)-Delta(2,4)-
dienoyl-CoA isomerase, 
mitochondrial 
-3,35928 6,34E-34 8,62191 2,58E-02 CPD O75976 Carboxypeptidase D 
-1,93777 6,85E-237 9,63746 2,64E-02 APLP2 Q06481 Amyloid protein homolog 
-3,33875 2,05E-23 8,67018 2,67E-02 PYGB P11216 
Glycogen phosphorylase, 
brain form 
-1,93098 1,15E-170 9,1758 2,68E-02 TPI P60174 
Triosephosphate 
isomerase 
3,25511 2,30E-12 7,06405 2,87E-02 hucep-1 O43159 Cerebral protein 1 
3,25439 1,35E-02 6,99382 2,87E-02 DCAF13 Q9NV06 
DDB1- and CUL4-
associated factor 13 
4,0069 4,54E-07 7,82092 2,95E-02 ASE1 O15446-2 A34.5 
4,62526 5,64E-42 8,4304 2,96E-02 KIAA0112 Q15050 
Ribosome biogenesis 
regulatory protein 
homolog 
-4,94615 8,02E-13 8,04068 3,03E-02 VTI1 Q9UEU0 
Vesicle transport through 
interaction with t-SNAREs 
homolog 1B 
4,49643 3,49E-08 7,58307 3,05E-02 CHP Q99653 Calcineurin B homolog 
-4,32766 5,05E-07 8,12519 3,05E-02 DXS423E Q14683 Sb1.8 
3,9751 4,34E-21 7,7343 3,07E-02 CCNYL1 Q8N7R7 Cyclin-Y-like protein 1 
-2,80453 3,13E-03 6,64125 3,08E-02 ARFRP1 Q13795 
ADP-ribosylation factor-
related protein 1 
-4,92631 3,89E-49 7,97187 3,11E-02 BMPR2 Q13873 
Bone morphogenetic 
protein receptor type II 
4,47818 3,48E-04 7,40221 3,12E-02 AROS Q86WX3 
40S ribosomal protein 
S19-binding protein 1 
4,46464 5,76E-03 7,31827 3,17E-02 CBP20 P52298 
20 kDa nuclear cap-
binding protein 
4,56503 6,22E-19 8,16862 3,17E-02 KIAA0690 Q5JTH9 RRP12-like protein 
-2,78437 7,88E-35 6,70791 3,19E-02 DER12 Q14542 
36 kDa nucleolar protein 
HNP36 
-3,23278 6,65E-54 8,57145 3,22E-02 COMT P21964 
Catechol O-
methyltransferase 
-2,77667 3,05E-27 7,0454 3,24E-02 RAB6B Q9NRW1 
Ras-related protein Rab-
6B 
-2,77571 1,67E-22 7,01397 3,24E-02 HIAT1 Q96MC6 
Hippocampus abundant 
transcript 1 protein 
3,91623 5,03E-22 8,09826 3,30E-02 WDR3 Q9UNX4 
WD repeat-containing 
protein 3 
4,51208 3,94E-16 8,15045 3,38E-02 DDX21 Q9NY93 
ATP-dependent 61 kDa 
nucleolar RNA helicase 
-3,18463 9,80E-103 9,061 3,50E-02 HPR1 Q96FV9 hTREX84 
3,86008 1,56E-41 8,07646 3,53E-02 PPAN C9J3F9 
Putative uncharacterized 
protein PPAN 
-3,99944 5,43E-03 7,72555 3,56E-02 C20orf129 Q9H4H8 Protein FAM83D 
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3,85347 5,65E-19 8,01098 3,56E-02 ABH5 Q6P6C2-1 
Alkylated DNA repair 
protein alkB homolog 5 
3,23246 2,24E-67 8,96215 3,59E-02 KIAA0052 P42285 
ATP-dependent helicase 
SKIV2L2 
-3,98749 3,33E-08 7,43345 3,61E-02 GNA14 O95837 
Guanine nucleotide-
binding protein subunit 
alpha-14 
4,33895 2,73E-04 7,70762 3,69E-02 KPNA3 O00505 Importin alpha Q2 
3,11807 5,91E-17 6,83124 3,70E-02 RAB5 P20339 
Ras-related protein Rab-
5A 
-2,69719 1,61E-04 7,15878 3,71E-02 ANTXR1 Q9H6X2 Anthrax toxin receptor 1 
-3,14978 9,44E-09 8,53168 3,71E-02 KIAA0102 E9PI68 
Microsomal signal 
peptidase 25 kDa subunit 
4,31875 1,16E-07 7,69045 3,78E-02 CCNT1 O60563 Cyclin-T1 
3,78641 3,34E-06 7,80493 3,86E-02 H1F5 P16401 Histone H1.5 
4,3888 1,58E-02 8,37568 3,89E-02 
 
H0Y670 
 
4,38486 2,46E-22 8,45171 3,91E-02 H2AFR Q96QV6 Histone H2A type 1-A 
-1,74221 1,18E-217 9,54518 3,98E-02 DNAPTP2 Q8NC42 
DNA polymerase-
transactivated protein 2 
-2,65296 3,81E-02 7,16125 3,99E-02 RAB33B Q9H082 
Ras-related protein Rab-
33B 
-3,89976 2,16E-05 7,48766 4,04E-02 GGH Q92820 Conjugase 
-4,69567 3,45E-07 7,74262 4,08E-02 GAP43 P17677-2 
Axonal membrane protein 
GAP-43 
4,33421 2,83E-20 8,24082 4,14E-02 NOC2L Q9Y3T9 NOC2-like protein 
3,71983 1,78E-14 8,10531 4,17E-02 NSUN5 Q96P11-4 
NOL1/NOP2/Sun domain 
family member 5 
3,71645 1,69E-09 8,03491 4,19E-02 EDC3 Q96F86 
Enhancer of mRNA-
decapping protein 3 
4,22559 3,24E-06 7,68891 4,22E-02 PRKAR1B P31321 
cAMP-dependent protein 
kinase type I-beta 
regulatory subunit 
4,31712 1,58E-36 8,35639 4,22E-02 ADPRT2 Q9UGN5 
NAD(+) ADP-
ribosyltransferase 2 
-2,61291 9,05E-03 6,77243 4,27E-02 SECTM1 Q8WVN6 Protein K12 
4,30173 6,94E-37 8,16643 4,29E-02 GIG38 O00422 
18 kDa Sin3-associated 
polypeptide 
-4,03918 2,27E-14 8,19973 4,35E-02 VAT1 Q99536 
Synaptic vesicle 
membrane protein VAT-1 
homolog 
4,284 3,63E-04 8,21846 4,38E-02 OGT O15294 
O-GlcNAc transferase 
subunit p110 
2,87872 6,26E-74 9,16447 4,42E-02 RBM28 Q9NW13 
RNA-binding motif protein 
28 
-1,68962 6,78E-106 9,21155 4,43E-02 QARS P47897 Glutamine--tRNA ligase 
2,87146 1,47E-249 9,35892 4,49E-02 XRN2 Q9H0D6 5-3 exoribonuclease 2 
-1,6805 9,14E-21 9,31035 4,52E-02 hCG_2001850 Q32Q12 
Nucleoside diphosphate 
kinase 
-1,67717 0,00E+00 10,3535 4,55E-02 HSP60 P10809 60 kDa chaperonin 
-3,02471 1,84E-133 8,69469 4,57E-02 EHD4 Q9H223 
EH domain-containing 
protein 4 
2,99814 9,64E-05 6,99799 4,59E-02 BANP Q8N9N5 
BEN domain-containing 
protein 1 
-3,00163 2,49E-24 8,61982 4,75E-02 GLUD P00367 
Glutamate 
dehydrogenase 1, 
mitochondrial 
2,84537 1,12E-40 9,23722 4,75E-02 KIAA0264 B4DRT2 
cDNA FLJ54536, highly 
similar to Mitochondrial 
28S ribosomal protein 
S27 
4,11872 1,27E-02 7,40358 4,77E-02 KIAA0016 Q15388 
Mitochondrial 20 kDa 
outer membrane protein 
-2,5239 7,56E-09 7,04242 4,94E-02 KIAA1734 Q9C0C9 Ubiquitin carrier protein O 
4,08778 1,76E-03 7,43561 4,95E-02 TAF12 Q16514 
Transcription initiation 
factor TFIID 20/15 kDa 
subunits 
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Supplementary Table S7. List of significant proteins detected in the first LE6 SILAC 
experiment. From the huge list of candidate LE6 interactors, 60 proteins were sorted according to 
their ratios (Ratio H/L) and p-values. In the table are shown the gene names, protein IDs (Uniprot) and 
the protein names of proteins detected in the first LE6 experiment. Proteins are sorted by descending 
ratios.  
 
Ratio H/L  p value H/L  Gene Names Protein IDs Protein Names 
4,255274 4,92E-18 
 
LE6 
 
2,631523 1,50E-03 MTA1 Q13330 Metastasis-associated protein MTA1 
2,33674 1,87E-06 EIF4F Q04637-9 Eukaryotic translation initiation factor 4 gamma 1 
2,322274 5,77E-03 BRE1B O75150 95 kDa retinoblastoma-associated protein 
2,250295 7,72E-03 C1orf28 Q6P1J9 Cell division cycle protein 73 homolog 
2,191878 2,94E-04 HSPC275 D6REX3 ABP125 
2,175397 1,03E-02 C20orf21 Q9BYJ9 
Dermatomyositis associated with cancer putative 
autoantigen 1 
2,151794 1,13E-02 LENG5 Q9BSV6 Leukocyte receptor cluster member 5 
2,10296 1,36E-02 COCA2 P40692 DNA mismatch repair protein Mlh1 
2,076901 2,24E-05 ATAD3A Q9NVI7-2 ATPase family AAA domain-containing protein 3A 
2,068293 1,55E-02 LONP Q86WA8 Lon protease-like protein 2 
2,053876 1,63E-02 MEL18 R4GMX3 DNA-binding protein Mel-18 
2,022368 1,83E-02 CHD4 Q14839-2 ATP-dependent helicase CHD4 
1,977023 2,15E-02 ANAPC7 Q9UJX3 Anaphase-promoting complex subunit 7 
1,922046 2,61E-02 EMP E7ESC7 Cell proliferation-inducing gene 5 protein 
1,901147 2,80E-02 hCG_22498 B4DWW4 
cDNA FLJ55599, highly similar to DNA replication 
licensing factor MCM3 
1,87688 3,04E-02 EIF4E2 O60573 eIF4E-like protein 4E-LP 
1,835358 1,77E-04 KAP1 Q13263 KRAB-associated protein 1 
1,819096 3,68E-02 OGFR Q9NZT2 Opioid growth factor receptor 
1,816477 3,71E-02 COG6 Q9Y2V7 Component of oligomeric Golgi complex 6 
1,813196 3,08E-03 BAP135 P78347 Bruton tyrosine kinase-associated protein 135 
1,803599 3,87E-02 HSPC024 Q9UBK9 Androgen receptor trapped clone 27 protein 
1,742869 4,70E-02 C9orf10 Q9NZB2-6 Constitutive coactivator of PPAR-gamma-like protein 1 
1,708894 5,48E-03 EDH17B4 P51659 17-beta-hydroxysteroid dehydrogenase 4 
1,696261 5,23E-04 RBAP48 Q09028 Chromatin assembly factor 1 subunit C 
1,683921 6,26E-03 CDC47 P33993 CDC47 homolog 
1,682933 6,30E-03 DAP5 P78344 Death-associated protein 5 
1,598079 9,77E-03 HDAC1 Q13547 Histone deacetylase 1 
1,592445 1,01E-02 GTF3C3 Q9Y5Q9 General transcription factor 3C polypeptide 3 
1,591201 1,01E-02 AOF2 F6S0T5 BRAF35-HDAC complex protein BHC110 
1,584289 1,05E-02 A2D Q8WWM7-3 Ataxin-2 domain protein 
1,574634 1,10E-02 ALDA P04075-2 Fructose-bisphosphate aldolase A 
1,546462 1,26E-02 POLRMT O00411 DNA-directed RNA polymerase, mitochondrial 
1,52301 1,42E-02 BCG1 Q9UNF1 11B6 
1,468583 2,64E-03 BAG2 O95816 BAG family molecular chaperone regulator 2 
1,451752 1,99E-02 DBC1 Q8N163 Deleted in breast cancer gene 1 protein 
1,440633 2,09E-02 HC9 P25789 Macropain subunit C9 
1,425459 2,25E-02 EIF2G P41091 Eukaryotic translation initiation factor 2 subunit 3 
1,418244 3,67E-03 HNRNPA0 Q13151 Heterogeneous nuclear ribonucleoprotein A0 
1,377179 2,79E-02 ALDH1B1 P30837 Aldehyde dehydrogenase 5 
1,303284 3,85E-02 HCFC1 A6NEM2 Putative uncharacterized protein HCFC1 
1,296663 3,96E-02 SND1 Q7KZF4 100 kDa coactivator 
1,271067 4,41E-02 LAS1L Q9Y4W2 Protein LAS1 homolog 
1,235482 1,13E-02 HSP27 P04792 28 kDa heat shock protein 
1,23493 1,13E-02 MYH9 P35579 Cellular myosin heavy chain, type A 
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1,225337 1,19E-02 MYH10 P35580-3 Cellular myosin heavy chain, type B 
1,215057 1,27E-02 NONO Q15233 54 kDa nuclear RNA- and DNA-binding protein 
1,202574 1,36E-02 FP17425 G8JLL9 Myosin heavy chain 14 
1,19415 1,43E-02 HNRPDL O14979 AU-rich element RNA-binding factor 
1,19333 1,43E-02 NUMA Q14980 Nuclear mitotic apparatus protein 1 
1,182184 1,52E-02 RPS11 P62280 40S ribosomal protein S11 
1,128095 2,05E-02 EIF3E P60228 eIF-3 p48 
1,106415 2,30E-02 WHIP Q96S55 ATPase WRNIP1 
1,101112 2,37E-02 GCN1L1 Q92616 GCN1-like protein 1 
1,054223 3,02E-02 NALP2 Q9NX02 NACHT, LRR and PYD domains-containing protein 2 
1,052833 3,04E-02 PAB1 P11940 Polyadenylate-binding protein 1 
1,011281 3,75E-02 APP1 Q13310-3 Activated-platelet protein 1 
1,000937 3,95E-02 DDX2A P60842 ATP-dependent RNA helicase eIF4A-1 
0,9942901 4,08E-02 NUP107 P57740 107 kDa nucleoporin 
0,9683488 4,63E-02 RPL10L F8W7C6 60S ribosomal protein L10-like 
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Fig. S8 Western blot to validate 17βHSD4 interaction with LE6. HA-tagged LE6 and 38E6 were 
tested for the binding to p300 (upper panel, IP) and MAML1 (middle upper panel, IP), that were used 
as positive controls for the pull down. KDM1A was not pulled down by neither LE6 nor 38E6 (central 
panel), as shown before. An HA signal was detected for the two proteins (lower panel) in both inputs 
(IN) and immunoprecipitates (IP) with the exception of LE6 and SE6 that were only visible in the IP. 
Molecular sizes are shown in kDa on the left. CMV: pCMV-N-Flag_Linker_HA empty vector; LE6: 
pCMV-N-Flag_Linker_HA-CRPVLE6; 38E6: pCMV-N-Flag_Linker_HA-HPV38E6. 
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Supplementary figure S9. Western blot showing no interaction between LE6 and HDAC1 and 2. 
E6 HA-tagged proteins were tested for the binding to HDAC1 and HDAC2 by CoIP. KDM1A was not 
pulled down by LE6 and by any of the other proteins analyzed (lower panel). An HA signal was 
detected for all the proteins (upper panel) in both the inputs (IN) and in the immunoprecipitates (IP), 
whereas bands for HDAC1 and HDAC2 were detected only in the IN. Molecular sizes are shown in 
kDa on the left. CMV: pCMV-N-Flag_Linker_HA empty vector; LE6: pCMV-N-Flag_Linker_HA-
CRPVLE6; SE6: pCMV-N-Flag_Linker_HA-CRPVSE6. 
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Supplementary Table S10. LE6 common hits between the two SILAC experiments. The lists of 
possible candidates of the first SILAC and the second SILAC experiment were compared and the 
common candidates were 304, sorted by descending ratios. This comparison, including also the non 
significant proteins, was made in order to test the reproducibility of SILAC, that in this case was 19%. 
In the table are shown the ratios (Ratio H/L for the first SILAC experiment and Ratio H/M for the 
second SILAC experiment) the p-values, the gene names, the protein IDs (Uniprot) and the protein 
names of all common proteins between the two SILAC experiments. Proteins are sorted by 
descending ratios. The significant common proteins between the two experiments are shown in results 
Table 7. 
 
Ratio H/L Ratio H/M 
p-value 
SILAC1 
p-value 
SILAC2 
Gene Names Protein IDs Protein Names 
4,274709 -6,63279 4,92E-18 1,10E-101 
 
LE6 
 
2,33674 -1,39665 1,87E-06 1,62E-03 EIF4F Q04637-9 
Eukaryotic translation 
initiation factor 4 gamma 1 
2,250295 -0,4113297 7,72E-03 1,63E-01 C1orf28 Q6P1J9 
Cell division cycle protein 73 
homolog 
2,151794 -2,312796 1,13E-02 6,56E-05 LENG5 Q9BSV6 
Leukocyte receptor cluster 
member 5 
2,024213 -0,6487561 2,24E-05 3,27E-02 ATAD3A Q9NVI7-2 
ATPase family AAA domain-
containing protein 3A 
2,009419 -0,8581225 9,00E-02 5,26E-03 ATAD3B Q5T9A4 
ATPase family AAA domain-
containing protein 3B 
1,901147 -0,09525 2,80E-02 7,52E-01 hCG_22498 B4DWW4 
cDNA FLJ55599, highly 
similar to DNA replication 
licensing factor MCM3 
1,842456 -0,03682186 5,23E-04 7,79E-01 RBAP48 Q09028 
Chromatin assembly factor 1 
subunit C 
1,835358 -0,7399261 1,77E-04 2,95E-02 KAP1 Q13263 KRAB-associated protein 1 
1,742869 -0,6515183 4,70E-02 2,90E-01 C9orf10 Q9NZB2-6 
Constitutive coactivator of 
PPAR-gamma-like protein 1 
1,710349 -1,047428 5,21E-02 7,89E-02 CDABP0017 Q9Y5Q8-3 
General transcription factor 
3C polypeptide 5 
1,708894 -2,919424 5,48E-03 4,13E-07 EDH17B4 P51659 
17-beta-hydroxysteroid 
dehydrogenase 4 
1,683921 -0,917243 6,26E-03 1,27E-01 CDC47 P33993 CDC47 homolog 
1,682933 -1,840836 6,30E-03 4,16E-05 DAP5 P78344 Death-associated protein 5 
1,644502 -0,6106313 6,37E-02 3,24E-01 MTA1L1 O94776 
Metastasis-associated 1-like 
1 
1,598079 -0,2825615 9,77E-03 6,84E-01 HDAC1 Q13547 Histone deacetylase 1 
1,597603 -0,3890544 7,32E-02 3,15E-01 NXF1 Q9UBU9 mRNA export factor TAP 
1,592445 -1,219539 1,01E-02 3,93E-02 GTF3C3 Q9Y5Q9 
General transcription factor 
3C polypeptide 3 
1,585636 -0,5412191 7,58E-02 3,88E-01 FARS Q9Y285 CML33 
1,584289 -1,645616 1,05E-02 2,31E-04 A2D Q8WWM7-3 Ataxin-2 domain protein 
1,574634 -2,18554 1,10E-02 1,86E-05 ALDA P04075-2 
Fructose-bisphosphate 
aldolase A 
1,566718 -0,2259193 8,00E-02 5,11E-01 G3BP Q13283 
ATP-dependent DNA 
helicase VIII 
1,537097 -0,4219598 8,71E-02 5,14E-01 FBP3 Q96I24 
Far upstream element-
binding protein 3 
1,505637 -0,612439 9,51E-02 3,23E-01 NOC2L Q9Y3T9 NOC2-like protein 
1,471604 -1,013917 1,26E-02 1,95E-02 POLRMT O00411 
DNA-directed RNA 
polymerase, mitochondrial 
1,470771 -0,7394202 1,05E-01 2,09E-02 CDC2L4 P50750-2 C-2K 
1,468583 -0,8122322 2,64E-03 8,12E-03 BAG2 O95816 
BAG family molecular 
chaperone regulator 2 
1,464198 -0,4999322 1,07E-01 2,15E-01 ATP5L O75964 
ATP synthase subunit g, 
mitochondrial 
1,451752 -0,8359862 1,99E-02 6,50E-03 DBC1 Q8N163 
Deleted in breast cancer 
gene 1 protein 
1,450855 -0,6110721 1,11E-01 3,24E-01 CLASP2 E7EW49 CLIP-associating protein 2 
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1,425459 -0,5071931 2,25E-02 8,64E-02 EIF2G P41091 
Eukaryotic translation 
initiation factor 2 subunit 3 
1,382003 -0,6893108 1,33E-01 1,00E-01 TSPYL Q9H0U9 
Testis-specific Y-encoded-
like protein 1 
1,345112 -0,1239841 1,46E-01 9,57E-01 GTF2H4 Q92759 
Basic transcription factor 2 
52 kDa subunit 
1,296663 -0,9981546 3,96E-02 2,13E-02 SND1 Q7KZF4 100 kDa coactivator 
1,287591 -0,148257 1,68E-01 8,65E-01 BIG3 P61964 
BMP2-induced 3-kb gene 
protein 
1,280897 -0,05338888 1,71E-01 9,98E-01 CDA016 E7ENQ6 
cDNA FLJ59191, highly 
similar to NADH 
dehydrogenase 1 
1,271067 -0,8579657 4,41E-02 1,55E-01 LAS1L Q9Y4W2 Protein LAS1 homolog 
1,226077 -0,2960843 1,95E-01 4,20E-01 EIF2AK2 P19525 
Eukaryotic translation 
initiation factor 2-alpha 
kinase 2 
1,222619 -0,4688307 5,38E-02 2,40E-01 LUZP1 Q86V48 Leucine zipper protein 1 
1,22002 -1,811422 1,13E-02 5,44E-05 HSP27 P04792 28 kDa heat shock protein 
1,219401 -0,4927483 1,98E-01 2,20E-01 MAP4 E7EVA0 
Microtubule-associated 
protein 4 
1,215057 -0,1141757 1,27E-02 5,57E-01 NONO Q15233 
54 kDa nuclear RNA- and 
DNA-binding protein 
1,194087 -0,03984416 2,10E-01 8,16E-01 PES1 O00541 Pescadillo homolog 
1,192005 -1,193998 2,11E-01 4,38E-02 TARDBP Q13148 TAR DNA-binding protein 43 
1,182565 -0,03185759 6,31E-02 9,69E-01 ABCE1 P61221 
2-5-oligoadenylate-binding 
protein 
1,182184 -0,7010133 1,52E-02 2,15E-02 RPS11 P62280 40S ribosomal protein S11 
1,157626 -0,1665512 2,29E-01 8,40E-01 RFC2 P35250 Activator 1 40 kDa subunit 
1,131985 -1,454743 7,67E-02 1,05E-03 GNB2L1 P63244 
Cell proliferation-inducing 
gene 21 protein 
1,128095 -0,4230233 2,05E-02 1,48E-01 EIF3E P60228 eIF-3 p48 
1,115633 -0,6751664 2,51E-01 2,65E-02 PAF1 Q8N7H5 
Pancreatic differentiation 
protein 2 
1,113434 -0,9097427 2,52E-01 1,30E-01 G7A P26640 Protein G7a 
1,111566 -0,7467126 8,28E-02 7,73E-02 DDX6 P26196 
ATP-dependent RNA 
helicase p54 
1,103397 -1,162783 8,54E-02 7,97E-03 HBP Q00341 
High density lipoprotein-
binding protein 
1,101112 -1,056311 2,37E-02 6,50E-04 GCN1L1 Q92616 GCN1-like protein 1 
1,096195 -0,6185616 8,77E-02 3,17E-01 DNAJC7 Q99615 
DnaJ homolog subfamily C 
member 7 
1,086852 -0,4734704 3,04E-02 1,12E-01 PAB1 P11940 
Polyadenylate-binding 
protein 1 
1,076285 -0,5101489 3,95E-02 9,71E-02 DDX2A P60842 
ATP-dependent RNA 
helicase eIF4A-1 
1,054223 -0,896818 3,02E-02 3,69E-02 NALP2 Q9NX02 
NACHT, LRR and PYD 
domains-containing protein 
2 
1,046002 -0,8368362 1,05E-01 5,01E-02 HMX3 I3L3A8 
Modulator of non-genomic 
activity of estrogen receptor 
1,039489 -1,862916 2,96E-01 1,39E-03 KIAA0607 Q9UBB6-3 Neurochondrin 
1,022616 -0,4862263 3,75E-02 2,26E-01 APP1 Q13310-3 Activated-platelet protein 1 
1,018064 -0,08074384 1,16E-01 7,28E-01 
AL022311.1-
001 
B0QY89 
Eukaryotic translation 
initiation factor 3, subunit E 
interacting protein 
0,9968225 -0,9438882 1,23E-01 2,87E-02 RFC4 P35249 Activator 1 37 kDa subunit 
0,9948694 -0,2337356 1,52E-01 6,74E-01 ARALAR2 Q9UJS0-2 
Calcium-binding 
mitochondrial carrier protein 
Aralar2 
0,9913903 -1,088838 3,26E-01 1,05E-01 BUB3 O43684 
Mitotic checkpoint protein 
BUB3 
0,986593 -0,6456156 3,30E-01 2,95E-01 BAM Q9UQE7 
Basement membrane-
associated chondroitin 
proteoglycan 
0,9769501 -0,5594943 1,21E-01 3,70E-01 EIF3G O75821 eIF3 p42 
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0,9570974 -0,3924401 1,43E-01 3,12E-01 ANT3 P12236 
Adenine nucleotide 
translocator 3 
0,9557592 -0,03500262 3,50E-01 9,74E-01 ARHGEF2 V9GYM8 
Rho/rac guanine nucleotide 
exchange factor (GEF) 2 
0,9419326 -1,028322 1,50E-01 8,48E-02 OK/SW-cl.29 P04818 Thymidylate synthase 
0,9382482 -0,4030458 5,34E-02 1,71E-01 D6S218E P62269 40S ribosomal protein S18 
0,9323636 -0,7194238 3,67E-01 8,72E-02 L18 Q9NXF1 
Testis-expressed sequence 
10 protein 
0,9281239 -1,059465 1,57E-01 7,53E-02 TUBG P23258 Gamma-1-tubulin 
0,922274 -0,2418162 5,75E-02 4,90E-01 CAD P27708 
Aspartate 
carbamoyltransferase 
0,9214364 -0,02947023 1,61E-01 8,12E-01 FAM98A Q8NCA5 Protein FAM98A 
0,9092739 -0,4550992 3,83E-01 1,26E-01 KIAA1649 Q9BY77 
46 kDa DNA polymerase 
delta interaction protein 
0,9081981 -0,1078188 1,68E-01 9,22E-01 POLR2B P30876 
DNA-directed RNA 
polymerase II 140 kDa 
polypeptide 
0,9065828 -0,518949 1,69E-01 2,00E-01 RFC5 P40937 Activator 1 36 kDa subunit 
0,9046575 -0,4661376 1,70E-01 2,42E-01 EIF3I Q13347 eIF3 p36 
0,9019578 -0,08133899 1,71E-01 9,59E-01 KIAA0095 Q8N1F7 93 kDa nucleoporin 
0,8938282 -0,8198776 6,55E-02 8,13E-03 RPS16 P62249 40S ribosomal protein S16 
0,8917302 -0,4027978 1,77E-01 2,04E-01 HRS Q13243 Delayed-early protein HRS 
0,8865891 -0,4444587 6,76E-02 2,62E-01 KIAA1835 P46060 
Ran GTPase-activating 
protein 1 
0,8831516 -0,1954012 5,63E-01 5,54E-01 SRPR P08240 Docking protein alpha 
0,8790784 -0,05752675 7,00E-02 7,66E-01 RBM14 Q96PK6 Paraspeckle protein 2 
0,8684497 -2,90996 4,14E-01 1,81E-10 PYCR2 Q96C36 
Pyrroline-5-carboxylate 
reductase 2 
0,8631455 -0,2947387 1,93E-01 3,03E-01 DDX1 Q92499 
ATP-dependent RNA 
helicase DDX1 
0,8482373 -1,20553 2,02E-01 4,17E-02 hCG_19946 Q5T1Z8 
Pumilio homolog 1 
(Drosophila) 
0,8468744 -0,9543055 2,03E-01 2,72E-02 DNAJB6 O75190 
DnaJ homolog subfamily B 
member 6 
0,8347112 -2,28736 2,11E-01 4,42E-07 PYCR1 B4DMU0 
Pyrroline-5-carboxylate 
reductase 
0,8321204 -0,7901599 4,42E-01 1,93E-01 ABCF3 Q9NUQ8 
ATP-binding cassette sub-
family F member 3 
0,8198317 -0,2338374 4,52E-01 5,00E-01 CLINT1 Q14677-3 Clathrin interactor 1 
0,8195047 -0,1525802 9,08E-02 5,59E-01 HYRC P78527 
DNA-dependent protein 
kinase catalytic subunit 
0,8193412 -0,6007742 2,21E-01 3,33E-01 MIP224 P43686 
26S protease regulatory 
subunit 6B 
0,8152475 -0,06540045 2,24E-01 7,27E-01 C14orf166 Q9Y224 UPF0568 protein C14orf166 
0,8063653 -0,4445961 4,63E-01 2,61E-01 KIAA1185 Q8N1G4 
Leucine-rich repeat-
containing protein 47 
0,7977601 -1,186886 4,70E-01 1,89E-01 CFIM25 O43809 
Cleavage and 
polyadenylation specificity 
factor 25 kDa subunit 
0,7965147 -0,2053804 2,20E-01 4,53E-01 DDX47 Q9H0S4 DEAD box protein 47 
0,7893537 -0,7181889 3,52E-01 2,40E-01 GOLGA2 Q08379 
130 kDa cis-Golgi matrix 
protein 
0,7861781 -0,1101371 1,42E-01 6,51E-01 OK/SW-cl.48 Q00325 
Phosphate carrier protein, 
mitochondrial 
0,7755984 -1,040794 4,88E-01 8,09E-02 CC2D1A Q6P1N0 
Coiled-coil and C2 domain-
containing protein 1A 
0,7724769 -1,322433 2,53E-01 2,76E-03 CDKN2 P42771-4 
Cyclin-dependent kinase 4 
inhibitor A 
0,7700256 -0,6743833 2,55E-01 1,60E-01 BZAP45 Q7L1Q6-3 
Basic leucine zipper and W2 
domain-containing protein 1 
0,7534333 -0,3404042 1,40E-01 5,94E-01 PSMD12 O00232 
26S proteasome non-
ATPase regulatory subunit 
12 
0,7463128 -0,1127087 2,73E-01 8,28E-01 MET Q9NWH9 
Modulator of estrogen-
induced transcription 
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0,7349155 -0,3078764 2,81E-01 3,90E-01 ADAR E7ENU4 
136 kDa double-stranded 
RNA-binding protein 
0,7282253 -0,1793022 2,87E-01 8,23E-01 GDI2 E7EU23 
Guanosine diphosphate 
dissociation inhibitor 2 
0,7250867 -0,0835081 5,32E-01 7,12E-01 MDS016 P82921 
28S ribosomal protein S21, 
mitochondrial 
0,724563 -0,1621698 2,90E-01 5,39E-01 POLR2E P19388 
DNA-directed RNA 
polymerase II 23 kDa 
polypeptide 
0,7151905 -0,1708324 1,39E-01 5,90E-01 hCG_1784554 B3KSH1 
cDNA FLJ36192 fis highly 
similar to Eukaryotic 
translation initiation factor 3 
subunit 5 
0,7124637 -0,2691297 2,99E-01 4,54E-01 E1BAP5 Q9BUJ2 
Adenovirus early region 1B-
associated protein 5 
0,7010611 -0,1971202 3,09E-01 4,69E-01 C22orf28 Q9Y3I0 UPF0027 protein C22orf28 
0,6927842 -0,3698369 3,16E-01 5,75E-01 DRG1 Q9Y295 
Developmentally-regulated 
GTP-binding protein 1 
0,6908193 -0,603161 3,17E-01 1,44E-01 AZI1 Q9UPN4 
5-azacytidine-induced 
protein 1 
0,6879565 -0,4525501 1,64E-01 1,31E-01 OK/SW-cl.26 P23396 40S ribosomal protein S3 
0,6833821 -0,5187837 3,24E-01 2,00E-01 APG2 P34932 Heat shock 70 kDa protein 4 
0,6789733 -0,6665076 3,27E-01 1,19E-01 CAPE O95347 
Chromosome-associated 
protein E 
0,675003 
-
0,00887090
9 
1,49E-01 8,46E-01 PSMD3 O43242 
26S proteasome non-
ATPase regulatory subunit 3 
0,6738277 -0,4786678 3,88E-01 3,71E-01 SRP54 P61011 
Signal recognition particle 
54 kDa protein 
0,6665748 -0,226088 5,84E-01 7,59E-01 NSUN2 Q08J23 
NOL1/NOP2/Sun domain 
family member 2 
0,6658475 -0,278636 1,62E-01 3,29E-01 SFRS6 Q13247 
Pre-mRNA-splicing factor 
SRP55 
0,6653928 -0,9656435 5,85E-01 1,07E-01 CYC1 P08574 Complex III subunit 4 
0,663208 -0,7522183 3,41E-01 3,10E-01 DNAJ1 P25685 
DnaJ homolog subfamily B 
member 1 
0,65764 -0,3273845 1,73E-01 3,96E-01 IQGAP1 P46940 p195 
0,6570912 -0,4030076 3,47E-01 3,01E-01 PRP4 O43172 PRP4 homolog 
0,6546189 -0,401692 1,75E-01 1,95E-01 RPS2 P15880 40S ribosomal protein S2 
0,6496614 -0,386506 2,22E-01 1,81E-01 BCLAF1 Q9NYF8 
Bcl-2-associated 
transcription factor 1 
0,6489255 -0,04149136 3,54E-01 7,92E-01 MBS O14974 
Myosin phosphatase-
targeting subunit 1 
0,6452405 -0,4680921 6,04E-01 1,94E-01 DIMT1 Q9UNQ2 18S rRNA dimethylase 
0,6444101 -0,4137109 3,48E-01 2,90E-01 PSMC5 P62195 
26S protease regulatory 
subunit 8 
0,641546 -1,16955 6,07E-01 4,85E-02 ATP5F1 P24539 
ATP synthase subunit b, 
mitochondrial 
0,6403432 -0,07728459 3,62E-01 7,34E-01 EIF3M Q7L2H7 
Eukaryotic translation 
initiation factor 3 subunit M 
0,6327336 -0,7722343 3,72E-01 2,04E-01 OK/SW-cl.21 P11172 OMPdecase 
0,6301259 -0,1606854 9,63E-01 6,05E-01 KIF2 O00139-4 Kinesin-2 
0,6295664 -0,4903345 3,72E-01 1,01E-01 KIF5B P33176 
Conventional kinesin heavy 
chain 
0,626953 -0,5054718 1,52E-01 9,14E-02 CCG2 P62701 
40S ribosomal protein S4, X 
isoform 
0,6248028 -0,4342859 3,76E-01 1,41E-01 DDX23 Q9BUQ8 
100 kDa U5 snRNP-specific 
protein 
0,6228366 -0,1071505 1,96E-01 6,58E-01 199G4 Q9NW64 
Pre-mRNA-splicing factor 
RBM22 
0,6161695 -0,0108174 3,84E-01 8,87E-01 AP2M1 Q96CW1 
Adapter-related protein 
complex 2 mu subunit 
0,6155104 -0,8755659 6,32E-01 1,46E-01 AASDHPPT Q9NRN7 
4-phosphopantetheinyl 
transferase 
0,6093767 -2,367359 6,38E-01 4,35E-05 EXOSC2 Q13868 
Exosome complex 
exonuclease RRP4 
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0,6009358 -0,1653211 3,94E-01 5,98E-01 CKAP5 Q14008-3 
Colonic and hepatic tumor 
over-expressed gene protein 
0,5941664 -0,1480491 2,17E-01 5,12E-01 MATR3 A8MXP9 
Putative uncharacterized 
protein MATR3 
0,5941664 -0,04720429 2,52E-01 7,98E-01 KIAA0389 E7EW20 Myosin-VI 
0,5918708 -0,1312816 4,08E-01 8,89E-01 COPB P53618 Beta-coat protein 
0,5869809 -0,04351208 2,24E-01 8,07E-01 ACIN1 Q9UKV3 
Apoptotic chromatin 
condensation inducer in the 
nucleus 
0,5847701 -0,2071779 2,24E-01 4,50E-01 ERH P84090 
Enhancer of rudimentary 
homolog 
0,5725987 -0,1508494 6,73E-01 8,62E-01 COPB2 P35606 Beta-coat protein 
0,5725017 -0,155984 2,32E-01 5,49E-01 PRPC8 Q6P2Q9 
220 kDa U5 snRNP-specific 
protein 
0,5723076 -1,515934 4,28E-01 9,75E-03 NDPKA P15531-2 
Granzyme A-activated 
DNase 
0,5722106 -0,7975886 6,74E-01 1,88E-01 KIAA0988 Q9BTW9-4 Beta-tubulin cofactor D 
0,5676428 -1,35487 4,32E-01 2,14E-02 HSD17B12 Q53GQ0 
17-beta-hydroxysteroid 
dehydrogenase 12 
0,563939 -0,1138167 2,41E-01 6,46E-01 DDX5 P17844 DEAD box protein 5 
0,5582676 -0,1448873 2,26E-01 5,75E-01 ARC34 O15144 
Actin-related protein 2/3 
complex subunit 2 
0,5530656 -0,3646635 4,48E-01 3,41E-01 FDFT1 P37268 
Farnesyl-diphosphate 
farnesyltransferase 
0,5472524 -0,8251334 6,98E-01 1,72E-01 PEX14 O75381 Peroxin-14 
0,5419112 -0,4905373 3,69E-01 4,39E-01 CPR3 O60884 
Cell cycle progression 
restoration gene 3 protein 
0,5413166 -0,3156301 2,60E-01 2,63E-01 HSPA1 P08107 
Heat shock 70 kDa protein 
1/2 
0,5408208 -0,5254133 4,60E-01 6,51E-01 ABCF2 Q75MJ1 
ATP-binding cassette, sub-
family F (GCN20), member 
2, isoform CRA_d 
0,5307699 -1,175371 4,71E-01 4,73E-02 HEATR2 Q86Y56 
HEAT repeat-containing 
protein 2 
0,5307699 -0,07512481 4,71E-01 7,37E-01 POLR2H P52434 
DNA-directed RNA 
polymerase II subunit H 
0,5301707 -0,1294814 4,27E-01 6,08E-01 ACTR3 P61158 Actin-like protein 3 
0,5216539 -0,2576488 2,76E-01 3,64E-01 BAT1 F8VQ10 
56 kDa U2AF65-associated 
protein 
0,516822 -0,08701293 2,65E-01 7,04E-01 ILF2 Q12905 
Interleukin enhancer-binding 
factor 2 
0,5155106 -0,2359087 4,88E-01 4,98E-01 ARPC1A Q92747 
Actin-related protein 2/3 
complex subunit 1A 
0,5139959 -0,113364 7,31E-01 6,77E-01 TCEB2 Q15370-2 Elongin 18 kDa subunit 
0,5075155 -0,2477481 7,38E-01 7,30E-01 PSMC1 P62191 
26S protease regulatory 
subunit 4 
0,5073125 -1,609068 4,97E-01 3,13E-04 HSPC O14818 
Proteasome subunit alpha 
type-7 
0,5060941 -1,124692 7,39E-01 5,83E-02 COPS4 D6RAX7 
COP9 signalosome complex 
subunit 4 
0,4897484 -0,3532843 5,16E-01 2,18E-01 PRP31 Q8WWY3 
Pre-mRNA-processing factor 
31 
0,4833644 -0,898108 5,24E-01 3,67E-02 WDR18 Q9BV38 
WD repeat-containing 
protein 18 
0,4730076 -0,09332488 3,23E-01 7,08E-01 KIAA0727 O94832 Myosin-Id 
0,4703026 -0,2797391 7,76E-01 3,26E-01 MYBBP1A Q9BQG0-2 Myb-binding protein 1A 
0,4699901 -0,03791745 3,26E-01 7,84E-01 SMU1 Q2TAY7 
Smu-1 suppressor of mec-8 
and unc-52 protein homolog 
0,468114 -0,05389804 5,41E-01 9,98E-01 PRI P13489 
Placental ribonuclease 
inhibitor 
0,4642501 -0,3791322 3,31E-01 3,44E-01 KIAA0221 Q92900 
ATP-dependent helicase 
RENT1 
0,458172 -0,352529 2,26E-01 3,54E-01 MTPAP Q9NVV4-2 mtPAP 
0,4528063 -0,4956745 3,59E-01 9,74E-02 PLEC1 Q15149 Hemidesmosomal protein 1 
0,4512243 -0,1260923 5,61E-01 8,96E-01 CAP Q01518 
Adenylyl cyclase-associated 
protein 1 
 143 
 
0,4413773 -1,106467 8,05E-01 1,13E-02 RPUSD4 Q96CM3 
RNA pseudouridylate 
synthase domain-containing 
protein 4 
0,4408458 -0,4284105 8,06E-01 5,07E-01 BAP28 Q9H583 
HEAT repeat-containing 
protein 1 
0,4398891 -0,3512768 9,57E-01 5,97E-01 GRWD Q9BQ67 
Glutamate-rich WD repeat-
containing protein 1 
0,4369081 -0,2665416 2,47E-01 3,47E-01 RPL17 P18621-3 60S ribosomal protein L17 
0,4312485 -0,5221155 3,66E-01 8,19E-02 ANT2 P05141 
Adenine nucleotide 
translocator 2 
0,4292143 -1,340258 5,87E-01 2,43E-03 POH1 O00487 
26S proteasome non-
ATPase regulatory subunit 
14 
0,4269625 -1,355202 8,20E-01 2,14E-02 PPP2R5D Q14738 
PP2A B subunit isoform 
B56-delta 
0,4247072 -0,08341635 5,92E-01 9,56E-01 FTP3 P55795 FTP-3 
0,420725 -0,3207744 5,97E-01 2,64E-01 PLRG1 A8MW61 
Putative uncharacterized 
protein PLRG1 
0,418136 -0,02494212 4,02E-01 8,60E-01 FXR1 P51114 
Fragile X mental retardation 
syndrome-related protein 1 
0,4138107 -0,3001286 3,80E-01 2,96E-01 RPL24 P83731 60S ribosomal protein L24 
0,4104497 -1,366429 6,10E-01 2,03E-02 AAAS Q9NRG9 Adracalin 
0,4062101 -0,1366007 4,18E-01 5,93E-01 ACTR2 P61160-2 Actin-like protein 2 
0,4031586 -0,525995 3,97E-01 3,90E-01 SNX3 O60493 Protein SDP3 
0,4003193 -0,2322265 4,00E-01 5,17E-01 PAB2 Q86U42 
Nuclear poly(A)-binding 
protein 1 
0,399882 -0,2695644 3,00E-01 3,42E-01 OK/SW-cl.82 P62244 40S ribosomal protein S15a 
0,3923174 -1,363048 6,32E-01 2,06E-02 SLC20A3 P53007 Citrate transport protein 
0,3906677 -0,08955901 4,75E-01 6,98E-01 EEF2 P13639 Elongation factor 2 
0,3875831 -0,7446564 4,15E-01 7,15E-03 CDC2 P06493 
Cell division control protein 2 
homolog 
0,3873625 -0,4609455 4,15E-01 5,74E-01 CNN2 B4DUT8 
cDNA FLJ52765, highly 
similar to Calponin-2 
0,3827226 -0,08071329 4,20E-01 7,19E-01 STAU O95793 
Double-stranded RNA-
binding protein Staufen 
homolog 1 
0,3811726 -0,1480171 4,21E-01 7,60E-01 PRO1677 Q7Z2W4 Zinc finger antiviral protein 
0,3807295 -0,2289595 4,37E-01 4,10E-01 DDX48 P38919 
ATP-dependent RNA 
helicase DDX48 
0,3800644 -0,4638874 4,42E-01 1,23E-01 THRAP3 Q9Y2W1 
Thyroid hormone receptor-
associated protein 3 
0,3792882 -0,1347621 6,48E-01 5,97E-01 MRPS25 P82663 
28S ribosomal protein S25, 
mitochondrial 
0,3703876 -0,2757514 8,80E-01 4,45E-01 PDHA1 P08559-4 PDHE1-A type I 
0,3674829 -0,7622405 8,83E-01 2,10E-01 KIAA1972 Q96DX4 
RING finger and SPRY 
domain-containing protein 1 
0,3606452 -0,4768998 6,72E-01 4,53E-01 KIAA0251 H3BND4 
Pyridoxal-dependent 
decarboxylase domain-
containing protein 1 
0,3598585 -0,1868858 6,73E-01 5,66E-01 PPP1CB P62140 
Serine/threonine-protein 
phosphatase PP1-beta 
catalytic subunit 
0,3588463 
-
0,00277261
5 
4,49E-01 9,07E-01 ARC20 P59998-3 
Actin-related protein 2/3 
complex subunit 4 
0,3572705 -0,6722437 6,53E-01 1,08E-01 CSNK1D H7BYT1 
Casein kinase I isoform 
delta 
0,3561438 -0,09326333 8,95E-01 9,42E-01 KIAA1101 O95747 
Oxidative stress-responsive 
1 protein 
0,3482324 -0,3852242 6,49E-01 5,57E-01 KIAA1352 Q9P2J5 Leucine--tRNA ligase 
0,3478923 -0,3659644 6,88E-01 5,80E-01 C8orf2 O94905 
Endoplasmic reticulum lipid 
raft-associated protein 2 
0,3478923 -0,1866887 4,62E-01 5,66E-01 C17orf85 Q53F19 Protein ELG 
0,3434647 -0,126549 4,76E-01 3,90E-01 CAPZA2 P47755 CapZ alpha-2 
0,3428961 -0,3012481 4,68E-01 4,14E-01 C1orf77 Q9Y3Y2-3 
Uncharacterized protein 
C1orf77 
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0,3422133 -0,3058241 9,09E-01 6,54E-01 CYFIP1 Q7L576 
Cytoplasmic FMR1-
interacting protein 1 
0,3325074 -0,02876362 4,81E-01 8,43E-01 KPNB1 Q14974 Importin subunit beta-1 
0,3287216 -0,1014434 4,80E-01 6,30E-01 ADTB2 P63010-2 
Adapter-related protein 
complex 2 beta subunit 
0,3249257 -0,1784857 7,18E-01 8,99E-01 DEF3 P78332 
Lung cancer antigen NY-LU-
12 
0,3221589 -0,09572784 9,31E-01 9,39E-01 CDC10 Q16181 CDC10 protein homolog 
0,315798 -0,08696698 4,70E-01 7,03E-01 DDX17 H3BLZ8 DEAD box protein 17 
0,3119681 -0,3964602 8,34E-01 1,78E-01 FUBP2 Q92945 
Far upstream element-
binding protein 2 
0,3076617 -0,2632653 7,41E-01 7,09E-01 SFRS4 Q08170 
Pre-mRNA-splicing factor 
SRP75 
0,3036931 -0,4517212 5,18E-01 4,63E-01 HSP105 Q92598 Antigen NY-CO-25 
0,3036931 -0,1249277 5,18E-01 6,18E-01 ADTAA O95782 
100 kDa coated vesicle 
protein A 
0,3026407 -0,4245522 7,47E-01 3,04E-01 LDC2 Q15287 
RNA-binding protein with 
serine-rich domain 1 
0,3002995 -0,1335746 5,62E-01 5,99E-01 AQR O60306 
Intron-binding protein 
aquarius 
0,2994792 -0,1229782 5,23E-01 6,16E-01 ASCC3L1 O75643 
Activating signal cointegrator 
1 complex subunit 3-like 1 
0,2961931 -0,08578761 5,28E-01 6,39E-01 GIG38 O00422 
18 kDa Sin3-associated 
polypeptide 
0,2930173 -0,0323002 6,46E-01 9,70E-01 ASNS O43776 Asparagine--tRNA ligase 
0,2899525 -0,2388339 5,37E-01 3,93E-01 ASF J3KTL2 Alternative-splicing factor 1 
0,2843957 -0,2157808 5,44E-01 4,34E-01 PTB P26599-3 
57 kDa RNA-binding protein 
PPTB-1 
0,2828548 -0,3994828 7,73E-01 5,40E-01 ERC55 F8WCY5 
Calcium-binding protein 
ERC-55 
0,2827364 -0,2969348 7,74E-01 4,19E-01 RBM4 Q9BWF3 Lark homolog 
0,2766753 -0,05427247 5,54E-01 7,67E-01 DC37 P82914 
28S ribosomal protein S15, 
mitochondrial 
0,2679552 -0,03194612 5,66E-01 8,35E-01 CGI-132 Q9Y3D3 
28S ribosomal protein S16, 
mitochondrial 
0,2665168 -0,07897503 7,95E-01 9,62E-01 
UNQ9342/PR
O34047 
Q6UXN9 Swd2 
0,2515676 -0,04568457 5,93E-01 8,11E-01 HNRNPC P07910-2 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 
0,2481705 -0,09690002 9,91E-01 7,03E-01 EXOSC4 Q9NPD3 
Exosome complex 
exonuclease RRP41 
0,2454957 -0,1234968 5,98E-01 6,28E-01 
RP11-
373M8.1-002 
E9PCT1 
Putative uncharacterized 
protein SRRM1 
0,245374 -0,04650377 5,98E-01 8,00E-01 
 
J3QR07 
 
0,2451305 -0,4363928 8,24E-01 2,69E-01 CDC40 O60508 
Cell division cycle 40 
homolog 
0,2382977 -0,09518836 9,81E-01 9,40E-01 AFAR O43488 AFB1 aldehyde reductase 1 
0,2370741 -0,3006438 6,09E-01 2,95E-01 HSP70B P17066 Heat shock 70 kDa protein 6 
0,2367069 -0,209278 9,40E-01 7,82E-01 SPNR Q96SI9 
Spermatid perinuclear RNA-
binding protein 
0,2342561 -0,2647378 6,13E-01 3,50E-01 HSC70 P11142 Heat shock 70 kDa protein 8 
0,2261386 -0,1740678 8,50E-01 8,30E-01 PSMC6 P62333 
26S protease regulatory 
subunit 10B 
0,2258919 -0,1460842 6,25E-01 5,72E-01 CALM H0Y7A7 Calmodulin 
0,2245343 -0,0987218 6,26E-01 6,77E-01 RPL28 P46779 60S ribosomal protein L28 
0,2107629 -0,2353821 9,52E-01 4,98E-01 KIAA0179 Q14684 
Ribosomal RNA processing 
protein 1 homolog B 
0,2063932 -0,5739177 8,77E-01 1,62E-01 DPM1 H0Y368 
Dolichyl-phosphate 
mannosyltransferase 
polypeptide 1, catalytic 
subunit 
0,2045164 -0,01152983 8,82E-01 9,06E-01 FHOD2 Q96PY5-3 
Formin homology 2 domain-
containing protein 2 
0,2018848 -0,084808 8,84E-01 7,09E-01 HDCMD11P P82673 
28S ribosomal protein S28, 
mitochondrial 
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0,2016338 -0,3116137 5,63E-01 4,01E-01 HSPC206 Q8NEY8 Gastric cancer antigen Ga50 
0,1991226 -0,05972046 6,25E-01 7,68E-01 OTT Q96T37 One-twenty two protein 1 
0,19131 -0,3442635 8,98E-01 3,63E-01 COPA P53621-2 Alpha-coat protein 
0,1851053 -0,2182962 9,26E-01 7,69E-01 DXS1179E P41743 
Atypical protein kinase C-
lambda/iota 
0,1791288 -0,1834249 6,94E-01 5,30E-01 CKAP4 Q07065 63 kDa membrane protein 
0,1741506 -0,3089483 6,06E-01 2,56E-01 RPL11 P62913 60S ribosomal protein L11 
0,1708224 -0,1417007 9,26E-01 5,41E-01 MRPS5 P82675 
28S ribosomal protein S5, 
mitochondrial 
0,169925 -0,1070572 9,10E-01 6,87E-01 MRL3 E7ETU7 
39S ribosomal protein L3, 
mitochondrial 
0,1655583 -0,2853896 7,14E-01 3,17E-01 ALY E9PB61 Ally of AML-1 and LEF-1 
0,1623389 -0,4681519 9,03E-01 4,63E-01 LETM1 O95202 
LETM1 and EF-hand 
domain-containing protein 1, 
mitochondrial 
0,153935 -0,2245869 9,50E-01 7,61E-01 ADE2 P22234-2 AIR carboxylase 
0,1515991 -0,137251 9,53E-01 6,40E-01 DDX39 O00148 
ATP-dependent RNA 
helicase DDX39 
0,1474369 -0,126612 9,59E-01 5,92E-01 FRG1 Q14331 FSHD region gene 1 protein 
0,1409095 -0,158526 7,52E-01 5,46E-01 KIAA0105 Q15007 Female-lethal(2)D homolog 
0,1403861 -0,02211194 7,53E-01 8,60E-01 SPTAN1 A6NG51 
Putative uncharacterized 
protein SPTAN1 
0,1268407 -0,3017816 8,66E-01 6,59E-01 C10orf2 Q96RR1 
Progressive external 
ophthalmoplegia 1 protein 
0,1180938 -0,06342424 7,87E-01 7,56E-01 EPRS P07814 
Bifunctional aminoacyl-tRNA 
synthetase 
0,1115655 -2,298176 9,91E-01 7,31E-05 PFN2 G5E9Q6 
Putative uncharacterized 
protein PFN2 
0,1050075 -0,078716 7,91E-01 5,29E-01 FMR1L2 P51116 
Fragile X mental retardation 
syndrome-related protein 2 
0,1042025 -0,23545 9,81E-01 7,46E-01 DDX36 Q9H2U1 DEAH box protein 36 
0,103934 -0,2578212 9,80E-01 4,69E-01 KIF23 Q02241 Kinesin-like protein 5 
0,1036654 -0,06469113 8,38E-01 7,44E-01 HNRNPF P52597 
Heterogeneous nuclear 
ribonucleoprotein F 
0,1024567 -0,1506733 9,78E-01 6,20E-01 KIAA0052 P42285 
ATP-dependent helicase 
SKIV2L2 
0,09531686 -0,07160316 8,23E-01 7,40E-01 C3orf5 P82650 
28S ribosomal protein S22, 
mitochondrial 
0,09423606 -0,2998621 9,67E-01 3,48E-01 BCAS2 O75934 
Breast carcinoma-amplified 
sequence 2 
0,09044699 -0,1746376 7,66E-01 5,30E-01 CGI-201 Q9BZJ0 Crooked neck homolog 
0,08990479 -0,4198159 9,55E-01 5,16E-01 CTNNB P35222 Beta-catenin 
0,0889556 -0,1278253 9,59E-01 6,12E-01 IK Q13123 Cytokine IK 
0,08460858 -0,213136 9,53E-01 4,39E-01 AP17 M0QYZ2 
Adapter-related protein 
complex 2 sigma subunit 
0,08351974 -0,1579786 9,52E-01 5,47E-01 PBSCF P62306 Sm protein F 
0,07915612 -0,5581129 8,45E-01 6,39E-02 KIAA0536 Q13523 PRP4 kinase 
0,07587489 -0,05282013 8,15E-01 9,99E-01 EMC19 E5RJR5 
Cyclin-A/CDK2-associated 
protein p19 
0,07573799 -0,8838215 8,15E-01 1,42E-01 SAKS1 Q04323-2 SAPK substrate protein 1 
0,07573799 -0,185868 9,41E-01 8,13E-01 MSS1 P35998 
26S protease regulatory 
subunit 7 
0,07423148 -0,5744547 8,57E-01 5,72E-02 DNAJ2 P31689 
DnaJ homolog subfamily A 
member 1 
0,07189995 -0,9445267 9,36E-01 2,86E-02 CDKN2 Q8N726 
Cyclin-dependent kinase 
inhibitor 2A, isoform 4 
0,07025199 -0,4081865 8,90E-01 1,59E-01 C20orf14 O94906 
Pre-mRNA-processing factor 
6 
0,06295063 -0,3755715 8,75E-01 5,68E-01 MARS P56192 Methionine--tRNA ligase 
0,06115411 -0,04494017 9,21E-01 8,04E-01 MRPS34 C9JJ19 
Putative uncharacterized 
protein MRPS34 
0,05727703 -0,455752 9,15E-01 4,76E-01 LMN1 P02545 70 kDa lamin 
0,05533457 -0,3679366 8,87E-01 2,08E-01 ATP5C P36542 
ATP synthase subunit 
gamma, mitochondrial 
 146 
 
0,04865466 -0,431423 8,97E-01 3,70E-01 LDHB P07195 LDH heart subunit 
0,044464 -0,1273052 9,04E-01 8,95E-01 CRM1 O14980 
Chromosome region 
maintenance 1 protein 
homolog 
0,04404436 -0,2810883 9,05E-01 3,24E-01 KIAA0663 O75152 
Zinc finger CCCH domain-
containing protein 11A 
0,0321009 -0,4759563 8,80E-01 4,54E-01 MRPP1 Q7L0Y3 
HBV pre-S2 trans-regulated 
protein 2 
0,01292609 -0,08897574 9,55E-01 7,15E-01 PSA Q9Y617 
Phosphohydroxythreonine 
aminotransferase 
0,00776951 -0,2093114 8,47E-01 4,24E-01 C21orf101 P82932 
28S ribosomal protein S6, 
mitochondrial 
0,00532814 -0,08228566 8,44E-01 7,04E-01 KIAA0264 B4DRT2 
cDNA FLJ54536, highly 
similar to Mitochondrial 28S 
ribosomal protein S27 
0,00173013 -0,3759646 9,73E-01 5,68E-01 EZR P15311 Cytovillin 
0,00158601 -0,07240693 7,41E-01 7,42E-01 ADTAB O94973-2 
100 kDa coated vesicle 
protein C 
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Supplementary Table S11. Comparison between SILAC and LFQ. Proteins detected in the two 
SILAC experiments and the LFQ proteome analysis were overlapped to make the analysis more 
stringent and detect only the strong LE6 binders detected in both approaches. and Finally, SILAC 
results were compared to the results obtained from the label free proteome analysis to determine 
whether relevant proteins were common to the two approaches. In the Table of 62 proteins are shown 
only protein IDs (Uniprot) and protein names. 
 
Protein IDs Protein names 
B0QY89 Eukaryotic translation initiation factor 3, subunit E interacting protein 
E5RJR5 Cyclin-A/CDK2-associated protein p19 
E9PCT1 Putative uncharacterized protein SRRM1 
J3QR07 Putative splicing factor YT521 
LE6 LE6 
O00411 DNA-directed RNA polymerase, mitochondrial 
O00541 Pescadillo homolog 
O14818 Proteasome subunit alpha type-7 
O43488 AFB1 aldehyde reductase 1 
O43684 Mitotic checkpoint protein BUB3 
O60306 Intron-binding protein aquarius 
O60508 Cell division cycle 40 homolog 
O75381 Peroxin-14 
O75821 eIF3 p42 
O95202 LETM1 and EF-hand domain-containing protein 1, mitochondrial 
O95816 BAG family molecular chaperone regulator 2 
P02545 70 kDa lamin 
P04792 28 kDa heat shock protein 
P04818 Thymidylate synthase 
P06493 Cell division control protein 2 homolog 
P08574 Complex III subunit 4 
P12236 Adenine nucleotide translocator 3 
P15311 Cytovillin 
P23258 Gamma-1-tubulin 
P26196 ATP-dependent RNA helicase p54 
P30876 DNA-directed RNA polymerase II 140 kDa polypeptide 
P33993 CDC47 homolog 
P35222 Beta-catenin 
P35249 Activator 1 37 kDa subunit 
P42285 ATP-dependent helicase SKIV2L2 
P46940 p195 
P51116 Fragile X mental retardation syndrome-related protein 2 
P53007 Citrate transport protein 
P60228 eIF-3 p48 
P78527 DNA-dependent protein kinase catalytic subunit 
Q00341 High density lipoprotein-binding protein 
Q13283 ATP-dependent DNA helicase VIII 
Q14008-3 Colonic and hepatic tumor over-expressed gene protein 
Q15149 Hemidesmosomal protein 1 
Q15287 RNA-binding protein with serine-rich domain 1 
Q2TAY7 Smu-1 suppressor of mec-8 and unc-52 protein homolog 
Q53GQ0 17-beta-hydroxysteroid dehydrogenase 12 
Q75MJ1 ATP-binding cassette, sub-family F (GCN20), member 2, isoform CRA_d 
Q86V48 Leucine zipper protein 1 
Q86Y56 HEAT repeat-containing protein 2 
Q8N163 Deleted in breast cancer gene 1 protein 
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Q8WWM7-3 Ataxin-2 domain protein 
Q92759 Basic transcription factor 2 52 kDa subunit 
Q92900 ATP-dependent helicase RENT1 
Q96C36 Pyrroline-5-carboxylate reductase 2 
Q99615 DnaJ homolog subfamily C member 7 
Q9BQG0-2 Myb-binding protein 1A 
Q9BV38 WD repeat-containing protein 18 
Q9NUQ8 ATP-binding cassette sub-family F member 3 
Q9NVV4-2 mtPAP 
Q9NYF8 Bcl-2-associated transcription factor 1 
Q9NZB2-6 Constitutive coactivator of PPAR-gamma-like protein 1 
Q9UBU9 mRNA export factor TAP 
Q9UJS0-2 Calcium-binding mitochondrial carrier protein Aralar2 
Q9Y2W1 Thyroid hormone receptor-associated protein 3 
Q9Y3D3 28S ribosomal protein S16, mitochondrial 
Q9Y3T9 NOC2-like protein 
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10. Abbreviations 
aa amino acid 
APS Ammoniumpersulfate 
ATP adenosine triphosphate 
BCC Basal cell carcinoma 
bp base pair 
BFP Blue fluorescent protein 
BPV Bovine papillomavirus 
BSA  Bovine serum albumin 
cAMP Cyclic adenosine monophosphate 
CAPS  N-cyclohexyl-3-aminopropanesulfonic acid 
CBP CREB-binding protein 
cDNA Complementary DNA 
CIN  Cervical intraepithelial neoplasia 
co Codon-optimized 
CoIP Co-immunoprecipitaion 
CREB cAMP responsive element binding protein 
CRPV Cottontail rabbit papillomavirus 
CS Calf serum 
Ct  Threshold cycle 
DAPI  4’,6-Diamidino-2-phenylindol 
DBD DNA-binding domain 
DMEM Dulbecco´s Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
dNTP  Deoxyribonucleotide triphosphate 
ds  double-stranded 
DTT Dithiothreitol 
E6AP E6-associated protein, E3 ubiquitin ligase 
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ECM Extracellular matrix 
EGF Epidermal Growth Factor 
ER  Endoplasmic reticulum 
EV  Epidermodysplasia verruciformis 
FACS Fluorescence Activated Cell Sorting  
FBS Fetal bovine serum 
FCS  Fetal calf serum 
Fig Figure 
FITC  Fluorescein isothiocyanate 
FRET Förster/fluorescence resonance energy transfer  
FSC Forward SCatter 
GFP Green fluorescent protein 
h Hours 
HA Human influenza hemagglutinin 
HPV Human papillomavirus 
HR-HPV High risk-HPV 
HRP Horseradish peroxidase 
HSPG Heparan sulfate proteoglycan 
ICC  Immunocytochemistry 
IF Immunofluorescence 
IN Input 
IP Immunoprecipitate 
kDa Kilodalton 
LC Liquid Chromatography 
LCR Long control region 
LE6 Long E6 
LR-HPV Low risk-HPV 
luc Luciferase 
M Molar 
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MCLB Mammalian cell lysis buffer 
MCS  Multiple cloning site 
Met/Ac Methanol/Acetone  
min Minutes 
mRNA Messenger RNA 
MS Mass Spectrometry 
NMSC  Non-melanoma skin cancer 
NP40 4-Nonylphenyl-polyethylene glycol 
nt Nucleotide 
OD Optical density 
ORF  Open reading frame 
pAE  Early polyadenylation site 
pAL Late polyadenylation site 
PBS  Phosphate buffered saline 
PBS-T PBS-Tween 
PCR Polimerase chain reaction 
PDZ  PSD-95, Discs-large, ZO-1 
PFA Paraformaldehyde 
PV papillomavirus 
qPCR  Quantitative PCR 
RLU  Relative light units 
rpm Rotations per minute 
RT  Room temperature 
s Seconds 
SCC Squamous cell carcinoma 
SD Standard deviation 
SDS-PAGE  Sodium Dodecyl Sulphate – PolyAcrylamide Gel Electrophoresis 
SE6 Short E6 
SILAC Stable isotope labeling by/with amino acids in cell culture 
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siRNA small interfering RNA 
SSC Side SCatter 
TBS  Tris-buffered saline 
TBS-T TBS-tween 
TEMED  Tetramethylethylendiamine 
Tm  Melting temperature 
Tris  Trishydroxymethylaminomethan 
URR Upstream regulatory region 
YFP Yellow fluorescent protein 
WT  Wildtype 
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